<SEC-DOCUMENT>0001493152-22-036302.txt : 20221222
<SEC-HEADER>0001493152-22-036302.hdr.sgml : 20221222
<ACCEPTANCE-DATETIME>20221222161529
ACCESSION NUMBER:		0001493152-22-036302
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		16
CONFORMED PERIOD OF REPORT:	20221221
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
ITEM INFORMATION:		Unregistered Sales of Equity Securities
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20221222
DATE AS OF CHANGE:		20221222

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Qualigen Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001460702
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				263474527
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37428
		FILM NUMBER:		221482128

	BUSINESS ADDRESS:	
		STREET 1:		2042 CORTE DEL NOGAL
		STREET 2:		CARLSBAD
		CITY:			CALIFORNIA
		STATE:			CA
		ZIP:			92011
		BUSINESS PHONE:		(760) 918-9165

	MAIL ADDRESS:	
		STREET 1:		2042 CORTE DEL NOGAL
		STREET 2:		CARLSBAD
		CITY:			CALIFORNIA
		STATE:			CA
		ZIP:			92011

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	RITTER PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	20090402
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>form8-k.htm
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:us-gaap-supplement="http://fasb.org/us-gaap-sup/2022q3" xmlns:srt-supplement="http://fasb.org/srt-sup/2022q3" xmlns:us-roles="http://fasb.org/us-roles/2022" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:srt="http://fasb.org/srt/2022" xmlns:QLGN="http://qualigeninc.com/20221221">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02B_US%2DGAAP%2D2022 -->
<!-- Field: Set; Name: xdx; ID: xdx_036_QLGN_qualigeninc.com_20221221 -->
<!-- Field: Set; Name: xdx; ID: xdx_04B_20221221_20221221 -->
<!-- Field: Set; Name: xdx; ID: xdx_055_edei%2D%2DEntityCentralIndexKey_0001460702 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="From2022-12-21to2022-12-21" name="dei:EntityCentralIndexKey">0001460702</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2022-12-21to2022-12-21" name="dei:AmendmentFlag">false</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="qlgn-20221221.xsd" xlink:type="simple" />
  </ix:references>
 <ix:resources>
    <xbrli:context id="From2022-12-21to2022-12-21">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-12-21</xbrli:startDate>
        <xbrli:endDate>2022-12-21</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 4pt solid; border-bottom: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>UNITED
STATES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>SECURITIES
AND EXCHANGE COMMISSION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 12pt"><b>Washington,
D.C. 20549</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>FORM
<span id="xdx_902_edei--DocumentType_c20221221__20221221_zpH3b0CqxzF7"><ix:nonNumeric contextRef="From2022-12-21to2022-12-21" name="dei:DocumentType">8-K</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CURRENT
REPORT</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Pursuant
to Section 13 or 15(d) of</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>The
Securities Exchange Act of 1934</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Date
of Report (Date of earliest event reported): <span id="xdx_905_edei--DocumentPeriodEndDate_c20221221__20221221_zi0uh3r6PIbh"><ix:nonNumeric contextRef="From2022-12-21to2022-12-21" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate">December 21, 2022</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b><span id="xdx_90C_edei--EntityRegistrantName_c20221221__20221221_zdFLfqq9CQZ9"><ix:nonNumeric contextRef="From2022-12-21to2022-12-21" name="dei:EntityRegistrantName">Qualigen
Therapeutics, Inc.</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Exact
name of registrant as specified in its charter)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90F_edei--EntityIncorporationStateCountryCode_c20221221__20221221_zPVmdfWnWH2h"><ix:nonNumeric contextRef="From2022-12-21to2022-12-21" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode">Delaware</ix:nonNumeric></span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90E_edei--EntityFileNumber_c20221221__20221221_zhC9oFi5XaQ6"><ix:nonNumeric contextRef="From2022-12-21to2022-12-21" name="dei:EntityFileNumber">001-37428</ix:nonNumeric></span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_904_edei--EntityTaxIdentificationNumber_c20221221__20221221_zEpjxgdtgDZg"><ix:nonNumeric contextRef="From2022-12-21to2022-12-21" name="dei:EntityTaxIdentificationNumber">26-3474527</ix:nonNumeric></span></b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(State
    or other jurisdiction</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">of
    incorporation)</span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Commission</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">File
    Number)</span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(I.R.S.
    Employer</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Identification
    No.)</span></p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_90F_edei--EntityAddressAddressLine1_c20221221__20221221_zVGp1U6W6RTh"><ix:nonNumeric contextRef="From2022-12-21to2022-12-21" name="dei:EntityAddressAddressLine1">2042
Corte Del Nogal</ix:nonNumeric></span>, <span id="xdx_903_edei--EntityAddressCityOrTown_c20221221__20221221_zhxDVuN940i1"><ix:nonNumeric contextRef="From2022-12-21to2022-12-21" name="dei:EntityAddressCityOrTown">Carlsbad</ix:nonNumeric></span>, <span id="xdx_909_edei--EntityAddressStateOrProvince_c20221221__20221221_zjM5MeY2gWc3"><ix:nonNumeric contextRef="From2022-12-21to2022-12-21" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince">California</ix:nonNumeric></span> <span id="xdx_90B_edei--EntityAddressPostalZipCode_c20221221__20221221_z4XuMFAC1a8a"><ix:nonNumeric contextRef="From2022-12-21to2022-12-21" name="dei:EntityAddressPostalZipCode">92011</ix:nonNumeric></span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Address
of principal executive offices) (Zip Code)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_901_edei--CityAreaCode_c20221221__20221221_zJ4n8PpZy8O1"><ix:nonNumeric contextRef="From2022-12-21to2022-12-21" name="dei:CityAreaCode">(760)</ix:nonNumeric></span>
<span id="xdx_903_edei--LocalPhoneNumber_c20221221__20221221_zEvcXGZ1MI3j"><ix:nonNumeric contextRef="From2022-12-21to2022-12-21" name="dei:LocalPhoneNumber">918-9165</ix:nonNumeric></span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Registrant&#8217;s
telephone number, including area code)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">n/a</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Former
name or former address, if changed since last report)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_edei--WrittenCommunications_c20221221__20221221_zSa9ot4ryRC4"><ix:nonNumeric contextRef="From2022-12-21to2022-12-21" format="ixt:booleanfalse" name="dei:WrittenCommunications">&#9744;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Written
    communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_edei--SolicitingMaterial_c20221221__20221221_zWOpIBenTZB8"><ix:nonNumeric contextRef="From2022-12-21to2022-12-21" format="ixt:booleanfalse" name="dei:SolicitingMaterial">&#9744;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Soliciting
    material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_edei--PreCommencementTenderOffer_c20221221__20221221_zsO5DvIavf6c"><ix:nonNumeric contextRef="From2022-12-21to2022-12-21" format="ixt:booleanfalse" name="dei:PreCommencementTenderOffer">&#9744;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement
    communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_edei--PreCommencementIssuerTenderOffer_c20221221__20221221_z1sddRnvgEV9"><ix:nonNumeric contextRef="From2022-12-21to2022-12-21" format="ixt:booleanfalse" name="dei:PreCommencementIssuerTenderOffer">&#9744;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement
    communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities
registered pursuant to Section 12(b) of the Act:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 38%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title
    of each class</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 20%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trading
    Symbol</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 38%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
    of each exchange on which registered</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_edei--Security12bTitle_c20221221__20221221_zI6pDZYy1ok7"><ix:nonNumeric contextRef="From2022-12-21to2022-12-21" name="dei:Security12bTitle">Common
    Stock, par value $.001 per share</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_edei--TradingSymbol_c20221221__20221221_zW3KG0nCh8Wa"><ix:nonNumeric contextRef="From2022-12-21to2022-12-21" name="dei:TradingSymbol">QLGN</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span>The
    <span id="xdx_900_edei--SecurityExchangeName_c20221221__20221221_zZLaMLhpael9"><ix:nonNumeric contextRef="From2022-12-21to2022-12-21" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName">Nasdaq</ix:nonNumeric></span> Capital Market of The Nasdaq Stock Market LLC</span></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act (&#167;230.405 of this
chapter) or Rule 12b-2 of the Exchange Act (&#167;240.12b-2 of this chapter).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging
growth company <span id="xdx_904_edei--EntityEmergingGrowthCompany_c20221221__20221221_z38Dihzh8GOj"><ix:nonNumeric contextRef="From2022-12-21to2022-12-21" format="ixt:booleanfalse" name="dei:EntityEmergingGrowthCompany">&#9744;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 1.5pt solid; border-bottom: Black 4pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
1.01. Entry into a Material Definitive Agreement.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 21, 2022, Qualigen Therapeutics, Inc. (the &#8220;Company&#8221;) entered into a Securities Purchase Agreement (&#8220;Agreement&#8221;)
with Alpha Capital Anstalt (&#8220;Alpha&#8221;), pursuant to which it agreed to issue to Alpha, an 8% Senior Convertible Debenture (the
&#8220;Debenture&#8221;) in the aggregate principal amount of $3,300,000 for a purchase price of $3,000,000. The Debenture will be convertible,
at any time, and from time to time, at Alpha&#8217;s option, into shares of common stock of the Company (the &#8220;Conversion Shares&#8221;),
at a price equal to $1.32 per share, subject to adjustment as described in the Debenture (the &#8220;Conversion Price&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the terms of the Agreement, the Company also agreed to issue to Alpha a common stock purchase warrant (the &#8220;Warrant&#8221;)
to purchase a number of shares of the common stock of the Company (the &#8220;Warrant Shares,&#8221; and, together with the Conversion
Shares, and any other shares of common stock of the Company that may otherwise become issuable pursuant to the terms of the Debenture
and Warrant, the &#8220;Underlying Shares&#8221;), equal to the number of Conversion Shares issuable upon conversion of the Debenture
as of the closing date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
transactions contemplated by the Agreement closed on December 22, 2022 (the &#8220;Closing Date&#8221;), at which time the Company delivered
to Alpha the Debenture and the Warrant, as described above (the &#8220;Transaction&#8221;). The exercise price of the Warrant (the &#8220;Exercise
Price&#8221;) is $1.65 (equal to 125% of the Conversion Price of the Debenture on the Closing Date). The Warrant entitles Alpha to purchase
up to 2,500,000 shares of common stock of the Company and may be exercised by Alpha, in whole or in part, at any time on or after June
22, 2023 and before June 22, 2028.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
proceeds from the Transaction will be dedicated to the Company&#8217;s efforts of advancing its QN-302 Investigative New Drug candidate
towards clinical trials and other working capital purposes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Commencing
June 1, 2023 and continuing on the first day of each month thereafter until the earlier of (i) December 22, 2025 (the &#8220;Maturity
Date&#8221;) and (ii) the full redemption of the Debenture (each such date, a &#8220;Monthly Redemption Date&#8221;), the Company will
redeem $110,000 plus accrued but unpaid interest, liquidated damages and any amounts then owing under the Debenture (the &#8220;Monthly
Redemption Amount&#8221;). The Monthly Redemption Amount will be paid in cash; provided that after the first two monthly redemptions,
the Company may elect to pay all or a portion of a Monthly Redemption Amount in shares of common stock of the Company, based on a conversion
price equal to the lesser of (i) the then Conversion Price of the Debenture and (ii) 85% of the average of the VWAPs (as defined in the
Debenture) for the five consecutive trading days ending on the trading day that is immediately prior to the applicable Monthly Redemption
Date. The Company may also redeem some or all of the then outstanding principal amount of the Debenture at any time for cash in
an amount equal to 105% of the then outstanding principal amount of the Debenture being redeemed plus accrued but unpaid interest, liquidated
damages and any amounts then owing under the Debenture. These monthly redemption and optional redemptions are subject to the satisfaction
of the Equity Conditions (as defined in the Debenture), which includes a condition that any shares to be issued to Alpha (including as
redemption, interest or otherwise, under the Debenture and/or Warrant) may not exceed, in the aggregate, 19.99% of the number of shares
of common stock of the Company outstanding on the date the Agreement is signed unless and until the Company has obtained stockholder
approval.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Debenture accrues interest at the rate of 8% per annum, which does not begin accruing until December 1, 2023, and will be payable on
a quarterly basis. Interest may be paid in cash or shares of common stock of the Company or a combination thereof at the option of the
Company; provided that interest may only be paid in shares if the Equity Conditions (as defined in the Debenture) have been satisfied,
including the stockholder approval condition as described above.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Both
the Debenture and the Warrant provide for adjustments to the Conversion Price and Exercise Price, respectively, in connection with stock
dividends and splits, subsequent equity sales and rights offerings, pro rata distributions, and certain fundamental transactions. Both
the Debenture and the Warrant include a beneficial ownership blocker of 9.99%, which may only be waived by Alpha upon 61 days&#8217;
notice to the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the terms of the Agreement, the Company agreed to file a prospectus supplement to the Company&#8217;s registration statement on Form
S-3 (No. 333-266430) (the &#8220;Existing S-3&#8221;) with the Securities and Exchange Commission (the &#8220;SEC&#8221;) to register
under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), the issuance of the maximum number of Underlying Shares
that it may register on the Existing S-3 pursuant to Instruction I.B.6 of Form S-3 as soon as reasonably practicable after the closing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, pursuant to the terms of the Agreement, the Company also entered into a registration rights agreement with Alpha (the &#8220;Registration
Rights Agreement&#8221;), on the Closing Date, pursuant to which it agreed to file one or more registration statements, as necessary,
and to the extent permissible, to register under the Securities Act the resale of the remaining Underlying Shares not otherwise registered
under the Existing S-3. The Registration Rights Agreement requires that the Company file, within 30 days after signing, a resale registration
statement and use commercially reasonable efforts to cause the resale registration statement to be declared effective by the SEC on or
before the 60<sup>th</sup> calendar day following the date of signing of the Registration Rights Agreement (or 120 days if such registration
statement is subject to full review by the SEC).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
foregoing descriptions of the Agreement, the Debenture, the Warrant and the Registration Rights Agreement do not purport to be complete
and are qualified in their entirety by reference to the full text of such documents, which are filed as Exhibits 10.1, 10.2, 4.1 and
10.3, respectively, and are incorporated herein by reference.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
2.03. Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
information set forth under Item 1.01 of this Current Report on Form 8-K is incorporated into this Item 2.03 by reference.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
3.02. Unregistered Sale of Equity Securities.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
information contained in Item 1.01 of this Current Report on Form 8-K with respect to the issuance of the Debenture and the Warrant is
incorporated into this Item 3.02 by reference.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Debenture and the Warrant will not to be registered under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;),
in reliance upon the exemption from registration provided by Section 4(a)(2) of the Securities Act for transactions not involving a public
offering.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
9.01. Financial Statements and Exhibits</b>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
Exhibits</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.75in"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibit</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">No.</span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; vertical-align: top; width: 0.1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Description</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex4-1.htm">Common Stock Purchase Warrant for 2,500,000 shares in favor of Alpha Capital Anstalt, dated December 22, 2022</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex10-1.htm">Securities Purchase Agreement, dated December 21, 2022, by and between Qualigen Therapeutics, Inc. and Alpha Capital Anstalt</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex10-2.htm">8% Senior Convertible Debenture Due December 22, 2025</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex10-3.htm">Registration Rights Agreement, dated December 22, 2022, by and between Qualigen Therapeutics, Inc. and Alpha Capital Anstalt</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">104</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cover
    Page Interactive Data File (embedded within the Inline XBRL document)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span>&#160;</p>


<!-- Field: Page; Sequence: 3 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SIGNATURES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">QUALIGEN
    THERAPEUTICS, INC.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 3%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 47%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
    December 22, 2022</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:
    </span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Michael S. Poirier&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Michael
    S. Poirier, Chief Executive Officer</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</body>
</html>
<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJxFjd0KgkAQhZ/Adxj2Oko3EvIyKYksRCK6XXKMJd2R2bWfR+ot25RoGBiGc75zhJiIjDa6QYbzqszhiG3XKIdQYo2M5oLekW53Cfhb4lVbx8q44f2BKXkGPbOYRvHFC4P1ri1WCURyJqOZlBAuk3kMxV4EXz0lU+sKjdOqAWUqKJg61ugUv8aEo3qSofY1VJ2QrSbj46bhKL9BhpGEA93Vg/hmIc9TEUyGCUTG1Hffmt46amHdYOu77Ij+N/gAHMJJUQ== -->
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.1
<SEQUENCE>2
<FILENAME>ex4-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
4.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NEITHER
THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION
OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED
(THE &ldquo;SECURITIES ACT&rdquo;), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT
UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS
OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS. THIS SECURITY AND THE SECURITIES ISSUABLE UPON EXERCISE
OF THIS SECURITY MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN SECURED BY SUCH SECURITIES.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>COMMON
STOCK PURCHASE WARRANT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>qualigen
therapeutics, inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 48%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrant
    Shares: 2,500,000</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 41%; text-align: right"><P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Initial
                                            Exercise Date: June 22, 2023</FONT></P>
                                             <P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin-left: 40pt; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issue
                                            Date: December 22, 2022</FONT></P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">THIS
COMMON STOCK PURCHASE WARRANT (the &ldquo;<U>Warrant</U>&rdquo;) certifies that, for value received, Alpha Capital Anstalt or its assigns
(the &ldquo;<U>Holder</U>&rdquo;) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter
set forth, at any time on or after the six month anniversary of the Issue Date (the &ldquo;<U>Initial Exercise Date</U>&rdquo;) and on
or prior to 5:00 p.m. (New York City time) on June 22, 2028 (the &ldquo;<U>Termination Date</U>&rdquo;) but not thereafter, to subscribe
for and purchase from Qualigen Therapeutics, Inc., a Delaware corporation (the &ldquo;<U>Company</U>&rdquo;), up to 2,500,000 shares
(as subject to adjustment hereunder, the &ldquo;<U>Warrant Shares</U>&rdquo;) of Common Stock. The purchase price of one share of Common
Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section
1</U>. <U>Definitions</U>. Capitalized terms used and not otherwise defined herein shall have the meanings set forth in that certain
Securities Purchase Agreement (the &ldquo;<U>Purchase Agreement</U>&rdquo;), dated December 21, 2022, among the Company and the purchasers
signatory thereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section
2</U>. <U>Exercise</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)
<U>Exercise of Warrant</U>. Exercise of the purchase rights represented by this Warrant may be made, in whole or in part, at any time
or times on or after the Initial Exercise Date and on or before the Termination Date by delivery to the Company of a duly executed PDF
copy submitted by e-mail (or e-mail attachment) of the Notice of Exercise in the form annexed hereto (the &ldquo;<U>Notice of Exercise</U>&rdquo;).
Within the earlier of (i) two (2) Trading Days and (ii) the number of Trading Days comprising the Standard Settlement Period (as defined
in Section 2(d)(i) herein) following the date of exercise as aforesaid, the Holder shall deliver the aggregate Exercise Price for the
shares specified in the applicable Notice of Exercise by wire transfer or cashier&rsquo;s check drawn on a United States bank unless
the cashless exercise procedure specified in Section 2(c) below is specified in the applicable Notice of Exercise. No ink-original Notice
of Exercise shall be required, nor shall any medallion guarantee (or other type of guarantee or notarization) of any Notice of Exercise
be required. Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender this Warrant to
the Company until the Holder has purchased all of the Warrant Shares available hereunder and the Warrant has been exercised in full,
in which case, the Holder shall surrender this Warrant to the Company for cancellation as soon as reasonably practicable after the date
on which the final Notice of Exercise is delivered to the Company. Partial exercises of this Warrant resulting in purchases of a portion
of the total number of Warrant Shares available hereunder shall have the effect of lowering the outstanding number of Warrant Shares
purchasable hereunder in an amount equal to the applicable number of Warrant Shares purchased. The Holder and the Company shall maintain
records showing the number of Warrant Shares purchased and the date of such purchases. The Company shall deliver any objection to any
Notice of Exercise within one (1) Business Day of receipt of such notice. Notwithstanding the foregoing, with respect to any Notice(s)
of Exercise delivered on or prior to 4:00 p.m. (New York City time) on the Trading Date prior to the Initial Exercise Date, which may
be delivered at any time after the time of execution of the Purchase Agreement, the Company agrees to deliver the Warrant Shares subject
to such notice(s) by 4:00 p.m. (New York City time) on the Initial Exercise Date and the Initial Exercise Date shall be the Warrant Share
Delivery Date (hereinafter defined) for purposes hereunder, provided that payment of the aggregate Exercise Price (other than in the
case of a cashless exercise) is received by such Warrant Share Delivery Date. <B>The Holder and any assignee, by acceptance of this Warrant,
acknowledge and agree that, by reason of the provisions of this paragraph, following the purchase of a portion of the Warrant Shares
hereunder, the number of Warrant Shares available for purchase hereunder at any given time may be less than the amount stated on the
face hereof.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)
<U>Exercise Price</U>. The exercise price per share of Common Stock under this Warrant shall be <B>$</B>1.65, subject to adjustment hereunder
(the &ldquo;<U>Exercise Price</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)
<U>Cashless Exercise</U>. If at the time of exercise hereof there is no effective registration statement registering, or the prospectus
contained therein is not available for the resale of the Warrant Shares by the Holder, then this Warrant may also be exercised, in whole
or in part, at such time by means of a &ldquo;cashless exercise&rdquo; in which the Holder shall be entitled to receive a number of Warrant
Shares equal to the quotient obtained by dividing [(A-B) (X)] by (A), where:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 99pt; text-align: justify; text-indent: -27pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(A)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.15in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">=</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">as
                                            applicable: (i) the VWAP on the Trading Day immediately preceding the date of the applicable
                                            Notice of Exercise if such Notice of Exercise is (1) both executed and delivered pursuant
                                            to Section 2(a) hereof on a day that is not a Trading Day or (2) both executed and delivered
                                            pursuant to Section 2(a) hereof on a Trading Day prior to the opening of &ldquo;regular trading
                                            hours&rdquo; (as defined in Rule 600(b) of Regulation NMS promulgated under the federal securities
                                            laws) on such Trading Day, (ii) at the option of the Holder, either (y) the VWAP on the Trading
                                            Day immediately preceding the date of the applicable Notice of Exercise or (z) the Bid Price
                                            of the Common Stock on the principal Trading Market as reported by Bloomberg L.P. (&ldquo;<U>Bloomberg</U>&rdquo;)
                                            as of the time of the Holder&rsquo;s execution of the applicable Notice of Exercise if such
                                            Notice of Exercise is executed during &ldquo;regular trading hours&rdquo; on a Trading Day
                                            and is delivered within two (2) hours thereafter (including until two (2) hours after the
                                            close of &ldquo;regular trading hours&rdquo; on a Trading Day) pursuant to Section 2(a) hereof
                                            or (iii) the VWAP on the date of the applicable Notice of Exercise if the date of such Notice
                                            of Exercise is a Trading Day and such Notice of Exercise is both executed and delivered pursuant
                                            to Section 2(a) hereof after the close of &ldquo;regular trading hours&rdquo; on such Trading
                                            Day;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in; text-align: right"></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(B)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.15in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">=</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            Exercise Price of this Warrant, as adjusted hereunder; and</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in; text-align: right"></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(X)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.15in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">=</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            number of Warrant Shares that would be issuable upon exercise of this Warrant in accordance
                                            with the terms of this Warrant if such exercise were by means of a cash exercise rather than
                                            a cashless exercise.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 103.5pt; text-align: justify; text-indent: -31.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">If
Warrant Shares are issued in such a cashless exercise, the parties acknowledge and agree that in accordance with Section 3(a)(9) of the
Securities Act, the holding period of the Warrant Shares being issued may be tacked on to the holding period of this Warrant. The Company
agrees not to take any position contrary to this Section 2(c).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Bid
Price</U>&rdquo; means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock
is then listed or quoted on a Trading Market, the bid price of the Common Stock for the time in question (or the nearest preceding date)
on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg (based on a Trading Day from 9:30 a.m.
(New York City time) to 4:02 p.m. (New York City time)), (b) if OTCQB or OTCQX is not a Trading Market, the volume weighted average price
of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Stock is not then
listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported on The Pink Open Market (or a similar
organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of the Common Stock so reported,
or (d) in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser selected in good
faith by the Purchasers of a majority in interest of the Securities then outstanding and reasonably acceptable to the Company, the fees
and expenses of which shall be paid by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 2; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>VWAP</U>&rdquo;
means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed
or quoted on a Trading Market, the daily volume weighted average price of the Common Stock for such date (or the nearest preceding date)
on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based on a Trading Day from 9:30
a.m. (New York City time) to 4:02 p.m. (New York City time)), (b) if OTCQB or OTCQX is not a Trading Market, the volume weighted average
price of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Stock is not
then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported on The Pink Open Market (or
a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of the Common
Stock so reported, or (d) in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser
selected in good faith by the Purchasers of a majority in interest of the Securities then outstanding and reasonably acceptable to the
Company, the reasonable, actual and documented fees and expenses of which shall be paid by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notwithstanding
anything herein to the contrary, on the Termination Date, this Warrant shall be automatically exercised via cashless exercise pursuant
to this Section 2(c).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)
<U>Mechanics of Exercise</U>.</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 117pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">i.
<U>Delivery of Warrant Shares Upon Exercise</U>. The Company shall cause the Warrant Shares purchased hereunder to be transmitted by
the Transfer Agent to the Holder by crediting the account of the Holder&rsquo;s or its designee&rsquo;s balance account with The Depository
Trust Company through its Deposit or Withdrawal at Custodian system (&ldquo;<U>DWAC</U>&rdquo;) if the Company is then a participant
in such system and either (A) there is an effective registration statement permitting the issuance of the Warrant Shares to or resale
of the Warrant Shares by the Holder or (B) the Warrant Shares are eligible for resale by the Holder without volume or manner-of-sale
limitations pursuant to Rule 144 (assuming cashless exercise of the Warrants), and otherwise by physical delivery of a certificate, registered
in the Company&rsquo;s share register in the name of the Holder or its designee, for the number of Warrant Shares to which the Holder
is entitled pursuant to such exercise to the address specified by the Holder in the Notice of Exercise by the date that is the earliest
of (i) two (2) Trading Days after the delivery to the Company of the Notice of Exercise, (ii) one (1) Trading Day after delivery of the
aggregate Exercise Price to the Company and (iii) the number of Trading Days comprising the Standard Settlement Period after the delivery
to the Company of the Notice of Exercise (such date, the &ldquo;<U>Warrant Share Delivery Date</U>&rdquo;). Upon delivery of the Notice
of Exercise, the Holder shall be deemed for all corporate purposes to have become the holder of record of the Warrant Shares with respect
to which this Warrant has been exercised, irrespective of the date of delivery of the Warrant Shares, provided that payment of the aggregate
Exercise Price (other than in the case of a cashless exercise) is received within the earlier of (i) two (2) Trading Days and (ii) the
number of Trading Days comprising the Standard Settlement Period following delivery of the Notice of Exercise. If the Company fails for
any reason to deliver to the Holder the Warrant Shares subject to a Notice of Exercise by the Warrant Share Delivery Date, the Company
shall pay to the Holder, in cash, as liquidated damages and not as a penalty, for each $1,000 of Warrant Shares subject to such exercise
(based on the VWAP of the Common Stock on the date of the applicable Notice of Exercise), $10 per Trading Day for each Trading Day after
such Warrant Share Delivery Date until such Warrant Shares are delivered or Holder rescinds such exercise. The Company agrees to maintain
a transfer agent that is a participant in the FAST program so long as this Warrant remains outstanding and exercisable. As used herein,
&ldquo;<U>Standard Settlement Period</U>&rdquo; means the standard settlement period, expressed in a number of Trading Days, on the Company&rsquo;s
primary Trading Market with respect to the Common Stock as in effect on the date of delivery of the Notice of Exercise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 117pt; text-align: justify; text-indent: 31.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 117pt; text-align: justify; text-indent: 31.5pt"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 117pt; text-align: justify; text-indent: 31.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii.
<U>Delivery of New Warrants Upon Exercise</U>. If this Warrant shall have been exercised in part, the Company shall, at the request of
a Holder and upon surrender of this Warrant certificate, at the time of delivery of the Warrant Shares, deliver to the Holder a new Warrant
evidencing the rights of the Holder to purchase the unpurchased Warrant Shares called for by this Warrant, which new Warrant shall in
all other respects be identical with this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 117pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">iii.
<U>Rescission Rights</U>. If the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares pursuant to Section
2(d)(i) by the Warrant Share Delivery Date, then the Holder will have the right to rescind such exercise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 117pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">iv.
<U>Compensation for Buy-In on Failure to Timely Deliver Warrant Shares Upon Exercise</U>. In addition to any other rights available to
the Holder, if the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares in accordance with the provisions
of Section 2(d)(i) above pursuant to an exercise on or before the Warrant Share Delivery Date, and if after such date the Holder is required
by its broker to purchase (in an open market transaction or otherwise) or the Holder&rsquo;s brokerage firm otherwise purchases, shares
of Common Stock to deliver in satisfaction of a sale by the Holder of the Warrant Shares which the Holder anticipated receiving upon
such exercise (a &ldquo;<U>Buy-In</U>&rdquo;), then the Company shall (A) pay in cash to the Holder the amount, if any, by which (x)
the Holder&rsquo;s total purchase price (including brokerage commissions, if any) for the shares of Common Stock so purchased exceeds
(y) the amount obtained by multiplying (1) the number of Warrant Shares that the Company was required to deliver to the Holder in connection
with the exercise at issue times (2) the price at which the sell order giving rise to such purchase obligation was executed, and (B)
at the option of the Holder, either reinstate the portion of the Warrant and equivalent number of Warrant Shares for which such exercise
was not honored (in which case such exercise shall be deemed rescinded) or deliver to the Holder the number of shares of Common Stock
that would have been issued had the Company timely complied with its exercise and delivery obligations hereunder. For example, if the
Holder purchases Common Stock having a total purchase price of $11,000 to cover a Buy-In with respect to an attempted exercise of shares
of Common Stock with an aggregate sale price giving rise to such purchase obligation of $10,000, under clause (A) of the immediately
preceding sentence the Company shall be required to pay the Holder $1,000. The Holder shall provide the Company written notice indicating
the amounts payable to the Holder in respect of the Buy-In and, upon request of the Company, evidence of the amount of such loss. Nothing
herein shall limit a Holder&rsquo;s right to pursue any other remedies available to it hereunder, at law or in equity including, without
limitation, a decree of specific performance and/or injunctive relief with respect to the Company&rsquo;s failure to timely deliver shares
of Common Stock upon exercise of the Warrant as required pursuant to the terms hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 117pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 117pt; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 117pt; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 117pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">v.
<U>No Fractional Shares or Scrip</U>. No fractional shares or scrip representing fractional shares shall be issued upon the exercise
of this Warrant. As to any fraction of a share which the Holder would otherwise be entitled to purchase upon such exercise, the Company
shall, at its election, either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied
by the Exercise Price or round up to the next whole share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 117pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">vi.
<U>Charges, Taxes and Expenses</U>. Issuance of Warrant Shares shall be made without charge to the Holder for any issue or transfer tax
or other incidental expense in respect of the issuance of such Warrant Shares, all of which taxes and expenses shall be paid by the Company,
and such Warrant Shares shall be issued in the name of the Holder or in such name or names as may be directed by the Holder; <U>provided</U>,
<U>however</U>, that, in the event that Warrant Shares are to be issued in a name other than the name of the Holder, this Warrant when
surrendered for exercise shall be accompanied by the Assignment Form attached hereto duly executed by the Holder and the Company may
require, as a condition thereto, the payment of a sum sufficient to reimburse it for any transfer tax incidental thereto. The Company
shall pay all Transfer Agent fees required for same-day processing of any Notice of Exercise and all fees to the Depository Trust Company
(or another established clearing corporation performing similar functions) required for same-day electronic delivery of the Warrant Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 117pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">vii.
<U>Closing of Books</U>. The Company will not close its stockholder books or records in any manner which prevents the timely exercise
of this Warrant, pursuant to the terms hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">e)
<U>Holder&rsquo;s Exercise Limitations</U>. The Company shall not effect any exercise of this Warrant, and a Holder shall not have the
right to exercise any portion of this Warrant, pursuant to Section 2 or otherwise, to the extent that after giving effect to such issuance
after exercise as set forth on the applicable Notice of Exercise, the Holder (together with the Holder&rsquo;s Affiliates, and any other
Persons acting as a group together with the Holder or any of the Holder&rsquo;s Affiliates (such Persons, &ldquo;<U>Attribution Parties</U>&rdquo;)),
would beneficially own in excess of the Beneficial Ownership Limitation (as defined below). For purposes of the foregoing sentence, the
number of shares of Common Stock beneficially owned by the Holder and its Attribution Parties shall include the number of shares of Common
Stock issuable upon exercise of this Warrant with respect to which such determination is being made, but shall exclude the number of
shares of Common Stock which would be issuable upon (i) exercise of the remaining, nonexercised portion of this Warrant beneficially
owned by the Holder or any of its Attribution Parties and (ii) exercise or conversion of the unexercised or nonconverted portion of any
other securities of the Company (including, without limitation, any other Common Stock Equivalents) subject to a limitation on conversion
or exercise analogous to the limitation contained herein beneficially owned by the Holder or any of its Attribution Parties. Except as
set forth in the preceding sentence, for purposes of this Section 2(e), beneficial ownership shall be calculated in accordance with Section
13(d) of the Exchange Act and the rules and regulations promulgated thereunder, it being acknowledged by the Holder that the Company
is not representing to the Holder that such calculation is in compliance with Section 13(d) of the Exchange Act and the Holder is solely
responsible for any schedules required to be filed in accordance therewith. To the extent that the limitation contained in this Section
2(e) applies, the determination of whether this Warrant is exercisable (in relation to other securities owned by the Holder together
with any Attribution Parties) and of which portion of this Warrant is exercisable shall be in the sole discretion of the Holder, and
the submission of a Notice of Exercise shall be deemed to be the Holder&rsquo;s determination of whether this Warrant is exercisable
(in relation to other securities owned by the Holder together with any Attribution Parties) and of which portion of this Warrant is exercisable,
in each case subject to the Beneficial Ownership Limitation, and the Company shall have no obligation to verify or confirm the accuracy
of such determination. In addition, a determination as to any group status as contemplated above shall be determined in accordance with
Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder. For purposes of this Section 2(e), in determining
the number of outstanding shares of Common Stock, a Holder may rely on the number of outstanding shares of Common Stock as reflected
in (A) the Company&rsquo;s most recent periodic or annual report filed with the Commission, as the case may be, (B) a more recent public
announcement by the Company or (C) a more recent written notice by the Company or the Transfer Agent setting forth the number of shares
of Common Stock outstanding. Upon the written or oral request of a Holder, the Company shall within one Trading Day confirm orally and
in writing to the Holder the number of shares of Common Stock then outstanding. In any case, the number of outstanding shares of Common
Stock shall be determined after giving effect to the conversion or exercise of securities of the Company, including this Warrant, by
the Holder or its Attribution Parties since the date as of which such number of outstanding shares of Common Stock was reported. The
&ldquo;<U>Beneficial Ownership Limitation</U>&rdquo; shall be 9.99% of the number of shares of the Common Stock outstanding immediately
after giving effect to the issuance of shares of Common Stock issuable upon exercise of this Warrant. The Holder, upon not less than
61 days&rsquo; prior notice to the Company, may increase or decrease the Beneficial Ownership Limitation provisions of this Section 2(e),
provided that the Beneficial Ownership Limitation in no event exceeds 9.99% of the number of shares of the Common Stock outstanding immediately
after giving effect to the issuance of shares of Common Stock upon exercise of this Warrant held by the Holder and the provisions of
this Section 2(e) shall continue to apply. Any increase in the Beneficial Ownership Limitation will not be effective until the 61<SUP>st
</SUP>day after such notice is delivered to the Company. The provisions of this paragraph shall be construed and implemented in a manner
otherwise than in strict conformity with the terms of this Section 2(e) to correct this paragraph (or any portion hereof) which may be
defective or inconsistent with the intended Beneficial Ownership Limitation herein contained or to make changes or supplements necessary
or desirable to properly give effect to such limitation. The limitations contained in this paragraph shall apply to a successor holder
of this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">f)
<U>Issuance Restrictions</U>. If the Company has not obtained Shareholder Approval, then the Company may not issue upon exercise of this
Warrant a number of shares of Common Stock, which, when aggregated with any shares of Common Stock issued (i) pursuant to the conversion
of any Debentures issued pursuant to the Purchase Agreement, (ii) upon prior exercise of this or any other Warrant issued pursuant to
the Purchase Agreement, would exceed 841,726, subject to adjustment for reverse and forward stock splits, stock dividends, stock combinations
and other similar transactions of the Common Stock that occur after the date of the Purchase Agreement (such number of shares, the &ldquo;<U>Issuable
Maximum</U>&rdquo;). The Holder and the holders of the other Warrants issued pursuant to the Purchase Agreement shall be entitled to
a portion of the Issuable Maximum equal to the quotient obtained by dividing (x) the Holder&rsquo;s original Subscription Amount by (y)
the aggregate original Subscription Amount of all holders pursuant to the Purchase Agreement. In addition, the Holder may allocate its
pro-rata portion of the Issuable Maximum among Warrants held by it in its sole discretion. Such portion shall be adjusted upward ratably
in the event a Purchaser no longer holds any Warrants and the amount of shares issued to such Purchaser pursuant to its Warrants was
less than such Purchaser&rsquo;s pro-rata share of the Issuable Maximum.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section
3</U>. <U>Certain Adjustments</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)
<U>Stock Dividends and Splits</U>. If the Company, at any time while this Warrant is outstanding: (i) pays a stock dividend or otherwise
makes a distribution or distributions on shares of its Common Stock or any other equity or equity equivalent securities payable in shares
of Common Stock (which, for avoidance of doubt, shall not include any shares of Common Stock issued by the Company upon exercise of this
Warrant), (ii) subdivides outstanding shares of Common Stock into a larger number of shares, (iii) combines (including by way of reverse
stock split) outstanding shares of Common Stock into a smaller number of shares, or (iv) issues by reclassification of shares of the
Common Stock any shares of capital stock of the Company, then in each case the Exercise Price shall be multiplied by a fraction of which
the numerator shall be the number of shares of Common Stock (excluding treasury shares, if any) outstanding immediately before such event
and of which the denominator shall be the number of shares of Common Stock outstanding immediately after such event, and the number of
shares issuable upon exercise of this Warrant shall be proportionately adjusted such that the aggregate Exercise Price of this Warrant
shall remain unchanged. Any adjustment made pursuant to this Section 3(a) shall become effective immediately after the record date for
the determination of stockholders entitled to receive such dividend or distribution and shall become effective immediately after the
effective date in the case of a subdivision, combination or re-classification.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)
<U>Subsequent Equity Sales</U>. Following the receipt of Shareholder Approval, if the Company or any Subsidiary thereof, as applicable,
at any time while this Warrant is outstanding, shall sell, enter into an agreement to sell, or grant any option to purchase, or sell
or grant any right to reprice, or otherwise dispose of or issue (or announce any offer, sale, grant or any option to purchase or other
disposition) any Common Stock or Common Stock Equivalents, at an effective price per share less than the Exercise Price then in effect
(such lower price, the &ldquo;<U>Base Share Price</U>&rdquo; and such issuances collectively, a &ldquo;<U>Dilutive Issuance</U>&rdquo;)
(it being understood and agreed that if the holder of the Common Stock or Common Stock Equivalents so issued shall at any time, whether
by operation of purchase price adjustments, reset provisions, floating conversion, exercise or exchange prices or otherwise, or due to
warrants, options or rights per share which are issued in connection with such issuance, be entitled to receive shares of Common Stock
at an effective price per share that is less than the Exercise Price, such issuance shall be deemed to have occurred for less than the
Exercise Price on such date of the Dilutive Issuance at such effective price), then simultaneously with the consummation (or, if earlier,
the announcement) of each Dilutive Issuance the Exercise Price shall be reduced and only reduced to equal the Base Share Price, provided
that the Base Share Price shall not be less than $0.260 (subject to adjustment for reverse and forward stock splits, recapitalizations
and similar transactions following the date of the Purchase Agreement). Notwithstanding the foregoing, no adjustments shall be made,
paid or issued under this Section 3(b) in respect of an Exempt Issuance. The Company shall notify the Holder, in writing, no later than
the Trading Day following the issuance or deemed issuance of any Common Stock or Common Stock Equivalents subject to this Section 3(b),
indicating therein the applicable issuance price, or applicable reset price, exchange price, conversion price and other pricing terms
(such notice, the &ldquo;<U>Dilutive Issuance Notice</U>&rdquo;). For purposes of clarification, whether or not the Company provides
a Dilutive Issuance Notice pursuant to this Section 3(b), upon the occurrence of any Dilutive Issuance, the Holder is entitled to receive
a number of Warrant Shares based upon the Base Share Price regardless of whether the Holder accurately refers to the Base Share Price
in the Notice of Exercise. If the Company enters into a Variable Rate Transaction, the Company shall be deemed to have issued Common
Stock or Common Stock Equivalents at the lowest possible price, conversion price or exercise price at which such securities may be issued,
converted or exercised.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)
<U>Subsequent Rights Offerings</U>. In addition to any adjustments pursuant to Section 3(a) above, if at any time the Company grants,
issues or sells any Common Stock Equivalents or rights to purchase stock, warrants, securities or other property pro rata to the record
holders of any class of shares of Common Stock (the &ldquo;<U>Purchase Rights</U>&rdquo;), then the Holder will be entitled to acquire,
upon the terms applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired if the Holder had
held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise
hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the date on which a record is taken for
the grant, issuance or sale of such Purchase Rights, or, if no such record is taken, the date as of which the record holders of shares
of Common Stock are to be determined for the grant, issue or sale of such Purchase Rights (<U>provided</U>, <U>however</U>, that, to
the extent that the Holder&rsquo;s right to participate in any such Purchase Right would result in the Holder exceeding the Beneficial
Ownership Limitation, then the Holder shall not be entitled to participate in such Purchase Right to such extent (or beneficial ownership
of such shares of Common Stock as a result of such Purchase Right to such extent) and such Purchase Right to such extent shall be held
in abeyance for the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership
Limitation).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)
<U>Pro Rata Distributions</U>. During such time as this Warrant is outstanding, if the Company shall declare or make any dividend or
other distribution of its assets (or rights to acquire its assets) to holders of shares of Common Stock, by way of return of capital
or otherwise (including, without limitation, any distribution of cash, stock or other securities, property or options by way of a dividend,
spin off, reclassification, corporate rearrangement, scheme of arrangement or other similar transaction) (a &ldquo;<U>Distribution</U>&rdquo;),
at any time after the issuance of this Warrant, then, in each such case, the Holder shall be entitled to participate in such Distribution
to the same extent that the Holder would have participated therein if the Holder had held the number of shares of Common Stock acquirable
upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation, the Beneficial
Ownership Limitation) immediately before the date of which a record is taken for such Distribution, or, if no such record is taken, the
date as of which the record holders of shares of Common Stock are to be determined for the participation in such Distribution (<U>provided</U>,
<U>however</U>, that, to the extent that the Holder&rsquo;s right to participate in any such Distribution would result in the Holder
exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such Distribution to such extent
(or in the beneficial ownership of any shares of Common Stock as a result of such Distribution to such extent) and the portion of such
Distribution shall be held in abeyance for the benefit of the Holder until such time, if ever, as its right thereto would not result
in the Holder exceeding the Beneficial Ownership Limitation).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">e)
<U>Fundamental Transaction</U>. If, at any time while this Warrant is outstanding, (i) the Company, directly or indirectly, in one or
more related transactions effects any merger or consolidation of the Company with or into another Person, (ii) the Company (or any Subsidiary),
directly or indirectly, effects any sale, lease, license, assignment, transfer, conveyance or other disposition of all or substantially
all of its assets in one or a series of related transactions, (iii) any, direct or indirect, purchase offer, tender offer or exchange
offer (whether by the Company or another Person) is completed pursuant to which holders of Common Stock are permitted to sell, tender
or exchange their shares for other securities, cash or property and has been accepted by the holders of 50% or more of the outstanding
Common Stock or 50% or more of the voting power of the common equity of the Company, (iv) the Company, directly or indirectly, in one
or more related transactions effects any reclassification, reorganization or recapitalization of the Common Stock or any compulsory share
exchange pursuant to which the Common Stock is effectively converted into or exchanged for other securities, cash or property, or (v)
the Company, directly or indirectly, in one or more related transactions consummates a stock or share purchase agreement or other business
combination (including, without limitation, a reorganization, recapitalization, spin-off, merger or scheme of arrangement) with another
Person or group of Persons whereby such other Person or group acquires 50% or more of the outstanding shares of Common Stock or 50% or
more of the voting power of the common equity of the Company (each a &ldquo;<U>Fundamental Transaction</U>&rdquo;), then, upon any subsequent
exercise of this Warrant, the Holder shall have the right to receive, for each Warrant Share that would have been issuable upon such
exercise immediately prior to the occurrence of such Fundamental Transaction, at the option of the Holder (without regard to any limitation
in Section 2(e) or Section 2(f) on the exercise of this Warrant), the number of shares of Common Stock of the successor or acquiring
corporation or of the Company, if it is the surviving corporation, and any additional consideration (the &ldquo;<U>Alternate Consideration</U>&rdquo;)
receivable as a result of such Fundamental Transaction by a holder of the number of shares of Common Stock for which this Warrant is
exercisable immediately prior to such Fundamental Transaction (without regard to any limitation in Section 2(e) or Section 2(f) on the
exercise of this Warrant). For purposes of any such exercise, the determination of the Exercise Price shall be appropriately adjusted
to apply to such Alternate Consideration based on the amount of Alternate Consideration issuable in respect of one share of Common Stock
in such Fundamental Transaction, and the Company shall apportion the Exercise Price among the Alternate Consideration in a reasonable
manner reflecting the relative value of any different components of the Alternate Consideration. If holders of Common Stock are given
any choice as to the securities, cash or property to be received in a Fundamental Transaction, then the Holder shall be given the same
choice as to the Alternate Consideration it receives upon any exercise of this Warrant following such Fundamental Transaction. The Company
shall cause any successor entity in a Fundamental Transaction in which the Company is not the survivor (the &ldquo;<U>Successor Entity</U>&rdquo;)
to assume in writing all of the obligations of the Company under this Warrant and the other Transaction Documents in accordance with
the provisions of this Section 3(e) pursuant to written agreements in form and substance reasonably satisfactory to the Holder and approved
by the Holder (without unreasonable delay) prior to such Fundamental Transaction and shall, at the option of the Holder, deliver to the
Holder in exchange for this Warrant a security of the Successor Entity evidenced by a written instrument substantially similar in form
and substance to this Warrant which is exercisable for a corresponding number of shares of capital stock of such Successor Entity (or
its parent entity) equivalent to the shares of Common Stock acquirable and receivable upon exercise of this Warrant (without regard to
any limitations on the exercise of this Warrant) prior to such Fundamental Transaction, and with an exercise price which applies the
exercise price hereunder to such shares of capital stock (but taking into account the relative value of the shares of Common Stock pursuant
to such Fundamental Transaction and the value of such shares of capital stock, such number of shares of capital stock and such exercise
price being for the purpose of protecting the economic value of this Warrant immediately prior to the consummation of such Fundamental
Transaction), and which is reasonably satisfactory in form and substance to the Holder. Upon the occurrence of any such Fundamental Transaction,
the Successor Entity shall be added to the term &ldquo;Company&rdquo; under this Warrant (so that from and after the occurrence or consummation
of such Fundamental Transaction, each and every provision of this Warrant and the other Transaction Documents referring to the &ldquo;Company&rdquo;
shall refer instead to each of the Company and the Successor Entity or Successor Entities, jointly and severally), and the Successor
Entity or Successor Entities, jointly and severally with the Company, may exercise every right and power of the Company prior thereto
and the Successor Entity or Successor Entities shall assume all of the obligations of the Company prior thereto under this Warrant and
the other Transaction Documents with the same effect as if the Company and such Successor Entity or Successor Entities, jointly and severally,
had been named as the Company herein. For the avoidance of doubt, the Holder shall be entitled to the benefits of the provisions of this
Section 3(e) regardless of (i) whether the Company has sufficient authorized shares of Common Stock for the issuance of Warrant Shares
and/or (ii) whether a Fundamental Transaction occurs prior to the Initial Exercise Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">f)
<U>Calculations</U>. All calculations under this Section 3 shall be made to the nearest cent or the nearest 1/100th of a share, as the
case may be. For purposes of this Section 3, the number of shares of Common Stock deemed to be issued and outstanding as of a given date
shall be the sum of the number of shares of Common Stock (excluding treasury shares, if any) issued and outstanding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">g)
<U>Notice to Holder</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">i.
<U>Adjustment to Exercise Price</U>. Whenever the Exercise Price is adjusted pursuant to any provision of this Section 3, the Company
shall promptly deliver to the Holder by email a notice setting forth the Exercise Price after such adjustment and any resulting adjustment
to the number of Warrant Shares and setting forth a brief statement of the facts requiring such adjustment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii.
<U>Notice to Allow Exercise by Holder</U>. If (A) the Company shall declare a dividend (or any other distribution in whatever form) on
the Common Stock, (B) the Company shall declare a special nonrecurring cash dividend on or a redemption of the Common Stock, (C) the
Company shall authorize the granting to all holders of the Common Stock rights or warrants to subscribe for or purchase any shares of
capital stock of any class or of any rights, (D) the approval of any stockholders of the Company shall be required in connection with
any reclassification of the Common Stock, any consolidation or merger to which the Company (or any of its Subsidiaries) is a party, any
sale or transfer of all or substantially all of its assets, or any compulsory share exchange whereby the Common Stock is converted into
other securities, cash or property, or (E) the Company shall authorize the voluntary or involuntary dissolution, liquidation or winding
up of the affairs of the Company, then, in each case, the Company shall cause to be delivered by email to the Holder at its last email
address as it shall appear upon the Warrant Register of the Company, at least 20 calendar days prior to the applicable record or effective
date hereinafter specified, a notice stating (x) the date on which a record is to be taken for the purpose of such dividend, distribution,
redemption, rights or warrants, or if a record is not to be taken, the date as of which the holders of the Common Stock of record to
be entitled to such dividend, distributions, redemption, rights or warrants are to be determined or (y) the date on which such reclassification,
consolidation, merger, sale, transfer or share exchange is expected to become effective or close, and the date as of which it is expected
that holders of the Common Stock of record shall be entitled to exchange their shares of the Common Stock for securities, cash or other
property deliverable upon such reclassification, consolidation, merger, sale, transfer or share exchange; provided that the failure to
deliver such notice or any defect therein or in the delivery thereof shall not affect the validity of the corporate action required to
be specified in such notice. To the extent that any notice provided in this Warrant constitutes, or contains, material, non-public information
regarding the Company or any of the Subsidiaries, the Company shall simultaneously file such notice with the Commission pursuant to a
Current Report on Form 8-K. The Holder shall remain entitled to exercise this Warrant during the period commencing on the date of such
notice to the effective date of the event triggering such notice except as may otherwise be expressly set forth herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section
4</U>. <U>Transfer of Warrant</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)
<U>Transferability</U>. Subject to compliance with any applicable securities laws and the conditions set forth in Section 4(d) hereof
and to the provisions of Section 4.1 of the Purchase Agreement, this Warrant and all rights hereunder (including, without limitation,
any registration rights) are transferable, in whole or in part, upon surrender of this Warrant at the principal office of the Company
or its designated agent, together with a written assignment of this Warrant substantially in the form attached hereto duly executed by
the Holder or its agent or attorney and funds sufficient to pay any transfer taxes payable upon the making of such transfer. Upon such
surrender and, if required, such payment, the Company shall execute and deliver a new Warrant or Warrants in the name of the assignee
or assignees, as applicable, and in the denomination or denominations specified in such instrument of assignment, and shall issue to
the assignor a new Warrant evidencing the portion of this Warrant not so assigned, and this Warrant shall promptly be cancelled. Notwithstanding
anything herein to the contrary, the Holder shall not be required to physically surrender this Warrant to the Company unless the Holder
has assigned this Warrant in full, in which case, the Holder shall surrender this Warrant to the Company within three (3) Trading Days
of the date on which the Holder delivers an assignment form to the Company assigning this Warrant in full. The Warrant, if properly assigned
in accordance herewith, may be exercised by a new holder for the purchase of Warrant Shares without having a new Warrant issued.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)
<U>New Warrants</U>. This Warrant may be divided or combined with other Warrants upon presentation hereof at the aforesaid office of
the Company, together with a written notice specifying the names and denominations in which new Warrants are to be issued, signed by
the Holder or its agent or attorney. Subject to compliance with Section 4(a), as to any transfer which may be involved in such division
or combination, the Company shall execute and deliver a new Warrant or Warrants in exchange for the Warrant or Warrants to be divided
or combined in accordance with such notice. All Warrants issued on transfers or exchanges shall be dated the Initial Exercise Date and
shall be identical with this Warrant except as to the number of Warrant Shares issuable pursuant thereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)
<U>Warrant Register</U>. The Company shall register this Warrant, upon records to be maintained by the Company for that purpose (the
&ldquo;<U>Warrant Register</U>&rdquo;), in the name of the record Holder hereof from time to time. The Company may deem and treat the
registered Holder of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder,
and for all other purposes, absent actual notice to the contrary.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)
<U>Transfer Restrictions</U>. If, at the time of the surrender of this Warrant in connection with any transfer of this Warrant, the transfer
of this Warrant shall not be either (i) registered pursuant to an effective registration statement under the Securities Act and under
applicable state securities or blue sky laws or (ii) eligible for resale without volume or manner-of-sale restrictions or current public
information requirements pursuant to Rule 144, the Company may require, as a condition of allowing such transfer, that the Holder or
transferee of this Warrant, as the case may be, comply with the provisions of Section 5.7 of the Purchase Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">e)
<U>Representation by the Holder</U>. The Holder, by the acceptance hereof, represents and warrants that it is acquiring this Warrant
and, upon any exercise hereof, will acquire the Warrant Shares issuable upon such exercise, for its own account and not with a view to
or for distributing or reselling such Warrant Shares or any part thereof in violation of the Securities Act or any applicable state securities
law, except pursuant to sales registered or exempted under the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section
5</U>. <U>Miscellaneous</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)
<U>No Rights as Stockholder Until Exercise; No Settlement in Cash</U>. This Warrant does not entitle the Holder to any voting rights,
dividends or other rights as a stockholder of the Company prior to the exercise hereof as set forth in Section 2(d)(i), except as expressly
set forth in Section 3. Without limiting any rights of a Holder to receive Warrant Shares on a &ldquo;cashless exercise&rdquo; pursuant
to Section 2(c) or to receive cash payments pursuant to Section 2(d)(i) and Section 2(d)(iv) herein, in no event shall the Company be
required to net cash settle an exercise of this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)
<U>Loss, Theft, Destruction or Mutilation of Warrant</U>. The Company covenants that upon receipt by the Company of evidence reasonably
satisfactory to it of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to the Warrant Shares,
and in case of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which, in the case of the Warrant,
shall not include the posting of any bond), and upon surrender and cancellation of such Warrant or stock certificate, if mutilated, the
Company will make and deliver a new Warrant or stock certificate of like tenor and dated as of such cancellation, in lieu of such Warrant
or stock certificate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)
<U>Saturdays, Sundays, Holidays, etc</U>. If the last or appointed day for the taking of any action or the expiration of any right required
or granted herein shall not be a Business Day, then such action may be taken or such right may be exercised on the next succeeding Business
Day.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)
<U>Authorized Shares</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company covenants that, during the period the Warrant is outstanding, it will reserve from its authorized and unissued Common Stock a
sufficient number of shares to provide for the issuance of the Warrant Shares upon the exercise of any purchase rights under this Warrant.
The Company further covenants that its issuance of this Warrant shall constitute full authority to its officers who are charged with
the duty of issuing the necessary Warrant Shares upon the exercise of the purchase rights under this Warrant. The Company will take all
such reasonable action as may be necessary to assure that such Warrant Shares may be issued as provided herein without violation of any
applicable law or regulation, or of any requirements of the Trading Market upon which the Common Stock may be listed. The Company covenants
that all Warrant Shares which may be issued upon the exercise of the purchase rights represented by this Warrant will, upon exercise
of the purchase rights represented by this Warrant and payment for such Warrant Shares in accordance herewith, be duly authorized, validly
issued, fully paid and nonassessable and free from all taxes, liens and charges created by the Company in respect of the issue thereof
(other than taxes in respect of any transfer occurring contemporaneously with such issue).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
and to the extent as waived or consented to by the Holder, the Company shall not by any action, including, without limitation, amending
its certificate of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale
of securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant,
but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such actions as may be necessary
or appropriate to protect the rights of Holder as set forth in this Warrant against impairment. Without limiting the generality of the
foregoing, the Company will (i) not increase the par value of any Warrant Shares above the amount payable therefor upon such exercise
immediately prior to such increase in par value, (ii) take all such action as may be necessary or appropriate in order that the Company
may validly and legally issue fully paid and nonassessable Warrant Shares upon the exercise of this Warrant and (iii) use commercially
reasonable efforts to obtain all such authorizations, exemptions or consents from any public regulatory body having jurisdiction thereof,
as may be, necessary to enable the Company to perform its obligations under this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Before
taking any action which would result in an adjustment in the number of Warrant Shares for which this Warrant is exercisable or in the
Exercise Price, the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary from
any public regulatory body or bodies having jurisdiction thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">e)
<U>Jurisdiction</U>. All questions concerning the construction, validity, enforcement and interpretation of this Warrant shall be determined
in accordance with the provisions of the Purchase Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">f)
<U>Restrictions</U>. The Holder acknowledges that the Warrant Shares acquired upon the exercise of this Warrant, if not registered, and
the Holder does not utilize cashless exercise, will have restrictions upon resale imposed by state and federal securities laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">g)
<U>Nonwaiver and Expenses</U>. No course of dealing or any delay or failure to exercise any right hereunder on the part of Holder shall
operate as a waiver of such right or otherwise prejudice the Holder&rsquo;s rights, powers or remedies. Without limiting any other provision
of this Warrant or the Purchase Agreement, if the Company willfully and knowingly fails to comply with any provision of this Warrant,
which results in any material damages to the Holder, the Company shall pay to the Holder such amounts as shall be sufficient to cover
any costs and expenses including, but not limited to, reasonable attorneys&rsquo; fees, including those of appellate proceedings, incurred
by the Holder in collecting any amounts due pursuant hereto or in otherwise enforcing any of its rights, powers or remedies hereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">h)
<U>Notices</U>. Any notice, request or other document required or permitted to be given or delivered to the Holder by the Company shall
be delivered in accordance with the notice provisions of the Purchase Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">i)
<U>Limitation of Liability</U>. No provision hereof, in the absence of any affirmative action by the Holder to exercise this Warrant
to purchase Warrant Shares, and no enumeration herein of the rights or privileges of the Holder, shall give rise to any liability of
the Holder for the purchase price of any Common Stock or as a stockholder of the Company, whether such liability is asserted by the Company
or by creditors of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">j)
<U>Remedies</U>. The Holder, in addition to being entitled to exercise all rights granted by law, including recovery of damages, will
be entitled to specific performance of its rights under this Warrant. The Company agrees that monetary damages would not be adequate
compensation for any loss incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees to waive and not to
assert the defense in any action for specific performance that a remedy at law would be adequate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">k)
<U>Successors and Assigns</U>. Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby shall
inure to the benefit of and be binding upon the successors and permitted assigns of the Company and the successors and permitted assigns
of Holder. The provisions of this Warrant are intended to be for the benefit of any Holder from time to time of this Warrant and shall
be enforceable by the Holder or holder of Warrant Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">l)
<U>Amendment</U>. This Warrant may be modified or amended or the provisions hereof waived with the written consent of the Company and
the Holder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">m)
<U>Severability</U>. Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective and valid
under applicable law, but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such provision shall
be ineffective to the extent of such prohibition or invalidity, without invalidating the remainder of such provisions or the remaining
provisions of this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">n)
<U>Headings</U>. The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be deemed
a part of this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">********************</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(Signature
Page Follows)</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IN
WITNESS WHEREOF, the Company has caused this Warrant to be executed by its officer thereunto duly authorized as of the date first above
indicated.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>qualigen
                                            theapeutics, inc.</B></FONT></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></P></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 47%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
                                            Michael S. Poirier</I></FONT></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Michael
    S. Poirier</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTICE
OF EXERCISE</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">To:
qualaigen therapeutics, inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)
The undersigned hereby elects to purchase ________ Warrant Shares of the Company pursuant to the terms of the attached Warrant (only
if exercised in full), and tenders herewith payment of the exercise price in full, together with all applicable transfer taxes, if any.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)
Payment shall take the form of (check applicable box):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[
] in lawful money of the United States; or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[
] [if permitted the cancellation of such number of Warrant Shares as is necessary, in accordance with the formula set forth in subsection
2(c), to exercise this Warrant with respect to the maximum number of Warrant Shares purchasable pursuant to the cashless exercise procedure
set forth in subsection 2(c).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)
Please issue said Warrant Shares in the name of the undersigned or in such other name as is specified below:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">_______________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Warrant Shares shall be delivered to the following DWAC Account Number:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">_______________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">_______________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">_______________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)
<U>Accredited Investor</U>. The undersigned is an &ldquo;accredited investor&rdquo; as defined in Regulation D promulgated under the
Securities Act of 1933, as amended.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">[SIGNATURE
OF HOLDER]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
of Investing Entity: ___________________________________________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Signature
of Authorized Signatory of Investing Entity</I>: _____________________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
of Authorized Signatory: _______________________________________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title
of Authorized Signatory: ________________________________________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
___________________________________________________________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>EXHIBIT
B</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">ASSIGNMENT
FORM</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 10.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 10.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(To
assign the foregoing Warrant, execute this form and supply required information. Do not use this form to purchase shares.)</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 10.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 10.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">FOR
VALUE RECEIVED, the foregoing Warrant and all rights evidenced thereby are hereby assigned to</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 10%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Please
    Print)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Please
    Print)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phone
    Number:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email
    Address:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated:
_______________ __, ______ &nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Holder&rsquo;s
Signature: <U>_____________________</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Holder&rsquo;s
Address: <U>_____________________</U></FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 14; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>3
<FILENAME>ex10-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
10.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SECURITIES
PURCHASE AGREEMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Securities Purchase Agreement (this &ldquo;<U>Agreement</U>&rdquo;) is dated as of December 21, 2022, between Qualigen Therapeutics,
Inc., a Delaware corporation (the &ldquo;<U>Company</U>&rdquo;), and each purchaser identified on the signature pages hereto (each, including
its successors and assigns, a &ldquo;<U>Purchaser</U>&rdquo; and collectively, the &ldquo;<U>Purchasers</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">WHEREAS,
subject to the terms and conditions set forth in this Agreement and pursuant to Section 4(a)(2) of the Securities Act (as defined below),
the Company desires to issue and sell to each Purchaser, and each Purchaser, severally and not jointly, desires to purchase from the
Company, securities of the Company as more fully described in this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOW,
THEREFORE, IN CONSIDERATION of the mutual covenants contained in this Agreement, and for other good and valuable consideration, the receipt
and adequacy of which are hereby acknowledged, the Company and each Purchaser agree as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ARTICLE
I.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>DEFINITIONS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.1
<U>Definitions</U>. In addition to the terms defined elsewhere in this Agreement: (a) capitalized terms that are not otherwise defined
herein have the meanings given to such terms in the Debentures (as defined herein), and (b) the following terms have the meanings set
forth in this Section 1.1:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Acquiring
Person</U>&rdquo; shall have the meaning ascribed to such term in Section 4.7.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Action</U>&rdquo;
shall have the meaning ascribed to such term in Section 3.1(j).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Affiliate</U>&rdquo;
means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common control
with a Person, as such terms are used in and construed under Rule 405 under the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Board
of Directors</U>&rdquo; means the board of directors of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Business
Day</U>&rdquo; means any day other than Saturday, Sunday or other day on which commercial banks in The City of New York are authorized
or required by law to remain closed; <U>provided</U>, <U>however</U>, for clarification, commercial banks shall not be deemed to be authorized
or required by law to remain closed due to &ldquo;stay at home&rdquo;, &ldquo;shelter-in-place&rdquo;, &ldquo;non-essential employee&rdquo;
or any other similar orders or restrictions or the closure of any physical branch locations at the direction of any governmental authority
so long as the electronic funds transfer systems (including for wire transfers) of commercial banks in The City of New York are generally
open for use by customers on such day.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Closing</U>&rdquo;
means the closing of the purchase and sale of the Securities pursuant to Section 2.1.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Closing
Date</U>&rdquo; means the Trading Day on which all of the Transaction Documents have been executed and delivered by the applicable parties
thereto, and all conditions precedent to (i) the Purchasers&rsquo; obligations to pay the Subscription Amount and (ii) the Company&rsquo;s
obligations to deliver the Securities, in each case, have been satisfied or waived.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Commission</U>&rdquo;
means the United States Securities and Exchange Commission.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Common
Stock</U>&rdquo; means the common stock of the Company, par value $0.001 per share, and any other class of securities into which such
securities may hereafter be reclassified or changed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Common
Stock Equivalents</U>&rdquo; means any securities of the Company or the Subsidiaries which would entitle the holder thereof to acquire
at any time Common Stock, including, without limitation, any debt, preferred stock, right, option, warrant or other instrument that is
at any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive, Common Stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Company
Counsel</U>&rdquo; means Reed Smith LLP, with offices located at 599 Lexington Avenue, New York, New York 10022.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Conversion
Price</U>&rdquo; shall have the meaning ascribed to such term in the Debentures.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Conversion
Shares</U>&rdquo; shall have the meaning ascribed to such term in the Debentures.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Debentures</U>&rdquo;
means the 8% Senior Convertible Debentures due, subject to the terms therein, 36 months from their date of issuance, issued by the Company
to the Purchasers hereunder, in the form of <U>Exhibit A</U> attached hereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Disclosure
Schedules</U>&rdquo; shall have the meaning ascribed to such term in Section 3.1.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Disclosure
Time</U>&rdquo; means, (i) if this Agreement is signed on a day that is not a Trading Day or after 9:00 a.m. (New York City time) and
before midnight (New York City time) on any Trading Day, 9:01 a.m. (New York City time) on the Trading Day immediately following the
date hereof and (ii) if this Agreement is signed between midnight (New York City time) and 9:00 a.m. (New York City time) on any Trading
Day, no later than 9:01 a.m. (New York City time) on the date hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>EGS</U>&rdquo;
means Ellenoff Grossman &amp; Schole LLP, with offices located at 1345 Avenue of the Americas, New York, New York 10105-0302.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Effective
Date</U>&rdquo; means the earliest of the date that (a) the initial Registration Statement has been declared effective by the Commission,
(b) all of the Underlying Shares have been sold pursuant to Rule 144 or may be sold pursuant to Rule 144 without the requirement for
the Company to be in compliance with the current public information required under Rule 144 and without volume or manner-of-sale restrictions,
(c) following the one year anniversary of the Closing Date provided that a holder of the Underlying Shares is not an Affiliate of the
Company or (d) all of the Underlying Shares may be sold pursuant to an exemption from registration under Section 4(a)(1) of the Securities
Act without volume or manner-of-sale restrictions and Company Counsel has delivered to such holders a standing written unqualified opinion
that resales may then be made by such holders of the Underlying Shares pursuant to such exemption which opinion shall be in form and
substance reasonably acceptable to such holders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Evaluation
Date</U>&rdquo; shall have the meaning ascribed to such term in Section 3.1(s).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Exchange
Act</U>&rdquo; means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Exempt
Issuance</U>&rdquo; means the issuance of (a) shares of Common Stock or options issued to employees, officers or directors of the Company
pursuant to any stock or option plan duly adopted for such purpose, by a majority of the non-employee members of the Board of Directors
or a majority of the members of a committee of non-employee directors established for such purpose for services rendered to the Company,
(b) securities issued upon the exercise or exchange of or conversion of any Securities issued hereunder and/or other securities exercisable
or exchangeable for or convertible into shares of Common Stock issued and outstanding on the date of this Agreement, provided that such
securities have not been amended since the date of this Agreement to increase the number of such securities or to decrease the exercise
price, exchange price or conversion price of such securities (other than in connection with stock splits or combinations) or to extend
the term of such securities, (c) unregistered securities issued in exchange for services provided to the Company or its Subsidiaries,
so long as the value of the securities issued does not exceed $200,000 for any one service provider or $500,000 in the aggregate, and
(d) securities issued pursuant to acquisitions or strategic transactions approved by a majority of the disinterested directors of the
Company, provided that any such issuance shall only be to a Person (or to the equityholders of a Person) which is, itself or through
its subsidiaries, an operating company or an owner of an asset in a business synergistic with the business of the Company and shall provide
to the Company additional benefits in addition to the investment of funds, but shall not include a transaction in which the Company is
issuing securities primarily for the purpose of raising capital or to an entity whose primary business is investing in securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>FCPA</U>&rdquo;
means the Foreign Corrupt Practices Act of 1977, as amended.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>FDA</U>&rdquo;
shall have the meaning ascribed to such term in Section 3.1(ll).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>FDCA</U>&rdquo;
shall have the meaning ascribed to such term in Section 3.1(ll).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>GAAP</U>&rdquo;
shall have the meaning ascribed to such term in Section 3.1(h).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Indebtedness</U>&rdquo;
shall have the meaning ascribed to such term in Section 3.1(bb).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Intellectual
Property Rights</U>&rdquo; shall have the meaning ascribed to such term in Section 3.1(p).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Legend
Removal Date</U>&rdquo; shall have the meaning ascribed to such term in Section 4.1(c).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Liens</U>&rdquo;
means a lien, charge, pledge, security interest, encumbrance, right of first refusal, preemptive right or other restriction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Material
Adverse Effect</U>&rdquo; shall have the meaning assigned to such term in Section 3.1(n).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Material
Permits</U>&rdquo; shall have the meaning ascribed to such term in Section 3.1(m).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Maximum
Rate</U>&rdquo; shall have the meaning ascribed to such term in Section 5.17.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Participation
Maximum</U>&rdquo; shall have the meaning ascribed to such term in Section 4.12(a).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Person</U>&rdquo;
means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability
company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Pharmaceutical
Product</U>&rdquo; shall have the meaning ascribed to such term in Section 3.1(ll).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Pre-Notice</U>&rdquo;
shall have the meaning ascribed to such term in Section 4.12(b).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Principal
Amount</U>&rdquo; means, as to each Purchaser, the amounts set forth below such Purchaser&rsquo;s signature block on the signature pages
hereto next to the heading &ldquo;Principal Amount,&rdquo; in United States Dollars, which shall equal such Purchaser&rsquo;s Subscription
Amount multiplied by 1.10.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Pro
Rata Portion</U>&rdquo; shall have the meaning ascribed to such term in Section 4.12(e).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Proceeding</U>&rdquo;
means an action, claim, suit, investigation or proceeding (including, without limitation, an informal investigation or partial proceeding,
such as a deposition), whether commenced or threatened.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Public
Information Failure</U>&rdquo; shall have the meaning ascribed to such term in Section 4.3(b).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Public
Information Failure Payments</U>&rdquo; shall have the meaning ascribed to such term in Section 4.3(b).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Purchaser
Party</U>&rdquo; shall have the meaning ascribed to such term in Section 4.10.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Registration
Rights Agreement</U>&rdquo; means the Registration Rights Agreement, dated on or about the date hereof, among the Company and the Purchasers,
in the form of <U>Exhibit B</U> attached hereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Registration
Statement</U>&rdquo; means a registration statement meeting the requirements set forth in the Registration Rights Agreement and covering
the resale of the Underlying Shares by each Purchaser as provided for in the Registration Rights Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Required
Approvals</U>&rdquo; shall have the meaning ascribed to such term in Section 3.1(e).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Required
Minimum</U>&rdquo; means, as of any date, the maximum aggregate number of shares of Common Stock then issued or potentially issuable
in the future pursuant to the Transaction Documents, including any Underlying Shares issuable upon exercise in full of all Warrants or
conversion in full of all Debentures, ignoring any conversion or exercise limits set forth therein, and assuming that the Conversion
Price is at all times on and after the date of determination 75% of the then Conversion Price on the Trading Day immediately prior to
the date of determination.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Rule
144</U>&rdquo; means Rule 144 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended from time to
time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same effect as such Rule.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Rule
424</U>&rdquo; means Rule 424 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended or interpreted
from time to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same purpose and effect
as such Rule.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>SEC
Reports</U>&rdquo; shall have the meaning ascribed to such term in Section 3.1(h).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Securities</U>&rdquo;
means the Debentures, the Warrants, the Warrant Shares and the Underlying Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Securities
Act</U>&rdquo; means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Shareholder
Approval</U>&rdquo; means such approval as may be required by the applicable rules and regulations of the Nasdaq Stock Market (or any
successor entity) from the shareholders of the Company with respect to the transactions contemplated by the Transaction Documents, including
the issuance of all of the Underlying Shares in excess of 19.99% of the issued and outstanding Common Stock on the Closing Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Short
Sales</U>&rdquo; means all &ldquo;short sales&rdquo; as defined in Rule 200 of Regulation SHO under the Exchange Act (but shall not be
deemed to include locating and/or borrowing shares of Common Stock).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Subscription
Amount</U>&rdquo; means, as to each Purchaser, the aggregate amount to be paid for Debentures and Warrants purchased hereunder as specified
below such Purchaser&rsquo;s name on the signature page of this Agreement and next to the heading &ldquo;Subscription Amount,&rdquo;
in United States dollars and in immediately available funds.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Subsequent
Financing</U>&rdquo; shall have the meaning ascribed to such term in Section 4.12(a).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Subsequent
Financing Notice</U>&rdquo; shall have the meaning ascribed to such term in Section 4.12(b).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Subsidiary</U>&rdquo;
means any subsidiary of the Company as set forth on <U>Schedule 3.1(a)</U> and shall, where applicable, also include any direct or indirect
subsidiary of the Company formed or acquired after the date hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Subsidiary
Guarantee</U>&rdquo; means the Subsidiary Guarantee, dated the date hereof, by Qualigen, Inc. in favor of the Purchasers, in the form
of <U>Exhibit F</U> attached hereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Trading
Day</U>&rdquo; means a day on which the principal Trading Market is open for trading.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Trading
Market</U>&rdquo; means any of the following markets or exchanges on which the Common Stock is listed or quoted for trading on the date
in question: the NYSE American, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market, the New York Stock
Exchange, the Pink Open Market, OTCQB or the OTCQX (or any successors to any of the foregoing).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Transaction
Documents</U>&rdquo; means this Agreement, the Debentures, the Warrants, the Registration Rights Agreement, the Subsidiary Guarantee,
all exhibits and schedules thereto and hereto and any other documents or agreements executed in connection with the transactions contemplated
hereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Transfer
Agent</U>&rdquo; means EQ Shareowner Services, the current transfer agent of the Company, with a mailing address of 1110 Centre Point
Curve, Suite 101, Mendota Heights, MN 55120-4101, and any successor transfer agent of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Underlying
Shares</U>&rdquo; means the Warrant Shares and shares of Common Stock issued and issuable pursuant to the terms of the Debenture, including
without limitation, shares of Common Stock issued and issuable in lieu of the cash payment of interest on the Debentures in accordance
with the terms of the Debentures, in each case without respect to any limitation or restriction on the conversion of the Debentures or
the exercise of the Warrants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Variable
Rate Transaction</U>&rdquo; shall have the meaning ascribed to such term in Section 4.13(b).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>VWAP</U>&rdquo;
means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed
or quoted on a Trading Market, the daily volume weighted average price of the Common Stock for such date (or the nearest preceding date)
on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based on a Trading Day from 9:30
a.m. (New York City time) to 4:02 p.m. (New York City time)), (b) if OTCQB or OTCQX is not a Trading Market, the volume weighted average
price of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Stock is not
then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported on the Pink Open Market (or
a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of the Common
Stock so reported, or (d) in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser
selected in good faith by the Purchasers of a majority in interest of the Securities then outstanding and reasonably acceptable to the
Company, the reasonable, actual and documented fees and expenses of which shall be paid by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Warrants</U>&rdquo;
means, collectively, the Common Stock purchase warrants delivered to the Purchasers at the Closing in accordance with Section 2.2(a)
hereof, which Warrants shall be exercisable six months after the Closing Date and have a term of exercise equal to 5 years, in the form
of <U>Exhibit C</U> attached hereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Warrant
Shares</U>&rdquo; means the shares of Common Stock issuable upon exercise of the Warrants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ARTICLE
II.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PURCHASE
AND SALE</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.1
<U>Closing</U>. On the Closing Date, upon the terms and subject to the conditions set forth herein, substantially concurrent with the
execution and delivery of this Agreement by the parties hereto, the Company agrees to sell, and the Purchasers, severally and not jointly,
agree to purchase, an aggregate of $3,300,000 in principal amount of the Debentures. Each Purchaser shall deliver to the Company via
wire transfer immediately available funds equal to such Purchaser&rsquo;s Subscription Amount as set forth on the signature page hereto
executed by such Purchaser, and the Company shall deliver to each Purchaser its respective Debenture and a Warrant, as determined pursuant
to Section 2.2(a), and the Company and each Purchaser shall deliver the other items set forth in Section 2.2 deliverable at the Closing.
Upon satisfaction of the covenants and conditions set forth in Sections 2.2 and 2.3, the Closing shall take place remotely by electronic
transfer of the Closing documentation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.2
<U>Deliveries</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
On or prior to the Closing Date, the Company shall deliver or cause to be delivered to each Purchaser the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
this Agreement duly executed by the Company;</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
a legal opinion of Company Counsel, substantially in the form of <U>Exhibit D</U> attached hereto;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)
a Debenture with a principal amount equal to such Purchaser&rsquo;s Subscription Amount, registered in the name of such Purchaser;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)
a Warrant registered in the name of such Purchaser to purchase up to a number of shares of Common Stock equal to 100% of such Purchaser&rsquo;s
Conversion Shares on the Closing Date, with an exercise price equal to the initial Conversion Price, subject to adjustment therein;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v)
the Company shall have provided each Purchaser with the Company&rsquo;s wire instructions, on Company letterhead and executed by the
Chief Executive Officer or Chief Financial Officer or other authorized officers of the Company; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(vi)
the Registration Rights Agreement duly executed by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
On or prior to the Closing Date, each Purchaser shall deliver or cause to be delivered to the Company, the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
this Agreement duly executed by such Purchaser;</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
such Purchaser&rsquo;s Subscription Amount by wire transfer to the account specified in writing by the Company; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)
the Registration Rights Agreement duly executed by such Purchaser.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.3
<U>Closing Conditions</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
The obligations of the Company hereunder in connection with the Closing are subject to the following conditions being met:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
the accuracy in all material respects (or, to the extent representations or warranties are qualified by materiality, in all respects)
on the Closing Date of the representations and warranties of the Purchasers contained herein (unless as of a specific date therein in
which case they shall be accurate in all material respects (or, to the extent representations or warranties are qualified by materiality,
in all respects) as of such date);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
all obligations, covenants and agreements of each Purchaser required to be performed at or prior to the Closing Date shall have been
performed; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)
the delivery by each Purchaser of the items set forth in Section 2.2(b) of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
The respective obligations of the Purchasers hereunder in connection with the Closing are subject to the following conditions being met:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
the accuracy in all material respects (or, to the extent representations or warranties are qualified by materiality or Material Adverse
Effect, in all respects) when made and on the Closing Date of the representations and warranties of the Company contained herein (unless
as of a specific date therein in which case they shall be accurate in all material respects or, to the extent representations or warranties
are qualified by materiality or Material Adverse Effects, in all respects) as of such date);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
all obligations, covenants and agreements of the Company required to be performed at or prior to the Closing Date shall have been performed;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)
the delivery by the Company of the items set forth in Section 2.2(a) of this Agreement;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)
there shall have been no Material Adverse Effect with respect to the Company since the date hereof;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v)
from the date hereof to the Closing Date, trading in the Common Stock shall not have been suspended by the Commission or the Company&rsquo;s
principal Trading Market and, at any time prior to the Closing Date, trading in securities generally as reported by Bloomberg L.P. shall
not have been suspended or limited, or minimum prices shall not have been established on securities whose trades are reported by such
service, or on any Trading Market, nor shall a banking moratorium have been declared either by the United States or New York State authorities
nor shall there have occurred any material outbreak or escalation of hostilities or other national or international calamity of such
magnitude in its effect on, or any material adverse change in, any financial market which, in each case, in the reasonable judgment of
such Purchaser, makes it impracticable or inadvisable to purchase the Securities at the Closing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ARTICLE
III.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>REPRESENTATIONS
AND WARRANTIES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1
<U>Representations and Warranties of the Company</U>. Except as set forth in the Disclosure Schedules, which Disclosure Schedules shall
be deemed a part hereof and shall qualify any representation or otherwise made herein to the extent of the disclosure contained in the
corresponding section of the Disclosure Schedules, the Company hereby makes the following representations and warranties to each Purchaser:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
<U>Subsidiaries</U>. All of the direct and indirect subsidiaries of the Company are set forth on <U>Schedule 3.1(a)</U>. The Company
owns, directly or indirectly, all of the capital stock or other equity interests of each Subsidiary as described on <U>Schedule 3.1(a)
</U>free and clear of any Liens, and all of the issued and outstanding shares of capital stock of each Subsidiary are validly issued
and are fully paid, non-assessable and free of preemptive and similar rights to subscribe for or purchase securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
<U>Organization and Qualification</U>. The Company and each of the Subsidiaries is an entity duly incorporated or otherwise organized,
validly existing and in good standing under the laws of the jurisdiction of its incorporation or organization, with the requisite power
and authority to own and use its properties and assets and to carry on its business as currently conducted. Neither the Company nor any
Subsidiary is in violation nor default of any of the provisions of its respective certificate or articles of incorporation, bylaws or
other organizational or charter documents. Each of the Company and the Subsidiaries is duly qualified to conduct business and is in good
standing as a foreign corporation or other entity in each jurisdiction in which the nature of the business conducted or property owned
by it makes such qualification necessary, except where the failure to be so qualified or in good standing, as the case may be, could
not have or reasonably be expected to result in: (i) a material adverse effect on the legality, validity or enforceability of any Transaction
Document, (ii) a material adverse effect on the results of operations, assets, business, prospects or condition (financial or otherwise)
of the Company and the Subsidiaries, taken as a whole, or (iii) a material adverse effect on the Company&rsquo;s ability to perform in
any material respect on a timely basis its obligations under any Transaction Document (any of (i), (ii) or (iii), a &ldquo;<U>Material
Adverse Effect</U>&rdquo;) and no Proceeding has been instituted in any such jurisdiction revoking, limiting or curtailing or seeking
to revoke, limit or curtail such power and authority or qualification.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
<U>Authorization; Enforcement</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
The Company has the requisite corporate power and authority to enter into and to consummate the transactions contemplated by this Agreement
and each of the other Transaction Documents and otherwise to carry out its obligations hereunder and thereunder. The execution and delivery
of this Agreement and each of the other Transaction Documents by the Company and the consummation by it of the transactions contemplated
hereby and thereby have been duly authorized by all necessary action on the part of the Company and no further action is required by
the Company, the Board of Directors or the Company&rsquo;s stockholders in connection herewith or therewith other than in connection
with the Required Approvals. This Agreement and each other Transaction Document to which the Company is a party has been (or upon delivery
will have been) duly executed by the Company and, when delivered in accordance with the terms hereof and thereof, will constitute the
valid and binding obligation of the Company enforceable against the Company in accordance with its terms, except (i) as limited by general
equitable principles and applicable bankruptcy, insolvency, reorganization, moratorium and other laws of general application affecting
enforcement of creditors&rsquo; rights generally, (ii) as limited by laws relating to the availability of specific performance, injunctive
relief or other equitable remedies and (iii) insofar as indemnification and contribution provisions may be limited by applicable law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
With respect to the Subsidiary Guarantee, Qualigen, Inc. has the requisite corporate power and authority to enter into and to consummate
the transactions contemplated by such agreement and otherwise to carry out its obligations thereunder. The execution and delivery of
the Subsidiary Guarantee and the consummation by Qualigen, Inc. of the transactions contemplated thereby have been duly authorized by
all necessary action on its part, and no further action is required by Qualigen, Inc., or its board of directors or stockholders in connection
therewith. The Subsidiary Guarantee has been (or upon delivery will have been) duly executed by Qualigen, Inc. and, when delivered in
accordance with the terms thereof, will constitute the valid and binding obligation of Qualigen, Inc. enforceable against Qualigen, Inc.
in accordance with its terms, except (A) as listed by general equitable principals and applicable bankruptcy, insolvency, reorganization,
moratorium and other laws of general application affecting enforcement of creditors&rsquo; rights generally, (B) as limited by laws relating
to the availability of specific performance, injunctive relief or other equitable remedies and (C) insofar as indemnification and contribution
provisions may be limited by applicable law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
<U>No Conflicts</U>. The execution, delivery and performance by the Company of this Agreement and the other Transaction Documents to
which it is a party, the issuance and sale of the Securities and the consummation by it of the transactions contemplated hereby and thereby
do not and will not (i) conflict with or violate any provision of the Company&rsquo;s or any Subsidiary&rsquo;s certificate or articles
of incorporation, bylaws or other organizational or charter documents, (ii) conflict with, or constitute a default (or an event that
with notice or lapse of time or both would become a default) under, result in the creation of any Lien upon any of the properties or
assets of the Company or any Subsidiary, or give to others any rights of termination, amendment, anti-dilution or similar adjustments,
acceleration or cancellation (with or without notice, lapse of time or both) of, any agreement, credit facility, debt or other instrument
(evidencing a Company or Subsidiary debt or otherwise) or other understanding to which the Company or any Subsidiary is a party or by
which any property or asset of the Company or any Subsidiary is bound or affected, or (iii) subject to the Required Approvals, conflict
with or result in a violation of any law, rule, regulation, order, judgment, injunction, decree or other restriction of any court or
governmental authority to which the Company or a Subsidiary is subject (including federal and state securities laws and regulations),
or by which any property or asset of the Company or a Subsidiary is bound or affected; except in the case of each of clauses (ii) and
(iii), such as would not reasonably be expected to result in a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)
<U>Filings, Consents and Approvals</U>. The Company is not required to obtain any consent, waiver, authorization or order of, give any
notice to, or make any filing or registration with, any court or other federal, state, local or other governmental authority or other
Person in connection with the execution, delivery and performance by the Company of the Transaction Documents, other than: (i) the filings
required pursuant to Section 4.6 of this Agreement, (ii) the filing with the Commission pursuant to the Registration Rights Agreement,
(iii) the notice and/or application(s) to each applicable Trading Market for the issuance and sale of the Securities and the listing
of the Conversion Shares and Warrant Shares for trading thereon in the time and manner required thereby, (iv) any filings required to
be made under applicable state securities laws and (v) Shareholder Approval (collectively, the &ldquo;<U>Required Approvals</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)
<U>Issuance of the Securities</U>. The Securities are duly authorized and, when issued and paid for in accordance with the applicable
Transaction Documents, will be duly and validly issued, fully paid and nonassessable, free and clear of all Liens imposed by the Company
other than restrictions on transfer provided for in the Transaction Documents. The Underlying Shares, when issued in accordance with
the terms of the Transaction Documents, will be validly issued, fully paid and nonassessable, free and clear of all Liens imposed by
the Company other than restrictions on transfer provided for in the Transaction Documents. The Company has reserved from its duly authorized
capital stock a number of shares of Common Stock for issuance of the Underlying Shares at least equal to the Required Minimum on the
date hereof. The board of directors of the Company has reserved 2,554,184_ shares available under its effective shelf registration on
Form S-3, File No. 333-266430 (the &ldquo;Form S-3&rdquo;) for issuance of Underlying Shares, and the Company shall file as soon as reasonably
practicable after the Closing Date a prospectus supplement to the Form S-3 registering the issuance of such Underlying Shares as permitted
under Instruction I.B.6 of Form S-3.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)
<U>Capitalization</U>. The capitalization of the Company as of the date hereof is as set forth on <U>Schedule 3.1(g)</U>, which <U>Schedule
3.1(g)</U> shall also include the number of shares of Common Stock owned beneficially, and of record, by Affiliates of the Company as
of the date hereof. The Company has not issued any capital stock since its most recently filed periodic report under the Exchange Act,
other than pursuant to the exercise of employee stock options under the Company&rsquo;s stock option plans, the issuance of shares of
Common Stock to employees pursuant to the Company&rsquo;s employee stock purchase plans and pursuant to the conversion and/or exercise
of Common Stock Equivalents outstanding as of the date of the most recently filed periodic report under the Exchange Act. No Person has
any right of first refusal, preemptive right, right of participation, or any similar right to participate in the transactions contemplated
by the Transaction Documents. Except as set forth on <U>Schedule 3.1(g)</U> or as a result of the purchase and sale of the Securities,
there are no outstanding options, warrants, scrip rights to subscribe to, calls or commitments of any character whatsoever relating to,
or securities, rights or obligations convertible into or exercisable or exchangeable for, or giving any Person any right to subscribe
for or acquire, any shares of Common Stock or the capital stock of the Company, or contracts, commitments, understandings or arrangements
by which the Company is or may become bound to issue additional shares of Common Stock or Common Stock Equivalents or capital stock.
The issuance and sale of the Securities will not obligate the Company or any Subsidiary to issue shares of Common Stock or other securities
to any Person (other than the Purchasers). Except as set forth on <U>Schedule 3.1(g)</U>, there are no outstanding securities or instruments
of the Company with any provision that adjusts the exercise, conversion, exchange or reset price of such security or instrument upon
an issuance of securities by the Company. There are no outstanding securities or instruments of the Company that contain any redemption
or similar provisions, and there are no contracts, commitments, understandings or arrangements by which the Company is or may become
bound to redeem a security of the Company. The Company does not have any stock appreciation rights or &ldquo;phantom stock&rdquo; plans
or agreements or any similar plan or agreement. All of the outstanding shares of capital stock of the Company are duly authorized, validly
issued, fully paid and nonassessable, have been issued in compliance with all federal and state securities laws, and none of such outstanding
shares was issued in violation of any preemptive rights or similar rights to subscribe for or purchase securities. No further approval
or authorization of any stockholder, the Board of Directors or others is required for the issuance and sale of the Securities other than
the Shareholder Approval. There are no stockholders agreements, voting agreements or other similar agreements with respect to the Company&rsquo;s
capital stock to which the Company is a party or, to the knowledge of the Company, between or among any of the Company&rsquo;s stockholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)
<U>SEC Reports; Financial Statements</U>. The Company has filed all reports, schedules, forms, statements and other documents required
to be filed by the Company under the Securities Act and the Exchange Act, including pursuant to Section 13(a) or 15(d) thereof, for the
two years preceding the date hereof (or such shorter period as the Company was required by law or regulation to file such material) (the
foregoing materials, including the exhibits thereto and documents incorporated by reference therein, being collectively referred to herein
as the &ldquo;<U>SEC Reports</U>&rdquo;) on a timely basis or has received a valid extension of such time of filing and has filed any
such SEC Reports prior to the expiration of any such extension, except where the failure to so file has not and could not reasonably
be expected to result in a Material Adverse Effect. As of their respective dates, the SEC Reports complied in all material respects with
the requirements of the Securities Act and the Exchange Act, as applicable, and none of the SEC Reports, when filed, contained any untrue
statement of a material fact or omitted to state a material fact required to be stated therein or necessary in order to make the statements
therein, in the light of the circumstances under which they were made, not misleading. The Company has never been an issuer subject to
Rule 144(i) under the Securities Act. The financial statements of the Company included in the SEC Reports comply in all material respects
with applicable accounting requirements and the rules and regulations of the Commission with respect thereto as in effect at the time
of filing. Such financial statements have been prepared in accordance with United States generally accepted accounting principles applied
on a consistent basis during the periods involved (&ldquo;<U>GAAP</U>&rdquo;), except as may be otherwise specified in such financial
statements or the notes thereto and except that unaudited financial statements may not contain all footnotes required by GAAP, and fairly
present in all material respects the financial position of the Company and its consolidated Subsidiaries as of and for the dates thereof
and the results of operations and cash flows for the periods then ended, subject, in the case of unaudited statements, to normal, immaterial,
year-end audit adjustments.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
<U>Material Changes; Undisclosed Events, Liabilities or Developments</U>. Since the date of the latest audited financial statements included
within the SEC Reports, except as specifically disclosed in a subsequent SEC Report filed prior to the date hereof or as set forth on
<U>Schedule 3.1(i)</U>, (i) there has been no event, occurrence or development that has had or that would reasonably be expected to result
in a Material Adverse Effect, (ii) the Company has not incurred any liabilities (contingent or otherwise) other than (A) trade payables
and accrued expenses incurred in the ordinary course of business consistent with past practice and (B) liabilities not required to be
reflected in the Company&rsquo;s financial statements pursuant to GAAP or disclosed in filings made with the Commission, (iii) the Company
has not altered its method of accounting, (iv) the Company has not declared or made any dividend or distribution of cash or other property
to its stockholders or purchased, redeemed or made any agreements to purchase or redeem any shares of its capital stock and (v) the Company
has not issued any equity securities to any officer, director or Affiliate, except pursuant to existing Company stock option plans. The
Company does not have pending before the Commission any request for confidential treatment of information. Except for the issuance of
the Securities contemplated by this Agreement or as set forth on <U>Schedule 3.1(i)</U>, no event, liability, fact, circumstance, occurrence
or development has occurred or exists or is reasonably expected to occur or exist with respect to the Company or its Subsidiaries or
their respective businesses, prospects, properties, operations, assets or financial condition, that would be required to be disclosed
by the Company under applicable securities laws at the time this representation is made or deemed made that has not been publicly disclosed
at least 1 Trading Day prior to the date that this representation is made.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(j)
<U>Litigation</U>. Except as set forth on <U>Schedule 3.1(j)</U>, there is no action, suit, inquiry, notice of violation, proceeding
or investigation pending or, to the knowledge of the Company, threatened against or affecting the Company, any Subsidiary or any of their
respective properties before or by any court, arbitrator, governmental or administrative agency or regulatory authority (federal, state,
county, local or foreign) (collectively, an &ldquo;<U>Action</U>&rdquo;). None of the Actions set forth on <U>Schedule 3.1(j)</U>, (i)
adversely affects or challenges the legality, validity or enforceability of any of the Transaction Documents or the Securities or (ii)
would, if there were an unfavorable decision, have or reasonably be expected to result in a Material Adverse Effect. Neither the Company
nor any Subsidiary, nor any director or officer thereof, is or has been the subject of any Action involving a claim of violation of or
liability under federal or state securities laws or a claim of breach of fiduciary duty. There has not been, and to the knowledge of
the Company, there is not pending or contemplated, any investigation by the Commission involving the Company or any current or former
director or officer of the Company. The Commission has not issued any stop order or other order suspending the effectiveness of any registration
statement filed by the Company or any Subsidiary under the Exchange Act or the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(k)
<U>Labor Relations</U>. No labor dispute exists or, to the knowledge of the Company, is imminent with respect to any of the employees
of the Company, which would reasonably be expected to result in a Material Adverse Effect. None of the Company&rsquo;s or its Subsidiaries&rsquo;
employees is a member of a union that relates to such employee&rsquo;s relationship with the Company or such Subsidiary, and neither
the Company nor any of its Subsidiaries is a party to a collective bargaining agreement, and the Company and its Subsidiaries believe
that their relationships with their employees are good. To the knowledge of the Company, no executive officer of the Company or any Subsidiary,
is, or is now expected to be, in violation of any material term of any employment contract, confidentiality, disclosure or proprietary
information agreement or non-competition agreement, or any other contract or agreement or any restrictive covenant in favor of any third
party, and the continued employment of each such executive officer does not subject the Company or any of its Subsidiaries to any liability
with respect to any of the foregoing matters. The Company and its Subsidiaries are in compliance with all U.S. federal, state, local
and foreign laws and regulations relating to employment and employment practices, terms and conditions of employment and wages and hours,
except where the failure to be in compliance would not, individually or in the aggregate, reasonably be expected to have a Material Adverse
Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(l)
<U>Compliance</U>. Neither the Company nor any Subsidiary: (i) is in default under or in violation of (and no event has occurred that
has not been waived that, with notice or lapse of time or both, would result in a default by the Company or any Subsidiary under), nor
has the Company or any Subsidiary received notice of a claim that it is in default under or that it is in violation of, any indenture,
loan or credit agreement or any other agreement or instrument to which it is a party or by which it or any of its properties is bound
(whether or not such default or violation has been waived), (ii) is in violation of any judgment, decree or order of any court, arbitrator
or other governmental authority or (iii) is or has been in violation of any statute, rule, ordinance or regulation of any governmental
authority, including without limitation all foreign, federal, state and local laws relating to taxes, environmental protection, occupational
health and safety, product quality and safety and employment and labor matters; except in the case of each of clauses (i), (ii) and (iii)
as would not have or reasonably be expected to result in a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(m)
<U>Environmental Laws</U>. The Company and its Subsidiaries (i) are in compliance with all federal, state, local and foreign laws relating
to pollution or protection of human health or the environment (including ambient air, surface water, groundwater, land surface or subsurface
strata), including laws relating to emissions, discharges, releases or threatened releases of chemicals, pollutants, contaminants, or
toxic or hazardous substances or wastes (collectively, &ldquo;<U>Hazardous Materials</U>&rdquo;) into the environment, or otherwise relating
to the manufacture, processing, distribution, use, treatment, storage, disposal, transport or handling of Hazardous Materials, as well
as all authorizations, codes, decrees, demands, or demand letters, injunctions, judgments, licenses, notices or notice letters, orders,
permits, plans or regulations, issued, entered, promulgated or approved thereunder (&ldquo;<U>Environmental Laws</U>&rdquo;); (ii) have
received all permits licenses or other approvals required of them under applicable Environmental Laws to conduct their respective businesses;
and (iii) are in compliance with all terms and conditions of any such permit, license or approval; except in the case of each of clauses
(i), (ii) and (iii), where the failure to so comply would not reasonably be expected to have, individually or in the aggregate, a Material
Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(n)
<U>Regulatory Permits</U>. The Company and the Subsidiaries possess all certificates, authorizations and permits issued by the appropriate
federal, state, local or foreign regulatory authorities necessary to conduct their respective businesses as described in the SEC Reports
(&ldquo;<U>Material Permits</U>&rdquo;), except where the failure to possess such permits could not reasonably be expected to result
in a Material Adverse Effect, and neither the Company nor any Subsidiary has received any notice of proceedings relating to the revocation
or modification of any Material Permit.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(o)
<U>Title to Assets</U>. The Company and the Subsidiaries have good and marketable title in fee simple to all real property owned by them
and good and marketable title in all personal property owned by them that is material to the business of the Company and the Subsidiaries,
in each case free and clear of all Liens, except for (i) Liens as do not materially affect the value of such property and do not materially
interfere with the use made and proposed to be made of such property by the Company and the Subsidiaries and (ii) Liens for the payment
of federal, state or other taxes, for which appropriate reserves have been made therefor in accordance with GAAP and, the payment of
which is neither delinquent nor subject to penalties. Any real property and facilities held under lease by the Company and the Subsidiaries
are held by them under valid, subsisting and enforceable leases with which the Company and the Subsidiaries are in compliance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(p)
<U>Intellectual Property</U>. The Company and the Subsidiaries have, or have rights to use, all patents, patent applications, trademarks,
trademark applications, service marks, trade names, trade secrets, inventions, copyrights, licenses and other intellectual property rights
and similar rights necessary or required for use in connection with their respective businesses as described in the SEC Reports (collectively,
the &ldquo;<U>Intellectual Property Rights</U>&rdquo;); except where the failure to so have would not reasonably be expected to have
a Material Adverse Effect. None of, and neither the Company nor any Subsidiary has received a notice (written or otherwise) that any
of, the Intellectual Property Rights has expired, terminated or been abandoned, or is expected to expire or terminate or be abandoned,
within two (2) years from the date of this Agreement. Neither the Company nor any Subsidiary has received, since the date of the latest
audited financial statements included within the SEC Reports, a written notice of a claim or otherwise has any knowledge that the Intellectual
Property Rights violate or infringe upon the rights of any Person, except as would not reasonably be expected to have a Material Adverse
Effect. To the knowledge of the Company, all such Intellectual Property Rights are enforceable and there is no existing infringement
by another Person of any of the Intellectual Property Rights. The Company and its Subsidiaries have taken reasonable security measures
to protect the secrecy, confidentiality and value of all of their intellectual properties, except where failure to do so would not, individually
or in the aggregate, reasonably be expected to have a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(q)
<U>Insurance</U>. The Company and the Subsidiaries are insured by insurers of recognized financial responsibility against such losses
and risks and in such amounts as are prudent and customary in the businesses in which the Company and the Subsidiaries are engaged, including,
but not limited to, directors and officers insurance coverage at least equal to the aggregate Subscription Amount. Neither the Company
nor any Subsidiary has any reason to believe that it will not be able to renew its existing insurance coverage as and when such coverage
expires or to obtain similar coverage from similar insurers as may be necessary to continue its business without a significant increase
in cost.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(r)
<U>Transactions with Affiliates and Employees</U>. Except as set forth in the SEC Reports or on <U>Schedule 3.1(r)</U>, none of the officers
or directors of the Company or any Subsidiary and, to the knowledge of the Company, none of the employees of the Company or any Subsidiary
is presently a party to any transaction with the Company or any Subsidiary (other than for services as employees, officers and directors),
including any contract, agreement or other arrangement providing for the furnishing of services to or by, providing for rental of real
or personal property to or from providing for the borrowing of money from or lending of money to, or otherwise requiring payments to
or from any officer, director or such employee or, to the knowledge of the Company, any entity in which any officer, director, or any
such employee has a substantial interest or is an officer, director, trustee, stockholder, member or partner, in each case in excess
of $120,000 other than for (i) payment of salary or consulting fees for services rendered, (ii) reimbursement for expenses incurred on
behalf of the Company and (iii) other employee benefits, including stock option agreements under any stock option plan of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(s)
<U>Sarbanes-Oxley; Internal Accounting Controls</U>. The Company and the Subsidiaries are in compliance with any and all applicable requirements
of the Sarbanes-Oxley Act of 2002, as amended, that are effective as of the date hereof, and any and all applicable rules and regulations
promulgated by the Commission thereunder that are effective as of the date hereof and as of the Closing Date. The Company and the Subsidiaries
maintain a system of internal accounting controls sufficient to provide reasonable assurance that: (i) transactions are executed in accordance
with management&rsquo;s general or specific authorizations, (ii) transactions are recorded as necessary to permit preparation of financial
statements in conformity with GAAP and to maintain asset accountability, (iii) access to assets is permitted only in accordance with
management&rsquo;s general or specific authorization, and (iv) the recorded accountability for assets is compared with the existing assets
at reasonable intervals and appropriate action is taken with respect to any differences. The Company and the Subsidiaries have established
disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the Company and the Subsidiaries and
designed such disclosure controls and procedures to ensure that information required to be disclosed by the Company in the reports it
files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the Commission&rsquo;s
rules and forms. The Company&rsquo;s certifying officers have evaluated the effectiveness of the disclosure controls and procedures of
the Company and the Subsidiaries as of the end of the period covered by the most recently filed periodic report under the Exchange Act
(such date, the &ldquo;<U>Evaluation Date</U>&rdquo;). The Company presented in its most recently filed periodic report under the Exchange
Act the conclusions of the certifying officers about the effectiveness of the disclosure controls and procedures based on their evaluations
as of the Evaluation Date. Since the Evaluation Date, there have been no changes in the internal control over financial reporting (as
such term is defined in the Exchange Act) that have materially affected, or is reasonably likely to materially affect, the internal control
over financial reporting of the Company and its Subsidiaries.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(t)
<U>Certain Fees</U>. No brokerage or finder&rsquo;s fees or commissions are or will be payable by the Company or any Subsidiaries to
any broker, financial advisor or consultant, finder, placement agent, investment banker, bank or other Person with respect to the transactions
contemplated by the Transaction Documents. The Purchasers shall have no obligation with respect to any fees or with respect to any claims
made by or on behalf of other Persons for fees of a type contemplated in this Section that may be due in connection with the transactions
contemplated by the Transaction Documents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(u)
<U>Private Placement</U>. Assuming the accuracy of the Purchasers&rsquo; representations and warranties set forth in Section 3.2, no
registration under the Securities Act is required for the offer and sale of the Securities by the Company to the Purchasers as contemplated
hereby. The issuance and sale of the Securities hereunder does not contravene the rules and regulations of the Trading Market.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v)
<U>Investment Company</U>. The Company is not, and is not an Affiliate of, and immediately after receipt of payment for the Securities,
will not be or be an Affiliate of, an &ldquo;investment company&rdquo; within the meaning of the Investment Company Act of 1940, as amended.
The Company shall conduct its business in a manner so that it will not become an &ldquo;investment company&rdquo; subject to registration
under the Investment Company Act of 1940, as amended.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(w)
<U>Registration Rights</U>. Other than each of the Purchasers, no Person has any right to cause the Company or any Subsidiary to effect
the registration under the Securities Act of any securities of the Company or any Subsidiaries.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(x)
<U>Listing and Maintenance Requirements</U>. The Common Stock is registered pursuant to Section 12(b) or 12(g) of the Exchange Act, and
the Company has taken no action designed to, or which to its knowledge is likely to have the effect of, terminating the registration
of the Common Stock under the Exchange Act nor has the Company received any notification that the Commission is contemplating terminating
such registration. Except as disclosed in the SEC Reports, the Company has not, in the 12 months preceding the date hereof, received
notice from any Trading Market on which the Common Stock is or has been listed or quoted to the effect that the Company is not in compliance
with the listing or maintenance requirements of such Trading Market. The Common Stock is currently eligible for electronic transfer through
the Depository Trust Company or another established clearing corporation and the Company is current in payment of the fees to the Depository
Trust Company (or such other established clearing corporation) in connection with such electronic transfer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(y)
<U>Application of Takeover Protections</U>. The Company and the Board of Directors have taken all necessary action, if any, in order
to render inapplicable any control share acquisition, business combination, poison pill (including any distribution under a rights agreement)
or other similar anti-takeover provision under the Company&rsquo;s certificate of incorporation (or similar charter documents) or the
laws of its state of incorporation that is or could become applicable to the Purchasers as a result of the Purchasers and the Company
fulfilling their obligations or exercising their rights under the Transaction Documents, including without limitation as a result of
the Company&rsquo;s issuance of the Securities and the Purchasers&rsquo; ownership of the Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(z)
<U>Disclosure</U>. Except with respect to the material terms and conditions of the transactions contemplated by the Transaction Documents,
the Company confirms that neither it nor any other Person acting on its behalf has provided any of the Purchasers or their agents or
counsel with any information that it believes constitutes or might constitute material, non-public information. The Company understands
and confirms that the Purchasers will rely on the foregoing representation in effecting transactions in securities of the Company. All
of the disclosure furnished by or on behalf of the Company to the Purchasers regarding the Company and its Subsidiaries, their respective
businesses and the transactions contemplated hereby, including the Disclosure Schedules to this Agreement, is true and correct and does
not contain any untrue statement of a material fact or omit to state any material fact necessary in order to make the statements made
therein, in the light of the circumstances under which they were made, not misleading. The Company acknowledges and agrees that no Purchaser
makes or has made any representations or warranties with respect to the transactions contemplated hereby other than those specifically
set forth in Section 3.2 hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(aa)
<U>No Integrated Offering</U>. Assuming the accuracy of the Purchasers&rsquo; representations and warranties set forth in Section 3.2,
neither the Company, nor any of its Affiliates, nor any Person acting on its or their behalf has, directly or indirectly, made any offers
or sales of any security or solicited any offers to buy any security, under circumstances that would cause this offering of the Securities
to be integrated with prior offerings by the Company for purposes of (i) the Securities Act which would require the registration of any
such securities under the Securities Act, or (ii) any applicable shareholder approval provisions of any Trading Market on which any of
the securities of the Company are listed or designated.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(bb)
<U>Solvency</U>. Based on the consolidated financial condition of the Company as of the Closing Date, after giving effect to the receipt
by the Company of the proceeds from the sale of the Securities hereunder, the fair saleable value of the Company&rsquo;s assets exceeds
the amount that will be required to be paid on or in respect of the Company&rsquo;s existing debts and other liabilities (including known
contingent liabilities) as they mature. The Company does not intend to incur debts beyond its ability to pay such debts as they mature
(taking into account the timing and amounts of cash to be payable on or in respect of its debt). <U>Schedule 3.1(bb)</U> sets forth as
of the date hereof all outstanding secured and unsecured Indebtedness of the Company or any Subsidiary, or for which the Company or any
Subsidiary has commitments. For the purposes of this Agreement, &ldquo;<U>Indebtedness</U>&rdquo; means (x) any liabilities for borrowed
money or amounts owed in excess of $50,000 (other than trade accounts payable incurred in the ordinary course of business), (y) all guaranties,
endorsements and other contingent obligations in respect of indebtedness of others, whether or not the same are or should be reflected
in the Company&rsquo;s consolidated balance sheet (or the notes thereto), except guaranties by endorsement of negotiable instruments
for deposit or collection or similar transactions in the ordinary course of business; and (z) the present value of any lease payments
in excess of $50,000 due under leases required to be capitalized in accordance with GAAP. Neither the Company nor any Subsidiary is in
default with respect to any Indebtedness.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 19; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(cc)
<U>Tax Status</U>. Except for matters that would not, individually or in the aggregate, have or reasonably be expected to result in a
Material Adverse Effect, the Company and its Subsidiaries each (i) has made or filed all United States federal, state and local income
and all foreign income and franchise tax returns, reports and declarations required by any jurisdiction to which it is subject, (ii)
has paid all taxes and other governmental assessments and charges that are material in amount, shown or determined to be due on such
returns, reports and declarations and (iii) has set aside on its books provision reasonably adequate for the payment of all material
taxes for periods subsequent to the periods to which such returns, reports or declarations apply. There are no unpaid taxes in any material
amount claimed to be due by the taxing authority of any jurisdiction, and the officers of the Company or of any Subsidiary know of no
basis for any such claim.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(dd)
<U>No General Solicitation</U>. Neither the Company nor any Person acting on behalf of the Company has offered or sold any of the Securities
by any form of general solicitation or general advertising. The Company has offered the Securities for sale only to the Purchasers and
certain other &ldquo;accredited investors&rdquo; within the meaning of Rule 501 under the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ee)
<U>Foreign Corrupt Practices</U>. Neither the Company nor any Subsidiary, nor to the knowledge of the Company or any Subsidiary, any
agent or other person acting on behalf of the Company or any Subsidiary, has (i) directly or indirectly, used any funds for unlawful
contributions, gifts, entertainment or other unlawful expenses related to foreign or domestic political activity, (ii) made any unlawful
payment to foreign or domestic government officials or employees or to any foreign or domestic political parties or campaigns from corporate
funds, (iii) failed to disclose fully any contribution made by the Company or any Subsidiary (or made by any person acting on its behalf
of which the Company is aware) which is in violation of law or (iv) violated in any material respect any provision of FCPA.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ff)
<U>Accountants</U>. The Company&rsquo;s accounting firm is set forth in the SEC Reports. To the knowledge and belief of the Company,
such accounting firm (i) is a registered public accounting firm as required by the Exchange Act and (ii) shall express its opinion with
respect to the financial statements to be included in the Company&rsquo;s Annual Report for the fiscal year ending December 31, 2022.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(gg)
<U>Seniority</U>. As of the Closing Date, no Indebtedness or other claim against the Company is senior to the Debentures in right of
payment, whether with respect to interest or upon liquidation or dissolution, or otherwise, other than indebtedness secured by purchase
money security interests (which is senior only as to underlying assets covered thereby) and capital lease obligations (which is senior
only as to the property covered thereby).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 20; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(hh)
<U>[Reserved]</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
<U>Acknowledgment Regarding Purchasers&rsquo; Purchase of Securities</U>. The Company acknowledges and agrees that each of the Purchasers
is acting solely in the capacity of an arm&rsquo;s length purchaser with respect to the Transaction Documents and the transactions contemplated
thereby. The Company further acknowledges that no Purchaser is acting as a financial advisor or fiduciary of the Company (or in any similar
capacity) with respect to the Transaction Documents and the transactions contemplated thereby and any advice given by any Purchaser or
any of their respective representatives or agents in connection with the Transaction Documents and the transactions contemplated thereby
is merely incidental to the Purchasers&rsquo; purchase of the Securities. The Company further represents to each Purchaser that the Company&rsquo;s
decision to enter into this Agreement and the other Transaction Documents has been based solely on the independent evaluation of the
transactions contemplated hereby by the Company and its representatives.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(jj)
<FONT STYLE="font-weight: normal"><U>Acknowledgment Regarding Purchaser&rsquo;s Trading Activity</U>. Anything in this Agreement or elsewhere
herein to the contrary notwithstanding (except for Sections 3.2(f) and 4.15 hereof), it is understood and acknowledged by the Company
that: (i) none of the Purchasers has been asked by the Company to agree, nor has any Purchaser agreed, to desist from purchasing or selling,
long and/or short, securities of the Company, or &ldquo;derivative&rdquo; securities based on securities issued by the Company or to
hold the Securities for any specified term, (ii) past or future open market or other transactions by any Purchaser, specifically including,
without limitation, Short Sales or &ldquo;derivative&rdquo; transactions, before or after the closing of this or future private placement
transactions, may negatively impact the market price of the Company&rsquo;s publicly-traded securities, (iii) any Purchaser, and counter-parties
in &ldquo;derivative&rdquo; transactions to which any such Purchaser is a party, directly or indirectly, may presently have a &ldquo;short&rdquo;
position in the Common Stock and (iv) each Purchaser shall not be deemed to have any affiliation with or control over any arm&rsquo;s
length counter-party in any &ldquo;derivative&rdquo; transaction. </FONT>The Company further understands and acknowledges that, <FONT STYLE="font-weight: normal">except
as prohibited under Sections 3.2(f) and 4.15 hereof, </FONT>(y) one or more Purchasers may engage in hedging activities at various times
during the period that the Securities are outstanding, including, without limitation, during the periods that the value of the Underlying
Shares deliverable with respect to Securities are being determined, and (z) such hedging activities (if any) could reduce the value of
the existing stockholders&rsquo; equity interests in the Company at and after the time that the hedging activities are being conducted.
The Company acknowledges that such aforementioned hedging activities do not constitute a breach of any of the Transaction Documents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(kk)
<U>Regulation M Compliance</U>. The Company has not, and to its knowledge no one acting on its behalf has, (i) taken, directly or indirectly,
any action designed to cause or to result in the stabilization or manipulation of the price of any security of the Company to facilitate
the sale or resale of any of the Securities, (ii) sold, bid for, purchased, or paid any compensation for soliciting purchases of, any
of the Securities, or (iii) paid or agreed to pay to any Person any compensation for soliciting another to purchase any other securities
of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 21; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ll)
<U>FDA</U>. As to each product subject to the jurisdiction of the U.S. Food and Drug Administration (&ldquo;<U>FDA</U>&rdquo;) under
the Federal Food, Drug and Cosmetic Act, as amended, and the regulations thereunder (&ldquo;<U>FDCA</U>&rdquo;) that is manufactured,
packaged, labeled, tested, distributed, sold, and/or marketed by the Company or any of its Subsidiaries (each such product, a &ldquo;<U>Pharmaceutical
Product</U>&rdquo;), such Pharmaceutical Product is being manufactured, packaged, labeled, tested, distributed, sold and/or marketed
by the Company in compliance with all applicable requirements under FDCA and similar laws, rules and regulations relating to registration,
investigational use, premarket clearance, licensure, or application approval, good manufacturing practices, good laboratory practices,
good clinical practices, product listing, quotas, labeling, advertising, record keeping and filing of reports, except where the failure
to be in compliance would not have a Material Adverse Effect. There is no pending, completed or, to the Company&rsquo;s knowledge, threatened,
action (including any lawsuit, arbitration, or legal or administrative or regulatory proceeding, charge, complaint, or investigation)
against the Company or any of its Subsidiaries, and none of the Company or any of its Subsidiaries has received any notice, warning letter
or other communication from the FDA or any other governmental entity, which (i) contests the premarket clearance, licensure, registration,
or approval of, the uses of, the distribution of, the manufacturing or packaging of, the testing of, the sale of, or the labeling and
promotion of any Pharmaceutical Product, (ii) withdraws its approval of, requests the recall, suspension, or seizure of, or withdraws
or orders the withdrawal of advertising or sales promotional materials relating to, any Pharmaceutical Product, (iii) imposes a clinical
hold on any clinical investigation by the Company or any of its Subsidiaries, (iv) enjoins production at any facility of the Company
or any of its Subsidiaries, (v) enters or proposes to enter into a consent decree of permanent injunction with the Company or any of
its Subsidiaries, or (vi) otherwise alleges any violation of any laws, rules or regulations by the Company or any of its Subsidiaries,
and which, either individually or in the aggregate, would have a Material Adverse Effect. The properties, business and operations of
the Company have been and are being conducted in all material respects in accordance with all applicable laws, rules and regulations
of the FDA. The Company has not been informed by the FDA that the FDA will prohibit the marketing, sale, license or use in the United
States of any product proposed to be developed, produced or marketed by the Company nor has the FDA expressed any concern as to approving
or clearing for marketing any product being developed or proposed to be developed by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(mm)
<U>Form S-3 Eligibility</U>. The Company is eligible to register the resale of the Underlying Shares for resale by the Purchaser on Form
S-3 promulgated under the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(nn)
<U>Stock Option Plans</U>. Each stock option granted by the Company under the Company&rsquo;s stock option plan was granted (i) in accordance
with the terms of the Company&rsquo;s stock option plan and (ii) with an exercise price at least equal to the fair market value of the
Common Stock on the date such stock option would be considered granted under GAAP and applicable law. No stock option granted under the
Company&rsquo;s stock option plan has been backdated. The Company has not knowingly granted, and there is no and has been no Company
policy or practice to knowingly grant, stock options prior to, or otherwise knowingly coordinate the grant of stock options with, the
release or other public announcement of material information regarding the Company or its Subsidiaries or their financial results or
prospects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 22; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(oo)
<U>Cybersecurity</U>. (i)(x) There has been no security breach or other compromise of or relating to any of the Company&rsquo;s or any
Subsidiary&rsquo;s information technology and computer systems, networks, hardware, software, data (including the data of its respective
customers, employees, suppliers, vendors and any third party data maintained by or on behalf of it), equipment or technology (collectively,
&ldquo;<U>IT Systems and Data</U>&rdquo;) and (y) the Company and the Subsidiaries have not been notified of, and has no knowledge of
any event or condition that would reasonably be expected to result in, any security breach or other compromise to its IT Systems and
Data; (ii) the Company and the Subsidiaries are presently in compliance with all applicable laws or statutes and all judgments, orders,
rules and regulations of any court or arbitrator or governmental or regulatory authority, internal policies and contractual obligations
relating to the privacy and security of IT Systems and Data and to the protection of such IT Systems and Data from unauthorized use,
access, misappropriation or modification, except as would not, individually or in the aggregate, have a Material Adverse Effect; (iii)
the Company and the Subsidiaries have implemented and maintained commercially reasonable safeguards to maintain and protect its material
confidential information and the integrity, continuous operation, redundancy and security of all IT Systems and Data; and (iv) the Company
and the Subsidiaries have implemented backup and disaster recovery technology consistent with industry standards and practices.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(pp)
<U>Office of Foreign Assets Control</U>. Neither the Company nor any Subsidiary nor, to the Company&rsquo;s knowledge, any director,
officer, agent, employee or affiliate of the Company or any Subsidiary is currently subject to any U.S. sanctions administered by the
Office of Foreign Assets Control of the U.S. Treasury Department (&ldquo;<U>OFAC</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(qq)
<U>U.S. Real Property Holding Corporation</U>. The Company is not and has never been a U.S. real property holding corporation within
the meaning of Section 897 of the Internal Revenue Code of 1986, as amended, and the Company shall so certify upon Purchaser&rsquo;s
request.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(rr)
<U>Bank Holding Company Act</U>. Neither the Company nor any of its Subsidiaries or Affiliates is subject to the Bank Holding Company
Act of 1956, as amended (the &ldquo;<U>BHCA</U>&rdquo;) and to regulation by the Board of Governors of the Federal Reserve System (the
&ldquo;<U>Federal Reserve</U>&rdquo;). Neither the Company nor any of its Subsidiaries or Affiliates owns or controls, directly or indirectly,
five percent (5%) or more of the outstanding shares of any class of voting securities or twenty-five percent or more of the total equity
of a bank or any entity that is subject to the BHCA and to regulation by the Federal Reserve. Neither the Company nor any of its Subsidiaries
or Affiliates exercises a controlling influence over the management or policies of a bank or any entity that is subject to the BHCA and
to regulation by the Federal Reserve.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 23; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ss)
<U>Money Laundering</U>. The operations of the Company and its Subsidiaries are and have been conducted at all times in compliance with
applicable financial record-keeping and reporting requirements of the Currency and Foreign Transactions Reporting Act of 1970, as amended,
applicable money laundering statutes and applicable rules and regulations thereunder (collectively, the &ldquo;<U>Money Laundering Laws</U>&rdquo;),
and no Action or Proceeding by or before any court or governmental agency, authority or body or any arbitrator involving the Company
or any Subsidiary with respect to the Money Laundering Laws is pending or, to the knowledge of the Company or any Subsidiary, threatened.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(tt)
<U>No Disqualification Events</U>. With respect to the Securities to be offered and sold hereunder in reliance on Rule 506 under the
Securities Act, none of the Company, any of its predecessors, any affiliated issuer, any director, executive officer, other officer of
the Company participating in the offering hereunder, any beneficial owner of 20% or more of the Company&rsquo;s outstanding voting equity
securities, calculated on the basis of voting power, nor any promoter (as that term is defined in Rule 405 under the Securities Act)
connected with the Company in any capacity at the time of sale (each, an &ldquo;<U>Issuer Covered Person</U>&rdquo; and, together, &ldquo;<U>Issuer
Covered Persons</U>&rdquo;) is subject to any of the &ldquo;Bad Actor&rdquo; disqualifications described in Rule 506(d)(1)(i) to (viii)
under the Securities Act (a &ldquo;<U>Disqualification Event</U>&rdquo;), except for a Disqualification Event covered by Rule 506(d)(2)
or (d)(3). The Company has exercised reasonable care to determine whether any Issuer Covered Person is subject to a Disqualification
Event. The Company has complied, to the extent applicable, with its disclosure obligations under Rule 506(e), and has furnished to the
Purchasers a copy of any disclosures provided thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(uu)
<U>Other Covered Persons</U>. The Company is not aware of any person (other than any Issuer Covered Person) that has been or will be
paid (directly or indirectly) remuneration for solicitation of purchasers in connection with the sale of any Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(vv)
<U>Notice of Disqualification Events</U>. The Company will notify the Purchasers in writing, prior to the Closing Date of (i) any Disqualification
Event relating to any Issuer Covered Person and (ii) any event that would, with the passage of time, become a Disqualification Event
relating to any Issuer Covered Person.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 24; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2
<U>Representations and Warranties of the Purchasers</U>. Each Purchaser, for itself and for no other Purchaser, hereby represents and
warrants as of the date hereof and as of the Closing Date to the Company as follows (unless as of a specific date therein, in which case
they shall be accurate as of such date):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
<U>Organization; Authority</U>. Such Purchaser is either an individual or an entity duly incorporated or formed, validly existing and
in good standing under the laws of the jurisdiction of its incorporation or formation with full right, corporate, partnership, limited
liability company or similar power and authority to enter into and to consummate the transactions contemplated by the Transaction Documents
and otherwise to carry out its obligations hereunder and thereunder. The execution and delivery of the Transaction Documents and performance
by such Purchaser of the transactions contemplated by the Transaction Documents have been duly authorized by all necessary corporate,
partnership, limited liability company or similar action, as applicable, on the part of such Purchaser. Each Transaction Document to
which it is a party has been duly executed by such Purchaser, and when delivered by such Purchaser in accordance with the terms hereof,
will constitute the valid and legally binding obligation of such Purchaser, enforceable against it in accordance with its terms, except
(i) as limited by general equitable principles and applicable bankruptcy, insolvency, reorganization, moratorium and other laws of general
application affecting enforcement of creditors&rsquo; rights generally, (ii) as limited by laws relating to the availability of specific
performance, injunctive relief or other equitable remedies and (iii) insofar as indemnification and contribution provisions may be limited
by applicable law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
<U>Own Account</U>. Such Purchaser understands that the Securities are &ldquo;restricted securities&rdquo; and have not been registered
under the Securities Act or any applicable state securities law and is acquiring the Securities as principal for its own account and
not with a view to or for distributing or reselling such Securities or any part thereof in violation of the Securities Act or any applicable
state securities law, has no present intention of distributing any of such Securities in violation of the Securities Act or any applicable
state securities law and has no direct or indirect arrangement or understandings with any other persons to distribute or regarding the
distribution of such Securities in violation of the Securities Act or any applicable state securities law (this representation and warranty
not limiting such Purchaser&rsquo;s right to sell the Securities pursuant to the Registration Statement or otherwise in compliance with
applicable federal and state securities laws). Such Purchaser is acquiring the Securities hereunder in the ordinary course of its business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
<U>Purchaser Status</U>. At the time such Purchaser was offered the Securities, it was, and as of the date hereof it is, and on each
date on which it exercises any Warrants or converts any Debentures it will be an &ldquo;accredited investor&rdquo; as defined in Rule
501(a)(1), (a)(2), (a)(3), (a)(7), (a)(8), (a)(9), (a)(12), or (a)(13) under the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
<U>Experience of Such Purchaser</U>. Such Purchaser, either alone or together with its representatives, has such knowledge, sophistication
and experience in business and financial matters so as to be capable of evaluating the merits and risks of the prospective investment
in the Securities, and has so evaluated the merits and risks of such investment. Such Purchaser is able to bear the economic risk of
an investment in the Securities and, at the present time, is able to afford a complete loss of such investment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)
<U>General Solicitation</U>. Such Purchaser is not, to such Purchaser&rsquo;s knowledge, purchasing the Securities as a result of any
advertisement, article, notice or other communication regarding the Securities published in any newspaper, magazine or similar media
or broadcast over television or radio or presented at any seminar or, to the knowledge of such Purchaser, any other general solicitation
or general advertisement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 25; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)
<U>Certain Transactions and Confidentiality</U>. Other than consummating the transactions contemplated hereunder, such Purchaser has
not, nor has any Person acting on behalf of or pursuant to any understanding with such Purchaser, directly or indirectly executed any
purchases or sales, including Short Sales, of the securities of the Company during the period commencing as of the time that such Purchaser
first received a term sheet (written or oral) from the Company or any other Person representing the Company setting forth the material
terms of the transactions contemplated hereunder and ending immediately prior to the execution hereof. Notwithstanding the foregoing,
in the case of a Purchaser that is a multi-managed investment vehicle whereby separate portfolio managers manage separate portions of
such Purchaser&rsquo;s assets and the portfolio managers have no direct knowledge of the investment decisions made by the portfolio managers
managing other portions of such Purchaser&rsquo;s assets, the representation set forth above shall only apply with respect to the portion
of assets managed by the portfolio manager that made the investment decision to purchase the Securities covered by this Agreement. Other
than to other Persons party to this Agreement or to such Purchaser&rsquo;s representatives, including, without limitation, its officers,
directors, partners, legal and other advisors, employees, agents and Affiliates, such Purchaser has maintained the confidentiality of
all disclosures made to it in connection with this transaction (including the existence and terms of this transaction). Notwithstanding
the foregoing, for the avoidance of doubt, nothing contained herein shall constitute a representation or warranty against, or a prohibition
of, any actions with respect to the borrowing of, arrangement to borrow, identification of the availability of, and/or securing of, securities
of the Company in order for such Purchaser (or its broker or other financial representative) to effect Short Sales or similar transactions
in the future.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)
<U>Access to Information</U>. Such Purchaser acknowledges that it has had the opportunity to review the Transaction Documents (including
all exhibits and schedules thereto) and the SEC Reports and has been afforded (i) the opportunity to ask such questions as it has deemed
necessary of, and to receive answers from, representatives of the Company concerning the terms and conditions of the offering of the
Securities and the merits and risks of investing in the Securities; (ii) access to information about the Company and its financial condition,
results of operations, business, properties, management and prospects sufficient to enable it to evaluate its investment; and (iii) the
opportunity to obtain such additional information that the Company possesses or can acquire without unreasonable effort or expense that
is necessary to make an informed investment decision with respect to the investment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company acknowledges and agrees that the representations contained in this Section 3.2 shall not modify, amend or affect such Purchaser&rsquo;s
right to rely on the Company&rsquo;s representations and warranties contained in this Agreement or any representations and warranties
contained in any other Transaction Document or any other document or instrument executed and/or delivered in connection with this Agreement
or the consummation of the transactions contemplated hereby. Notwithstanding the foregoing, for the avoidance of doubt, nothing contained
herein shall constitute a representation or warranty, or preclude any actions, with respect to locating or borrowing shares in order
to effect Short Sales or similar transactions in the future.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 26; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ARTICLE
IV.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>OTHER
AGREEMENTS OF THE PARTIES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1
<U>Transfer Restrictions</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
The Securities may only be disposed of in compliance with state and federal securities laws. In connection with any transfer of Securities
other than pursuant to an effective registration statement or Rule 144, to the Company or to an Affiliate of a Purchaser or in connection
with a pledge as contemplated in Section 4.1(b), the Company may require the transferor thereof to provide to the Company an opinion
of counsel selected by the transferor and reasonably acceptable to the Company, the form and substance of which opinion shall be reasonably
satisfactory to the Company, to the effect that such transfer does not require registration of such transferred Securities under the
Securities Act. As a condition of transfer, any such transferee shall agree in writing to be bound by the terms of this Agreement and
the Registration Rights Agreement and shall have the rights and obligations of a Purchaser under this Agreement and the Registration
Rights Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
The Purchasers agree to the imprinting, so long as is required by this Section 4.1, of a legend on any of the Securities in the following
form:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[NEITHER]
THIS SECURITY [NOR THE SECURITIES INTO WHICH THIS SECURITY IS [EXERCISABLE] [CONVERTIBLE]] HAS [NOT] BEEN REGISTERED WITH THE SECURITIES
AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES
ACT OF 1933, AS AMENDED (THE &ldquo;SECURITIES ACT&rdquo;), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE
REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION
REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS. THIS SECURITY [AND THE SECURITIES ISSUABLE
UPON [EXERCISE] [CONVERSION] OF THIS SECURITY] MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT WITH A REGISTERED BROKER-DEALER
OR OTHER LOAN WITH A FINANCIAL INSTITUTION THAT IS AN &ldquo;ACCREDITED INVESTOR&rdquo; AS DEFINED IN RULE 501(a) UNDER THE SECURITIES
ACT OR OTHER LOAN SECURED BY SUCH SECURITIES.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></P>

<!-- Field: Page; Sequence: 27; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company acknowledges and agrees that a Purchaser may from time to time pledge pursuant to a bona fide margin agreement with a registered
broker-dealer or grant a security interest in some or all of the Securities to a financial institution that is an &ldquo;accredited investor&rdquo;
as defined in Rule 501(a) under the Securities Act and who agrees to be bound by the provisions of this Agreement and, if required under
the terms of such arrangement, such Purchaser may transfer pledged or secured Securities to the pledgees or secured parties. Such a pledge
or transfer would not be subject to approval of the Company and no legal opinion of legal counsel of the pledgee, secured party or pledgor
shall be required in connection therewith. Further, no notice shall be required of such pledge, except where such pledge is required
to be disclosed by the Company in the reports it files or submits under the Exchange Act. At the appropriate Purchaser&rsquo;s expense,
the Company will execute and deliver such reasonable documentation as a pledgee or secured party of Securities may reasonably request
in connection with a pledge or transfer of the Securities, including, if the Securities are subject to registration pursuant to the Registration
Rights Agreement, the preparation and filing of any required prospectus supplement under Rule 424(b)(3) under the Securities Act or other
applicable provision of the Securities Act to appropriately amend the list of Selling Stockholders (as defined in the Registration Rights
Agreement) thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
Certificates evidencing the Underlying Shares shall not contain any legend (including the legend set forth in Section 4.1(b) hereof):
(i) while a registration statement (including the Registration Statement) covering the resale of such security is effective under the
Securities Act, (ii) following any sale of such Underlying Shares pursuant to Rule 144 (assuming cashless exercise of the Warrants),
(iii) if such Underlying Shares are eligible for sale under Rule 144 (assuming cashless exercise of the Warrants), without the requirement
for the Company to be in compliance with the current public information required under Rule 144 as to such Underlying Shares and without
volume or manner-of-sale restrictions or (iv) if such legend is not required under applicable requirements of the Securities Act (including
judicial interpretations and pronouncements issued by the staff of the Commission). The Company shall cause its counsel to issue a legal
opinion to the Transfer Agent promptly after the Effective Date if required by the Transfer Agent to effect the removal of the legend
hereunder, or if requested by a Purchaser, respectively, with respect to any Underlying Shares that are eligible for legend removal pursuant
to this Section 4.1(c). If all or any portion of a Debenture is converted or Warrant is exercised at a time when there is an effective
registration statement to cover the resale of the Underlying Shares, or if such Underlying Shares may be sold under Rule 144 without
the requirement for the Company to be in compliance with the current public information required under Rule 144 (assuming cashless exercise
of the Warrants) as to such Underlying Shares and without volume or manner-of-sale restrictions or if such legend is not otherwise required
under applicable requirements of the Securities Act (including judicial interpretations and pronouncements issued by the staff of the
Commission) then such Underlying Shares shall be issued free of all legends. The Company agrees that following the Effective Date or
at such time as such legend is no longer required under this Section 4.1(c), it will, no later than the later of (i) two (2) Trading
Days and (ii) the number of Trading Days comprising the Standard Settlement Period (as defined below) following the delivery by a Purchaser
to the Company or the Transfer Agent of a certificate representing Underlying Shares, as applicable, issued with a restrictive legend
(such date, the &ldquo;<U>Legend Removal Date</U>&rdquo;), deliver or cause to be delivered to such Purchaser a certificate representing
such shares that is free from all restrictive and other legends, to the extent that such shares are eligible for legend removal pursuant
to this Section 4.1(c). The Company may not make any notation on its records or give instructions to the Transfer Agent that enlarge
the restrictions on transfer set forth in this Section 4. Certificates for Underlying Shares subject to legend removal hereunder shall
be transmitted by the Transfer Agent to the Purchaser by crediting the account of the Purchaser&rsquo;s prime broker with the Depository
Trust Company System as directed by such Purchaser. As used herein, &ldquo;<U>Standard Settlement Period</U>&rdquo; means the standard
settlement period, expressed in a number of Trading Days, on the Company&rsquo;s primary Trading Market with respect to the Common Stock
as in effect on the date of delivery of a certificate representing Underlying Shares, as applicable, issued with a restrictive legend.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 28; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
In addition to such Purchaser&rsquo;s other available remedies, the Company shall pay to a Purchaser, in cash, (i) as partial liquidated
damages and not as a penalty, for each $1,000 of Underlying Shares (based on the VWAP of the Common Stock on the date such Securities
are submitted to the Transfer Agent) delivered for removal of the restrictive legend and subject to Section 4.1(c), $10 per Trading Day
for each Trading Day after the Legend Removal Date until such certificate is delivered without a legend and (ii) if (a) the Company fails
to, as required by Section 4.1(c), issue and deliver (or cause to be delivered) to a Purchaser by the Legend Removal Date a certificate
representing the Underlying Shares so delivered to the Company by such Purchaser that is free from all restrictive and other legends
and (b) after the Legend Removal Date such Purchaser purchases (in an open market transaction or otherwise) shares of Common Stock to
deliver in satisfaction of a sale by such Purchaser of all or any portion of the number of shares of Common Stock, or a sale of a number
of shares of Common Stock equal to all or any portion of the number of shares of Common Stock that such Purchaser anticipated receiving
from the Company without any restrictive legend pursuant to Section 4.1(c), then, an amount equal to the excess of such Purchaser&rsquo;s
total purchase price (including brokerage commissions and other reasonable and documented out-of-pocket expenses, if any) for the shares
of Common Stock so purchased (including brokerage commissions and other reasonable and documented out-of-pocket expenses, if any) (the
&ldquo;<FONT STYLE="font-weight: normal"><U>Buy-In Price</U></FONT>&rdquo;) over the product of (A) such number of Underlying Shares
that the Company was required to deliver to such Purchaser by the Legend Removal Date multiplied by (B) the lowest closing sale price
of the Common Stock on any Trading Day during the period commencing on the date of the delivery by such Purchaser to the Company of the
applicable Underlying Shares (as the case may be) and ending on the date of such delivery and payment under this clause (ii).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)
Each Purchaser, severally and not jointly with the other Purchasers, agrees with the Company that such Purchaser will sell any Securities
pursuant to either the registration requirements of the Securities Act, including any applicable prospectus delivery requirements, or
an exemption therefrom, and that if Securities are sold pursuant to a Registration Statement, they will be sold in compliance with the
plan of distribution set forth therein, and acknowledges that the removal of the restrictive legend from certificates representing Securities
as set forth in this Section 4.1 is predicated upon the Company&rsquo;s reliance upon this understanding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 29; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2
<U>Acknowledgment of Dilution</U>. The Company acknowledges that the issuance of the Securities may result in dilution of the outstanding
shares of Common Stock, which dilution may be substantial under certain market conditions. The Company further acknowledges that its
obligations under the Transaction Documents, including, without limitation, its obligation to issue the Underlying Shares pursuant to
the Transaction Documents, are unconditional and absolute and not subject to any right of set off, counterclaim, delay or reduction,
regardless of the effect of any such dilution or any claim the Company may have against any Purchaser and regardless of the dilutive
effect that such issuance may have on the ownership of the other stockholders of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3
<U>Furnishing of Information; Public Information</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
Until the earlier of the time that (i) no Purchaser owns Securities or (ii) the Warrants have expired, the Company covenants to use commercially
reasonable efforts to maintain the registration of the Common Stock under Section 12(b) or 12(g) of the Exchange Act and to timely file
(or obtain extensions in respect thereof and file within the applicable grace period) all reports required to be filed by the Company
after the date hereof pursuant to the Exchange Act, even if the Company is not then subject to the reporting requirements of the Exchange
Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
At any time during the period commencing from the six (6) month anniversary of the date hereof and ending at such time that all of the
Securities may be sold without the requirement for the Company to be in compliance with Rule 144(c)(1) and otherwise without restriction
or limitation pursuant to Rule 144, if the Company (i) shall fail for any reason to satisfy the current public information requirement
under Rule 144(c) or (ii) has ever been an issuer described in Rule 144 (i)(1)(i) or becomes an issuer in the future, and the Company
shall fail to satisfy any condition set forth in Rule 144(i)(2) (a &ldquo;<U>Public Information Failure</U>&rdquo;) then, in addition
to such Purchaser&rsquo;s other available remedies, the Company shall pay to Purchaser, in cash, as partial liquidated damages and not
as a penalty, by reason of any such delay in or reduction of its ability to sell the Securities, an amount in cash equal to one percent
(1.0%) of the aggregate Subscription Amount of such Purchaser&rsquo;s Securities on the day of a Public Information Failure and on every
thirtieth (30<SUP>th</SUP>) day thereafter (pro rated for periods totaling less than thirty days) thereafter until the earlier of (a)
the date such Public Information Failure is cured and (b) such time that such public information is no longer required for the Purchaser
to transfer the Underlying Shares pursuant to Rule 144. The payments to which a Purchaser shall be entitled pursuant to this Section
4.3(b) are referred to herein as &ldquo;<U>Public Information Failure Payments</U>.&rdquo; Public Information Failure Payments shall
be paid on the earlier of (i) the last day of the calendar month during which such Public Information Failure Payments are incurred and
(ii) the third (3<SUP>rd</SUP>) Business Day after the event or failure giving rise to the Public Information Failure Payments is cured.
In the event the Company fails to make Public Information Failure Payments in a timely manner, such Public Information Failure Payments
shall bear interest at the rate of 0.5% per month (prorated for partial months) until paid in full. Nothing herein shall limit such Purchaser&rsquo;s
right to pursue actual damages for the Public Information Failure, and such Purchaser shall have the right to pursue all remedies available
to it at law or in equity including, without limitation, a decree of specific performance and/or injunctive relief. Notwithstanding the
foregoing, no Public Information Failure Payments shall be due as a result of a Public Information Failure caused by or related to the
failure of NanoSynex Ltd. to provide timely information (including financial information) to the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 30; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.4
<U>Integration</U>. The Company shall not sell, offer for sale or solicit offers to buy or otherwise negotiate in respect of any security
(as defined in Section 2 of the Securities Act) that would be integrated with the offer or sale of the Securities in a manner that would
require the registration under the Securities Act of the sale of the Securities or that would be integrated with the offer or sale of
the Securities for purposes of the rules and regulations of any Trading Market such that it would require shareholder approval prior
to the closing of such other transaction unless shareholder approval is obtained before the closing of such subsequent transaction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.5
<U>Conversion and Exercise Procedures</U>. Each of the form of Notice of Exercise included in the Warrants and the form of Notice of
Conversion included in the Debentures set forth the totality of the procedures required of the Purchasers in order to exercise the Warrants
or convert the Debentures. Without limiting the preceding sentences, no ink-original Notice of Exercise or Notice of Conversion shall
be required, nor shall any medallion guarantee (or other type of guarantee or notarization) of any Notice of Exercise or Notice of Conversion
form be required in order to exercise the Warrants or convert the Debentures. No additional legal opinion, other information or instructions
shall be required of the Purchasers to exercise their Warrants or convert their Debentures. The Company shall honor exercises of the
Warrants and conversions of the Debentures and shall deliver Underlying Shares in accordance with the terms, conditions and time periods
set forth in the Transaction Documents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.6
<U>Securities Laws Disclosure; Publicity</U>. The Company shall (a) by the Disclosure Time, issue a press release disclosing the material
terms of the transactions contemplated hereby, and (b) file a Current Report on Form 8-K, including the Transaction Documents as exhibits
thereto, with the Commission within the time required by the Exchange Act. From and after the issuance of such press release, the Company
represents to the Purchasers that it shall have publicly disclosed all material, non-public information delivered to any of the Purchasers
by the Company or any of its Subsidiaries, or any of their respective officers, directors, employees, Affiliates or agents in connection
with the transactions contemplated by the Transaction Documents. In addition, effective upon the issuance of such press release, the
Company acknowledges and agrees that any and all confidentiality or similar obligations under any agreement, whether written or oral,
between the Company, any of its Subsidiaries or any of their respective officers, directors, employees, Affiliates or agents on the one
hand, and any of the Purchasers or any of their Affiliates on the other hand, shall terminate and be of no further force or effect. The
Company understands and confirms that each Purchaser shall be relying on the foregoing covenant in effecting transactions in securities
of the Company. The Company and each Purchaser shall consult with each other in issuing any other press releases with respect to the
transactions contemplated hereby, and neither the Company nor any Purchaser shall issue any such press release nor otherwise make any
such public statement without the prior consent of the Company, with respect to any press release of any Purchaser, or without the prior
consent of each Purchaser, with respect to any press release of the Company, which consent shall not unreasonably be withheld or delayed,
except if such disclosure is required by law, in which case the disclosing party shall promptly provide the other party with prior notice
of such public statement or communication. Notwithstanding the foregoing, the Company shall not publicly disclose the name of any Purchaser,
or include the name of any Purchaser in any filing with the Commission or any regulatory agency or Trading Market, without the prior
written consent of such Purchaser, except (a) as required by federal securities law in connection with (i) any registration statement
contemplated by the Registration Rights Agreement and (ii) the filing of final Transaction Documents with the Commission and (b) to the
extent such disclosure is required by law or Trading Market regulations, in which case the Company shall provide the Purchasers with
prior notice of such disclosure permitted under this clause (b) and reasonably cooperate with such Purchaser regarding such disclosure.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 31; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.7
<U>Shareholder Rights Plan</U>. No claim will be made or enforced by the Company or, with the consent of the Company, any other Person,
that any Purchaser is an &ldquo;<U>Acquiring Person</U>&rdquo; under any control share acquisition, business combination, poison pill
(including any distribution under a rights agreement) or similar anti-takeover plan or arrangement in effect or hereafter adopted by
the Company, or that any Purchaser could be deemed to trigger the provisions of any such plan or arrangement, by virtue of receiving
Securities under the Transaction Documents or under any other agreement between the Company and the Purchasers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.8
<U>Non-Public Information</U>. Except with respect to the material terms and conditions of the transactions contemplated by the Transaction
Documents, which shall be disclosed pursuant to Section 4.6, the Company covenants and agrees that neither it, nor any other Person acting
on its behalf will provide any Purchaser or its agents or counsel with any information that constitutes, or the Company reasonably believes
constitutes, material non-public information, unless prior thereto such Purchaser shall have consented in writing to the receipt of such
information and agreed in writing with the Company to keep such information confidential. The Company understands and confirms that each
Purchaser shall be relying on the foregoing covenant in effecting transactions in securities of the Company. To the extent that the Company,
any of its Subsidiaries, or any of their respective officers, director, agents, employees or Affiliates delivers any material, non-public
information to a Purchaser without such Purchaser&rsquo;s consent, the Company hereby covenants and agrees that such Purchaser shall
not have any duty of confidentiality to the Company, any of its Subsidiaries, or any of their respective officers, directors, employees,
Affiliates, or agents, or a duty to the Company, any of its Subsidiaries or any of their respective officers, directors, employees, Affiliates
or agents, not to trade on the basis of, such material, non-public information, provided that the Purchaser shall remain subject to applicable
law. To the extent that any notice provided pursuant to any Transaction Document constitutes, or contains, material, non-public information
regarding the Company or any Subsidiaries, the Company shall simultaneously with the delivery of such notice file such notice with the
Commission pursuant to a Current Report on Form 8-K. The Company understands and confirms that each Purchaser shall be relying on the
foregoing covenant in effecting transactions in securities of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.9
<U>Use of Proceeds</U>. Except as set forth on <U>Schedule 4.9</U> attached hereto, the Company shall use the net proceeds from the sale
of the Securities hereunder for working capital purposes and shall not use such proceeds: (a) for the satisfaction of any portion of
the Company&rsquo;s debt (other than payment of trade payables in the ordinary course of the Company&rsquo;s business and prior practices
or any debt owed to the Purchasers), (b) for the redemption of any Common Stock or Common Stock Equivalents, (c) for the settlement of
any outstanding litigation or (d) in violation of FCPA or OFAC regulations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.10
<U>Indemnification of Purchasers</U>. Subject to the provisions of this Section 4.10, the Company will indemnify and hold each Purchaser
and its directors, officers, shareholders, members, partners, employees and agents (and any other Persons with a functionally equivalent
role of a Person holding such titles notwithstanding a lack of such title or any other title), each Person who controls such Purchaser
(within the meaning of Section 15 of the Securities Act and Section 20 of the Exchange Act), and the directors, officers, shareholders,
agents, members, partners or employees (and any other Persons with a functionally equivalent role of a Person holding such titles notwithstanding
a lack of such title or any other title) of such controlling persons (each, a &ldquo;Purchaser Party&rdquo;) harmless from any and all
losses, liabilities, obligations, claims, contingencies, damages, costs and expenses, including all judgments, amounts paid in settlements,
court costs and reasonable attorneys&rsquo; fees and costs of investigation that any such Purchaser Party may suffer or incur as a result
of or relating to (a) any breach of any of the representations, warranties, covenants or agreements made by the Company in this Agreement
or in the other Transaction Documents or (b) any action instituted against the Purchaser Parties in any capacity, or any of them or their
respective Affiliates, by any stockholder of the Company who is not an Affiliate of such Purchaser Party, with respect to any of the
transactions contemplated by the Transaction Documents (unless such action is based upon a breach of such Purchaser Party&rsquo;s representations,
warranties or covenants under the Transaction Documents or any agreements or understandings such Purchaser Party may have with any such
stockholder or any violations by such Purchaser Party of state or federal securities laws or any conduct by such Purchaser Party which
is finally judicially determined to constitute fraud, gross negligence or willful misconduct). If any action shall be brought against
any Purchaser Party in respect of which indemnity may be sought pursuant to this Agreement, such Purchaser Party shall promptly notify
the Company in writing, and, the Company shall have the right to assume the defense thereof with counsel of its own choosing reasonably
acceptable to the Purchaser Party. Any Purchaser Party shall have the right to employ separate counsel in any such action and participate
in the defense thereof, but the fees and expenses of such counsel shall be at the expense of such Purchaser Party except to the extent
that (i) the employment thereof has been specifically authorized by the Company in writing, (ii) the Company has failed after a reasonable
period of time to assume such defense and to employ counsel or (iii) in such action there is, in the reasonable opinion of counsel a
material conflict on any material issue between the position of the Company and the position of such Purchaser Party, in which case the
Company shall be responsible for the reasonable fees and expenses of no more than one such separate counsel. The Company will not be
liable to any Purchaser Party under this Agreement (y) for any settlement by a Purchaser Party effected without the Company&rsquo;s prior
written consent, which shall not be unreasonably withheld or delayed; or (z) to the extent, but only to the extent that a loss, claim,
damage or liability is attributable to any Purchaser Party&rsquo;s breach of any of the representations, warranties, covenants or agreements
made by such Purchaser Party in this Agreement or in the other Transaction Documents. The indemnification required by this Section 4.10
shall be made by periodic payments of the amount thereof during the course of the investigation or defense, as and when bills are received
or are incurred. The indemnity agreements contained herein shall be in addition to any cause of action or similar right of any Purchaser
Party against the Company or others and any liabilities the Company may be subject to pursuant to law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 32; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.11
<U>Reservation and Listing of Securities</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
The Company shall maintain a reserve of the Required Minimum from its duly authorized shares of Common Stock for issuance pursuant to
the Transaction Documents in such amount as may then be required to fulfill its obligations in full under the Transaction Documents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
If, on any date, the number of authorized but unissued (and otherwise unreserved) shares of Common Stock is less than the Required Minimum
on such date, then the Board of Directors shall use commercially reasonable efforts to amend the Company&rsquo;s certificate or articles
of incorporation to increase the number of authorized but unissued shares of Common Stock to at least the Required Minimum at such time,
as soon as possible and in any event not later than the 75th day after such date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
The Company shall, if applicable: (i) in the time and manner required by the principal Trading Market, prepare and file with such Trading
Market an additional shares listing application covering a number of shares of Common Stock at least equal to the Required Minimum on
the date of such application, (ii) take all steps necessary to cause such shares of Common Stock to be approved for listing or quotation
on such Trading Market as soon as possible thereafter, (iii) provide to the Purchasers evidence of such listing or quotation and (iv)
use its commercially reasonable efforts to maintain the listing or quotation of such Common Stock on any date at least equal to the Required
Minimum on such date on such Trading Market or another Trading Market. The Company agrees to maintain the eligibility of the Common Stock
for electronic transfer through the Depository Trust Company or another established clearing corporation, including, without limitation,
by timely payment of fees to the Depository Trust Company or such other established clearing corporation in connection with such electronic
transfer. In addition, the Company shall hold a special meeting of shareholders (which may also be at the annual meeting of shareholders)
at the earliest practical date after the initial Monthly Redemption Date for the purpose of obtaining Shareholder Approval, with the
recommendation of the Company&rsquo;s Board of Directors that such proposal be approved, and the Company shall solicit proxies from its
shareholders in connection therewith in the same manner as all other management proposals in such proxy statement and all management-appointed
proxyholders shall vote their proxies in favor of such proposal. The Company shall use its reasonable best efforts to obtain such Shareholder
Approval. If the Company does not obtain Shareholder Approval at the first meeting, the Company shall call a meeting every four months
thereafter to seek Shareholder Approval until the earlier of the date Shareholder Approval is obtained or the Debentures are no longer
outstanding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 33; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.12
<U>Participation in Future Financing</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
From the date hereof until the date that is the 12 month anniversary of the Effective Date, upon any issuance by the Company or any of
its Subsidiaries of Common Stock or Common Stock Equivalents for cash consideration, Indebtedness or a combination of units thereof (a
&ldquo;<U>Subsequent Financing</U>&rdquo;), each Purchaser shall have the right to participate in up to an amount of the Subsequent Financing
equal to 50% of the Subsequent Financing (the &ldquo;<U>Participation Maximum</U>&rdquo;) on the same terms, conditions and price provided
for in the Subsequent Financing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
At least five (5) Trading Days prior to the closing of the Subsequent Financing, the Company shall deliver to each Purchaser a written
notice of its intention to effect a Subsequent Financing (&ldquo;<U>Pre-Notice</U>&rdquo;), which Pre-Notice shall ask such Purchaser
if it wants to review the details of such financing (such additional notice, a &ldquo;<U>Subsequent Financing Notice</U>&rdquo;). Upon
the request of a Purchaser, and only upon a request by such Purchaser, for a Subsequent Financing Notice, the Company shall promptly,
but no later than one (1) Trading Day after such request, deliver a Subsequent Financing Notice to such Purchaser. The Subsequent Financing
Notice shall describe in reasonable detail the proposed terms of such Subsequent Financing, the amount of proceeds intended to be raised
thereunder and the Person or Persons through or with whom such Subsequent Financing is proposed to be effected and shall include a term
sheet or similar document relating thereto as an attachment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
Any Purchaser desiring to participate in such Subsequent Financing must provide written notice to the Company by not later than 5:30
p.m. (New York City time) on the third (3rd) Trading Day after all of the Purchasers have received the Pre-Notice that such Purchaser
is willing to participate in the Subsequent Financing, the amount of such Purchaser&rsquo;s participation, and representing and warranting
that such Purchaser has such funds ready, willing, and available for investment on the terms set forth in the Subsequent Financing Notice.
If the Company receives no such notice from a Purchaser as of such third (3rd) Trading Day, such Purchaser shall be deemed to have notified
the Company that it does not elect to participate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
If by 5:30 p.m. (New York City time) on the third (3rd) Trading Day after all of the Purchasers have received the Pre-Notice, notifications
by the Purchasers of their willingness to participate in the Subsequent Financing (or to cause their designees to participate) is, in
the aggregate, less than the total amount of the Participation Maximum, then the Company may effect the remaining portion of such Subsequent
Financing (including remaining portion of the Participation Maximum) on the terms and with the Persons set forth in the Subsequent Financing
Notice.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)
If by 5:30 p.m. (New York City time) on the third (3rd) Trading Day after all of the Purchasers have received the Pre-Notice, the Company
receives responses to a Subsequent Financing Notice from Purchasers seeking to purchase more than the aggregate amount of the Participation
Maximum, each such Purchaser shall have the right to purchase its Pro Rata Portion (as defined below) of the Participation Maximum. &ldquo;<U>Pro
Rata Portion</U>&rdquo; means the ratio of (x) the Subscription Amount of Securities purchased on the Closing Date by a Purchaser participating
under this Section 4.12 and (y) the sum of the aggregate Subscription Amounts of Securities purchased on the Closing Date by all Purchasers
participating under this Section 4.12.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 34; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)
The Company must provide the Purchasers with a second Subsequent Financing Notice, and the Purchasers will again have the right of participation
set forth above in this Section 4.12, if the Subsequent Financing subject to the initial Subsequent Financing Notice is not consummated
for any reason on the terms set forth in such Subsequent Financing Notice within thirty (30) Trading Days after the date of the initial
Subsequent Financing Notice.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">(g)
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company and each Purchaser agree that if any Purchaser
elects to participate in the Subsequent Financing, the transaction documents related to the Subsequent Financing shall not include any
provisions whereby such Purchaser shall be required to agree to any restrictions on trading as to any Securities of the Company purchased
hereunder or be required to consent to any amendment to or termination of, or grant any waiver, release or the like under or in connection
with, this Agreement, without the prior written consent of such Purchaser.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)
<FONT STYLE="font-weight: normal">Notwithstanding anything to the contrary in this Section 4.12 and unless otherwise agreed to by such
Purchaser, the Company shall either confirm in writing to such Purchaser that the transaction with respect to the Subsequent Financing
has been abandoned or shall publicly disclose its intention to issue the securities in the Subsequent Financing, in either case in such
a manner such that such Purchaser will not be in possession of any material, non-public information, by the tenth (10th) Business Day
following delivery of the Subsequent Financing Notice. If by such tenth (10th) Business Day, no public disclosure regarding a transaction
with respect to the Subsequent Financing has been made, and no notice regarding the abandonment of such transaction has been received
by such Purchaser, such transaction shall be deemed to have been abandoned and such Purchaser shall not be deemed to be in possession
of any material, non-public information with respect to the Company or any of its Subsidiaries</FONT>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
Notwithstanding the foregoing, this Section 4.12 shall not apply in respect of an Exempt Issuance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.13
<U>Subsequent Equity Sales</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
From the date hereof until 90 days after the Effective Date, neither the Company nor any Subsidiary shall (i) issue, enter into any agreement
to issue or announce the issuance or proposed issuance of any shares of Common Stock or Common Stock Equivalents or (ii) file any registration
statement or any amendment or supplement thereto (other than an S-8 registration statement), in each case other than as contemplated
pursuant to the Registration Rights Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 35; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
From the date hereof until such time as no Purchaser holds any of the Warrants, the Company shall be prohibited from effecting or entering
into an agreement to effect any issuance by the Company or any of its Subsidiaries of Common Stock or Common Stock Equivalents (or a
combination of units thereof) involving a Variable Rate Transaction. &ldquo;<U>Variable Rate Transaction</U>&rdquo; means a transaction
in which the Company (i) issues or sells any debt or equity securities that are convertible into, exchangeable or exercisable for, or
include the right to receive, additional shares of Common Stock either (A) at a conversion price, exercise price or exchange rate or
other price that is based upon, and/or varies with, the trading prices of or quotations for the shares of Common Stock at any time after
the initial issuance of such debt or equity securities or (B) with a conversion, exercise or exchange price that is subject to being
reset at some future date after the initial issuance of such debt or equity security or upon the occurrence of specified or contingent
events directly or indirectly related to the business of the Company or the market for the Common Stock or (ii) enters into, or effects
a transaction under, any agreement, including, but not limited to, an equity line of credit or at-the-market offer, whereby the Company
may issue securities at a future determined price regardless of whether shares pursuant to such agreement have actually been issued and
regardless of whether such agreement is subsequently canceled; provided, that commencing six months after the Effective Date, the Company
may engage in an at-the-market offering, provided further, that 40% of the net proceeds from any such at-the-market offering shall be
used for Optional Redemptions under the Debenture. Any Purchaser shall be entitled to obtain injunctive relief against the Company to
preclude any such issuance, which remedy shall be in addition to any right to collect damages.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
Unless Shareholder Approval has been obtained and deemed effective, neither the Company nor any Subsidiary shall make any issuance whatsoever
of Common Stock or Common Stock Equivalents which would cause any adjustment of the Conversion Price to the extent the holders of Debentures
would not be permitted, pursuant to Section 4(e) of the Debentures to convert their respective outstanding Debentures and exercise their
respective Warrants in full, ignoring for such purposes the other conversion or exercise limitations therein. Any Purchaser shall be
entitled to obtain injunctive relief against the Company to preclude any such issuance, which remedy shall be in addition to any right
to collect damages.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
Notwithstanding the foregoing, this Section 4.13 shall not apply in respect of an Exempt Issuance, except that no Variable Rate Transaction
shall be an Exempt Issuance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.14
<U>Equal Treatment of Purchasers</U>. No consideration (including any modification of any Transaction Document) shall be offered or paid
to any Person to amend or consent to a waiver or modification of any provision of the Transaction Documents unless the same consideration
is also offered to all of the parties to such Transaction Documents. Further, the Company shall not make any payment of principal or
interest on the Debentures in amounts which are disproportionate to the respective principal amounts outstanding on the Debentures at
any applicable time. For clarification purposes, this provision constitutes a separate right granted to each Purchaser by the Company
and negotiated separately by each Purchaser, and is intended for the Company to treat the Purchasers as a class and shall not in any
way be construed as the Purchasers acting in concert or as a group with respect to the purchase, disposition or voting of Securities
or otherwise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 36; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.15
<U>Certain Transactions and Confidentiality</U>. Each Purchaser, severally and not jointly with the other Purchasers, covenants that
neither it, nor any Affiliate acting on its behalf or pursuant to any understanding with it will execute any purchases or sales, including
Short Sales, of any of the Company&rsquo;s securities during the period commencing with the execution of this Agreement and ending at
such time that the transactions contemplated by this Agreement are first publicly announced pursuant to the initial press release as
described in Section 4.6. Each Purchaser, severally and not jointly with the other Purchasers, covenants that until such time as the
transactions contemplated by this Agreement are publicly disclosed by the Company pursuant to the initial press release as described
in Section 4.6, such Purchaser will maintain the confidentiality of the existence and terms of this transaction and the information included
in the Transaction Documents and Disclosure Schedules (other than as disclosed to its legal and other representatives). Notwithstanding
the foregoing, and notwithstanding anything contained in this Agreement to the contrary, the Company expressly acknowledges and agrees
that (i) no Purchaser makes any representation, warranty or covenant hereby that it will not engage in effecting transactions in any
securities of the Company after the time that the transactions contemplated by this Agreement are first publicly announced pursuant to
the initial press release as described in Section 4.6, (ii) no Purchaser shall be restricted or prohibited from effecting any transactions
in any securities of the Company in accordance with applicable securities laws from and after the time that the transactions contemplated
by this Agreement are first publicly announced pursuant to the initial press release as described in Section 4.6 and (iii) no Purchaser
shall have any duty of confidentiality or duty not to trade in the securities of the Company to the Company, any of its Subsidiaries,
or any of their respective officers, directors, employees, Affiliates or agent, after the issuance of the initial press release as described
in Section 4.6. Notwithstanding the foregoing, in the case of a Purchaser that is a multi-managed investment vehicle whereby separate
portfolio managers manage separate portions of such Purchaser&rsquo;s assets and the portfolio managers have no direct knowledge of the
investment decisions made by the portfolio managers managing other portions of such Purchaser&rsquo;s assets, the covenant set forth
above shall only apply with respect to the portion of assets managed by the portfolio manager that made the investment decision to purchase
the Securities covered by this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.16
<U>Blue Sky Filings</U>. The Company shall take such action, if any, as the Company shall reasonably determine is necessary in order
to obtain an exemption for, or to qualify the Securities for, sale to the Purchasers at the Closing under applicable securities or &ldquo;Blue
Sky&rdquo; laws of the states of the United States, and shall provide evidence of such actions promptly upon request of any Purchaser.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ARTICLE
V.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>MISCELLANEOUS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.1
<U>Termination</U>. This Agreement may be terminated by any Purchaser, as to such Purchaser&rsquo;s obligations hereunder only and without
any effect whatsoever on the obligations between the Company and the other Purchasers, by written notice to the other parties, if the
Closing has not been consummated on or before the fifth (5<SUP>th</SUP>) Trading Day following the date hereof, <U>provided</U>, <U>however</U>,
that no such termination will affect the right of any party to sue for any breach by any other party (or parties).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 37; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.2
<U>Fees and Expenses</U>. At the Closing, the Company has agreed to reimburse Alpha Capital Anstalt (&ldquo;Alpha&rdquo;) the non-accountable
sum of $50,000 for its legal fees, inclusive of its out-of-pocket expenses. Accordingly, in lieu of the foregoing payments, the aggregate
amount that Alpha is to pay for the Securities at the Closing shall be reduced by $50,000 in lieu thereof. Except as expressly set forth
in the Transaction Documents to the contrary, each party shall pay the fees and expenses of its advisers, counsel, accountants and other
experts, if any, and all other expenses incurred by such party incident to the negotiation, preparation, execution, delivery and performance
of this Agreement. The Company shall pay all Transfer Agent fees (including, without limitation, any fees required for same-day processing
of any instruction letter delivered by the Company and any conversion or exercise notice delivered by a Purchaser), stamp taxes and other
taxes and duties levied in connection with the delivery of any Securities to the Purchasers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.3
<U>Entire Agreement</U>. The Transaction Documents, together with the exhibits and schedules thereto, contain the entire understanding
of the parties with respect to the subject matter hereof and thereof and supersede all prior agreements and understandings, oral or written,
with respect to such matters, which the parties acknowledge have been merged into such documents, exhibits and schedules.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.4
<U>Notices</U>. Any and all notices or other communications or deliveries required or permitted to be provided hereunder shall be in
writing and shall be deemed given and effective on the earliest of: (a) the time of transmission, if such notice or communication is
delivered via email attachment at the email address as set forth on the signature pages attached hereto at or prior to 5:30 p.m. (New
York City time) on a Trading Day, (b) the next Trading Day after the time of transmission, if such notice or communication is delivered
via email attachment as set forth on the signature pages attached hereto on a day that is not a Trading Day or later than 5:30 p.m. (New
York City time) on any Trading Day, (c) the second (2<SUP>nd</SUP>) Trading Day following the date of mailing, if sent by U.S. nationally
recognized overnight courier service or (d) upon actual receipt by the party to whom such notice is required to be given. The address
for such notices and communications shall be as set forth on the signature pages attached hereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.5
<U>Amendments; Waivers</U>. No provision of this Agreement may be waived, modified, supplemented or amended except in a written instrument
signed, in the case of an amendment, by the Company and Purchasers which purchased at least a majority in interest of the Securities
then outstanding or, in the case of a waiver, by the party against whom enforcement of any such waived provision is sought, provided
that if any amendment, modification or waiver disproportionately and adversely impacts a Purchaser (or group of Purchasers), the consent
of such disproportionately impacted Purchaser (or group of Purchasers) shall also be required. No waiver of any default with respect
to any provision, condition or requirement of this Agreement shall be deemed to be a continuing waiver in the future or a waiver of any
subsequent default or a waiver of any other provision, condition or requirement hereof, nor shall any delay or omission of any party
to exercise any right hereunder in any manner impair the exercise of any such right. Any proposed amendment or waiver that disproportionately,
materially and adversely affects the rights and obligations of any Purchaser relative to the comparable rights and obligations of the
other Purchasers shall require the prior written consent of such adversely affected Purchaser. Any amendment effected in accordance with
this Section 5.5 shall be binding upon each Purchaser and holder of Securities and the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 38; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.6
<U>Headings</U>. The headings herein are for convenience only, do not constitute a part of this Agreement and shall not be deemed to
limit or affect any of the provisions hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.7
<U>Successors and Assigns</U>. This Agreement shall be binding upon and inure to the benefit of the parties and their successors and
permitted assigns. The Company may not assign this Agreement or any rights or obligations hereunder without the prior written consent
of each Purchaser (other than by merger). Any Purchaser may assign any or all of its rights under this Agreement to any Person to whom
such Purchaser assigns or transfers any Securities, provided that such transferee agrees in writing to be bound, with respect to the
transferred Securities, by the provisions of the Transaction Documents that apply to the &ldquo;Purchasers.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.8
<U>No Third Party Beneficiaries</U>. This Agreement is intended for the benefit of the parties hereto and their respective successors
and permitted assigns and is not for the benefit of, nor may any provision hereof be enforced by, any other Person, except as otherwise
set forth in Section 4.10.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.9
<U>Governing Law</U>. All questions concerning the construction, validity, enforcement and interpretation of the Transaction Documents
shall be governed by and construed and enforced in accordance with the internal laws of the State of New York, without regard to the
principles of conflicts of law thereof. Each party agrees that all legal Proceedings concerning the interpretations, enforcement and
defense of the transactions contemplated by this Agreement and any other Transaction Documents (whether brought against a party hereto
or its respective affiliates, directors, officers, shareholders, partners, members, employees or agents) shall be commenced exclusively
in the state and federal courts sitting in the City of New York. Each party hereby irrevocably submits to the exclusive jurisdiction
of the state and federal courts sitting in the City of New York, Borough of Manhattan for the adjudication of any dispute hereunder or
in connection herewith or with any transaction contemplated hereby or discussed herein (including with respect to the enforcement of
any of the Transaction Documents), and hereby irrevocably waives, and agrees not to assert in any Action or Proceeding, any claim that
it is not personally subject to the jurisdiction of any such court, that such Action or Proceeding is improper or is an inconvenient
venue for such Proceeding. Each party hereby irrevocably waives personal service of process and consents to process being served in any
such Action or Proceeding by mailing a copy thereof via registered or certified mail or overnight delivery (with evidence of delivery)
to such party at the address in effect for notices to it under this Agreement and agrees that such service shall constitute good and
sufficient service of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process
in any other manner permitted by law. If any party shall commence an Action or Proceeding to enforce any provisions of the Transaction
Documents, then, in addition to the obligations of the Company under Section 4.10, the prevailing party in such Action or Proceeding
shall be reimbursed by the non-prevailing party for its reasonable attorneys&rsquo; fees and other costs and expenses incurred with the
investigation, preparation and prosecution of such Action or Proceeding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 39; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.10
<U>Survival</U>. The representations and warranties contained herein shall survive the Closing and the delivery of the Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.11
<U>Execution</U>. This Agreement may be executed in two or more counterparts, all of which when taken together shall be considered one
and the same agreement and shall become effective when counterparts have been signed by each party and delivered to each other party,
it being understood that the parties need not sign the same counterpart. In the event that any signature is delivered by e-mail delivery
of a &ldquo;.pdf&rdquo; format data file, such signature shall create a valid and binding obligation of the party executing (or on whose
behalf such signature is executed) with the same force and effect as if such &ldquo;.pdf&rdquo; signature page were an original thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.12
<U>Severability</U>. If any term, provision, covenant or restriction of this Agreement is held by a court of competent jurisdiction to
be invalid, illegal, void or unenforceable, the remainder of the terms, provisions, covenants and restrictions set forth herein shall
remain in full force and effect and shall in no way be affected, impaired or invalidated, and the parties hereto shall use their commercially
reasonable efforts to find and employ an alternative means to achieve the same or substantially the same result as that contemplated
by such term, provision, covenant or restriction. It is hereby stipulated and declared to be the intention of the parties that they would
have executed the remaining terms, provisions, covenants and restrictions without including any of such that may be hereafter declared
invalid, illegal, void or unenforceable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.13
<U>Rescission and Withdrawal Right</U>. Notwithstanding anything to the contrary contained in (and without limiting any similar provisions
of) any of the other Transaction Documents, whenever any Purchaser exercises a right, election, demand or option under a Transaction
Document and the Company does not timely perform its related obligations within the periods therein provided, then such Purchaser may
rescind or withdraw, in its sole discretion from time to time upon written notice to the Company, any relevant notice, demand or election
in whole or in part without prejudice to its future actions and rights; <U>provided</U>, <U>however</U>, that, in the case of a rescission
of a conversion of a Debenture or exercise of a Warrant, the applicable Purchaser shall be required to return any shares of Common Stock
subject to any such rescinded conversion or exercise notice concurrently with the return to such Purchaser of the aggregate exercise
price paid to the Company for such shares and the restoration of such Purchaser&rsquo;s right to acquire such shares pursuant to such
Purchaser&rsquo;s Warrant (including, issuance of a replacement warrant certificate evidencing such restored right).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.14
<U>Replacement of Securities</U>. If any certificate or instrument evidencing any Securities is mutilated, lost, stolen or destroyed,
the Company shall issue or cause to be issued in exchange and substitution for and upon cancellation thereof (in the case of mutilation),
or in lieu of and substitution therefor, a new certificate or instrument, but only upon receipt of evidence reasonably satisfactory to
the Company of such loss, theft or destruction. The applicant for a new certificate or instrument under such circumstances shall also
pay any reasonable third-party costs (including customary indemnity) associated with the issuance of such replacement Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 40; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.15
<U>Remedies</U>. In addition to being entitled to exercise all rights provided herein or granted by law, including recovery of damages,
each of the Purchasers and the Company will be entitled to specific performance under the Transaction Documents. The parties agree that
monetary damages may not be adequate compensation for any loss incurred by reason of any breach of obligations contained in the Transaction
Documents and hereby agree to waive and not to assert in any Action for specific performance of any such obligation the defense that
a remedy at law would be adequate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.16
<U>Payment Set Aside</U>. To the extent that the Company makes a payment or payments to any Purchaser pursuant to any Transaction Document
or a Purchaser enforces or exercises its rights thereunder, and such payment or payments or the proceeds of such enforcement or exercise
or any part thereof are subsequently invalidated, declared to be fraudulent or preferential, set aside, recovered from, disgorged by
or are required to be refunded, repaid or otherwise restored to the Company, a trustee, receiver or any other Person under any law (including,
without limitation, any bankruptcy law, state or federal law, common law or equitable cause of action), then to the extent of any such
restoration the obligation or part thereof originally intended to be satisfied shall be revived and continued in full force and effect
as if such payment had not been made or such enforcement or setoff had not occurred.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.17
<U>Usury</U>. To the extent it may lawfully do so, the Company hereby agrees not to insist upon or plead or in any manner whatsoever
claim, and will resist any and all efforts to be compelled to take the benefit or advantage of, usury laws wherever enacted, now or at
any time hereafter in force, in connection with any Action or Proceeding that may be brought by any Purchaser in order to enforce any
right or remedy under any Transaction Document. Notwithstanding any provision to the contrary contained in any Transaction Document,
it is expressly agreed and provided that the total liability of the Company under the Transaction Documents for payments in the nature
of interest shall not exceed the maximum lawful rate authorized under applicable law (the &ldquo;<U>Maximum Rate</U>&rdquo;), and, without
limiting the foregoing, in no event shall any rate of interest or default interest, or both of them, when aggregated with any other sums
in the nature of interest that the Company may be obligated to pay under the Transaction Documents exceed such Maximum Rate. It is agreed
that if the maximum contract rate of interest allowed by law and applicable to the Transaction Documents is increased or decreased by
statute or any official governmental action subsequent to the date hereof, the new maximum contract rate of interest allowed by law will
be the Maximum Rate applicable to the Transaction Documents from the effective date thereof forward, unless such application is precluded
by applicable law. If under any circumstances whatsoever, interest in excess of the Maximum Rate is paid by the Company to any Purchaser
with respect to indebtedness evidenced by the Transaction Documents, such excess shall be applied by such Purchaser to the unpaid principal
balance of any such indebtedness or be refunded to the Company, the manner of handling such excess to be at such Purchaser&rsquo;s election.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.18
<U>[</U>Reserved]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 41; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.19
<U>Liquidated Damages</U>. The Company&rsquo;s obligations to pay any partial liquidated damages or other amounts owing under the Transaction
Documents is a continuing obligation of the Company and shall not terminate until all unpaid partial liquidated damages and other amounts
have been paid notwithstanding the fact that the instrument or security pursuant to which such partial liquidated damages or other amounts
are due and payable shall have been canceled.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.20
<U>Saturdays, Sundays, Holidays, etc</U>. If the last or appointed day for the taking of any action or the expiration of any right required
or granted herein shall not be a Business Day, then such action may be taken or such right may be exercised on the next succeeding Business
Day.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.21
<U>Construction</U>. The parties agree that each of them and/or their respective counsel have reviewed and had an opportunity to revise
the Transaction Documents and, therefore, the normal rule of construction to the effect that any ambiguities are to be resolved against
the drafting party shall not be employed in the interpretation of the Transaction Documents or any amendments thereto. In addition, each
and every reference to share prices and shares of Common Stock in any Transaction Document shall be subject to adjustment for reverse
and forward stock splits, stock dividends, stock combinations and other similar transactions of the Common Stock that occur after the
date of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.22
<B><U>WAIVER OF JURY TRIAL</U>. IN ANY ACTION, SUIT, OR PROCEEDING IN ANY JURISDICTION BROUGHT BY ANY PARTY AGAINST ANY OTHER PARTY,
THE PARTIES EACH KNOWINGLY AND INTENTIONALLY, TO THE GREATEST EXTENT PERMITTED BY APPLICABLE LAW, HEREBY ABSOLUTELY, UNCONDITIONALLY,
IRREVOCABLY AND EXPRESSLY WAIVES FOREVER TRIAL BY JURY. </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(Signature
Pages Follow)</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>


<!-- Field: Page; Sequence: 42; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IN
WITNESS WHEREOF, the parties hereto have caused this Securities Purchase Agreement to be duly executed by their respective authorized
signatories as of the date first indicated above.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">QUALIGEN
                                            THERAPEUTICS, INC.</FONT></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Address
    for Notice:</U></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></P></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 45%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s
                                            Michael S. Poirier</I></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 45%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Email</U>:</FONT></P></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Michael
    S. Poirier</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">With
a copy to (which shall not constitute notice):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">With
a copy to (which shall not constitute note):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Wendy
Grasso</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reed
Smith LLP</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">599
Lexington Avenue</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">New
York, NY 10022</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">wgrasso@reedsmith.com
</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[REMAINDER
OF PAGE INTENTIONALLY LEFT BLANK</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SIGNATURE
PAGE FOR PURCHASER FOLLOWS]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 43; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">[PURCHASER
SIGNATURE PAGES TO QLGN SECURITIES PURCHASE AGREEMENT]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IN
WITNESS WHEREOF, the undersigned have caused this Securities Purchase Agreement to be duly executed by their respective authorized signatories
as of the date first indicated above.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
of Purchaser: ___<U>Alpha Capital Anstalt</U>_________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Signature
of Authorized Signatory of Purchaser</I>: __<I><U>/s/ Nicola Feuerstein</U></I>____________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
of Authorized Signatory: ___<U>Nicola Feuerstein</U>____________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title
of Authorized Signatory: ___<U>Chief Executive Officer</U>________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email
Address of Authorized Signatory: _____________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address
for Notice to Purchaser:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Altenbach
8</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9490
Vaduz, Liechtenstein</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Copy
to: LH Financial Services Corp.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">510
Madison Avenue, 14<SUP>th</SUP> Floor</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">New
York, NY 10022</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address
for Delivery of Securities to Purchaser (if not same as address for notice):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c/o
LH Financial Services Corp.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">510
Madison Avenue, 14th Floor</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">New
York, NY 10022</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attn:
Teresa Agresta</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subscription
Amount: $3,000,000</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Principal
Amount: $3,300,000</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrant
Shares: 2,500,000</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 44; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>4
<FILENAME>ex10-2.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: right; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right; text-indent: 0in"><B>Exhibit 10.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in">NEITHER THIS SECURITY NOR THE SECURITIES
INTO WHICH THIS SECURITY IS CONVERTIBLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION
OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE &ldquo;<U>SECURITIES ACT</U>&rdquo;),
AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT
TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE
WITH APPLICABLE STATE SECURITIES LAWS. THIS SECURITY AND THE SECURITIES ISSUABLE UPON CONVERSION OF THIS SECURITY MAY BE PLEDGED IN CONNECTION
WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN SECURED BY SUCH SECURITIES.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Original Issue Date: December 22, 2022</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Original Conversion Price (subject to adjustment herein):
<B>$</B>1.32</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right">$3,300,000</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>8% SENIOR
CONVERTIBLE DEBENTURE</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>DUE DECEMBER
22, 2025</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">THIS 8% SENIOR CONVERTIBLE DEBENTURE
is one of a series of duly authorized and validly issued 8% Senior Convertible Debentures of Qualigen Therapeutics, Inc., a Delaware corporation
(the &ldquo;<U>Company</U>&rdquo;), having its principal place of business at 2042 Corte de Nogal, Carlsbad, CA 92011, designated as its
8% Senior Convertible Debenture due December 22, 2025 (this debenture, as amended, restated, supplemented or otherwise modified from time
to time, the &ldquo;<U>Debenture</U>&rdquo; and, collectively with the other debentures of such series, the &ldquo;<U>Debentures</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">FOR VALUE RECEIVED, the Company
promises to pay to Alpha Capital Anstalt or its registered assigns (the &ldquo;<U>Holder</U>&rdquo;), or shall have paid pursuant to the
terms hereunder, the principal sum of $3,300,000 on December 22, 2025 (the &ldquo;<U>Maturity Date</U>&rdquo;) or such earlier date as
this Debenture is required or permitted to be repaid as provided hereunder, and to pay interest to the Holder on the aggregate unconverted
and then outstanding principal amount of this Debenture in accordance with the provisions hereof. This Debenture is subject to the following
additional provisions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><U>Section 1</U>. <U>Definitions</U>.
For the purposes hereof, in addition to the terms defined elsewhere in this Debenture, (a) capitalized terms not otherwise defined
herein shall have the meanings set forth in the Purchase Agreement and (b) the following terms shall have the following
meanings:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Alternate
Consideration</U>&rdquo; shall have the meaning set forth in Section 5(e).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Bankruptcy
Event</U>&rdquo; means any of the following events: (a) the Company or any Significant Subsidiary (as such term is defined in Rule 1-02(w)
of Regulation S-X) thereof commences a case or other proceeding under any bankruptcy, reorganization, arrangement, adjustment of debt,
relief of debtors, dissolution, insolvency or liquidation or similar law of any jurisdiction relating to the Company or any Significant
Subsidiary thereof, (b) there is commenced against the Company or any Significant Subsidiary thereof any such case or proceeding that
is not dismissed within 60 days after commencement, (c) the Company or any Significant Subsidiary thereof is adjudicated insolvent or
bankrupt or any order of relief or other order approving any such case or proceeding is entered, (d) the Company or any Significant Subsidiary
thereof suffers any appointment of any custodian or the like for it or any substantial part of its property that is not discharged or
stayed within 60 calendar days after such appointment, (e) the Company or any Significant Subsidiary thereof makes a general assignment
for the benefit of creditors, (f) the Company or any Significant Subsidiary thereof calls a meeting of its creditors with a view to arranging
a composition, adjustment or restructuring of its debts, (g) the Company or any Significant Subsidiary thereof admits in writing that
it is generally unable to pay its debts as they become due, (h) the Company or any Significant Subsidiary thereof, by any act or failure
to act, expressly indicates its consent to, approval of or acquiescence in any of the foregoing or takes any corporate or other action
for the purpose of effecting any of the foregoing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Base Conversion
Price</U>&rdquo; shall have the meaning set forth in Section 5(b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Beneficial
Ownership Limitation</U>&rdquo; shall have the meaning set forth in Section 4(d).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Business Day</U>&rdquo;
means any day other than Saturday, Sunday or other day on which commercial banks in The City of New York are authorized or required by
law to remain closed; <U>provided</U>, <U>however</U>, for clarification, commercial banks shall not be deemed to be authorized or required
by law to remain closed due to &ldquo;stay at home&rdquo;, &ldquo;shelter-in-place&rdquo;, &ldquo;non-essential employee&rdquo; or any
other similar orders or restrictions or the closure of any physical branch locations at the direction of any governmental authority so
long as the electronic funds transfer systems (including for wire transfers) of commercial banks in The City of New York are generally
are open for use by customers on such day.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Buy-In</U>&rdquo;
shall have the meaning set forth in Section 4(c)(v).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 2; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Change of
Control Transaction</U>&rdquo; means the occurrence after the date hereof of any of (a) an acquisition after the date hereof by an individual
or legal entity or &ldquo;group&rdquo; (as described in Rule 13d-5(b)(1) promulgated under the Exchange Act) of effective control (whether
through legal or beneficial ownership of capital stock of the Company, by contract or otherwise) of in excess of 50% of the voting securities
of the Company (other than by means of conversion or exercise of the Debentures and the Warrants issued together with the Debentures),
(b) the Company merges into or consolidates with any other Person, or any Person merges into or consolidates with the Company and, after
giving effect to such transaction, the stockholders of the Company immediately prior to such transaction own less than 50% of the aggregate
voting power of the Company or the successor entity of such transaction, (c) the Company (and all of its Subsidiaries, taken as a whole)
sells or transfers all or substantially all of its assets to another Person and the stockholders of the Company immediately prior to such
transaction own less than 50% of the aggregate voting power of the acquiring entity immediately after the transaction, (d) a replacement
at one time or within a three year period of more than one-half of the members of the Board of Directors which is not approved by a majority
of those individuals who are members of the Board of Directors on the Original Issue Date (or by those individuals who are serving as
members of the Board of Directors on any date whose nomination to the Board of Directors was approved by a majority of the members of
the Board of Directors who are members on the date hereof), or (e) the execution by the Company of an agreement to which the Company is
a party or by which it is bound, providing for any of the events set forth in clauses (a) through (d) above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Conversion
Date</U>&rdquo; shall have the meaning set forth in Section 4(a).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Conversion
Price</U>&rdquo; shall have the meaning set forth in Section 4(b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Conversion
Schedule</U>&rdquo; means the Conversion Schedule in the form of <U>Schedule 1</U> attached hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Conversion
Shares</U>&rdquo; means, collectively, the shares of Common Stock issuable upon conversion of this Debenture in accordance with the terms
hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Debenture
Register</U>&rdquo; shall have the meaning set forth in Section 2(c).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Dilutive Issuance</U>&rdquo;
shall have the meaning set forth in Section 5(b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Dilutive Issuance
Notice</U>&rdquo; shall have the meaning set forth in Section 5(b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Distribution</U>&rdquo;
shall have the meaning set forth in Section 5(d).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Effectiveness
Period</U>&rdquo; shall have the meaning set forth in the Registration Rights Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Equity Conditions</U>&rdquo;
means, during the period in question, (a) the Company shall have duly honored all conversions and redemptions scheduled to occur or occurring
by virtue of one or more Notices of Conversion of the Holder, if any, (b) the Company shall have paid all liquidated damages and other
amounts owing to the Holder in respect of this Debenture, (c)(i) there is an effective Registration Statement pursuant to which the Holder
is permitted to utilize the prospectus thereunder to resell all of the shares of Common Stock issuable pursuant to the Transaction Documents
(and the Company believes, in good faith, that such effectiveness will continue uninterrupted for the foreseeable future) or (ii) all
of the Conversion Shares issuable pursuant to the Transaction Documents (and shares issuable in lieu of cash payments of interest) may
be resold pursuant to Rule 144 without volume or manner-of-sale restrictions or current public information requirements as determined
by the counsel to the Company as set forth in a written opinion letter to such effect, addressed and acceptable to the Transfer Agent
and the Holder, (d) the Common Stock is trading on a Trading Market and all of the shares of Common Stock issuable pursuant to the Transaction
Documents are listed or quoted for trading on such Trading Market (and the Company believes, in good faith, that trading of the Common
Stock on a Trading Market will continue uninterrupted for the foreseeable future), (e) there is a sufficient number of authorized but
unissued and otherwise unreserved shares of Common Stock for the issuance of all of the shares of Common Stock then issuable pursuant
to the Transaction Documents, (f) there is no existing Event of Default and no existing event which, with the passage of time or the giving
of notice, would constitute an Event of Default, (g) the issuance of the shares in question (or, in the case of a Monthly Redemption or
Optional Redemption, the shares issuable upon conversion in full of the Monthly Redemption Amount or Optional Redemption Amount) to the
Holder would not violate the limitations set forth in Section 4(d) and Section 4(e) herein, (h) there has been no public announcement
of a pending or proposed Fundamental Transaction or Change of Control Transaction that has not been consummated, (i) the Holder is not
in possession of any information provided by the Company, any of its Subsidiaries, or any of their officers, directors, employees, agents
or Affiliates, that constitutes, or may constitute, material non-public information of the Company and (j) for each Trading Day in a period
of 20 consecutive Trading Days prior to the applicable date in question, the daily trading volume for the Common Stock on the principal
Trading Market exceeds $85,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Event of Default</U>&rdquo;
shall have the meaning set forth in Section 8(a).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Fundamental
Transaction</U>&rdquo; shall have the meaning set forth in Section 5(e).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Interest Conversion
Rate</U>&rdquo; means the lesser of (a) the Conversion Price or (b) 85% of the average of the VWAPs for the 5 consecutive Trading Days
ending on the Trading Day that is immediately prior to the applicable Interest Payment Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Interest Notice
Period</U>&rdquo; shall have the meaning set forth in Section 2(a).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Interest Payment
Date</U>&rdquo; shall have the meaning set forth in Section 2(a).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Interest Share
Amount</U>&rdquo; shall have the meaning set forth in Section 2(a).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Issuable Maximum</U>&rdquo;
shall have the meaning set forth in Section 4(e).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Late Fees</U>&rdquo;
shall have the meaning set forth in Section 2(d).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Mandatory
Default Amount</U>&rdquo; means the sum of (a) the greater of (i) the outstanding principal amount of this Debenture, plus all accrued
and unpaid interest hereon, divided by the Conversion Price on the date the Mandatory Default Amount is either (A) demanded (if demand
or notice is required to create an Event of Default) or otherwise due or (B) paid in full, whichever has a lower Conversion Price, multiplied
by the VWAP on the date the Mandatory Default Amount is either (x) demanded or otherwise due or (y) paid in full, whichever has a higher
VWAP, or (ii) 105% of the outstanding principal amount of this Debenture, plus 100% of accrued and unpaid interest hereon, and (b) all
other amounts, costs, expenses and liquidated damages due in respect of this Debenture.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Monthly Conversion
Period</U>&rdquo; shall have the meaning set forth in Section 6(a) hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Monthly Conversion
Price</U>&rdquo; shall have the meaning set forth in Section 6(a) hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Monthly Redemption</U>&rdquo;
means the redemption of this Debenture pursuant to Section 6(a) hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Monthly Redemption
Amount</U>&rdquo; means, as to a Monthly Redemption, $110,000, plus accrued but unpaid interest, liquidated damages and any other amounts
then owing to the Holder in respect of this Debenture.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Monthly Redemption
Date</U>&rdquo; means the 1<SUP>st</SUP> day of each month, commencing immediately on June 1, 2023, and terminating upon the earlier of
(i) the Maturity Date and (ii) the full redemption of this Debenture.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Monthly Redemption
Notice</U>&rdquo; shall have the meaning set forth in Section 6(a) hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>New York Courts</U>&rdquo;
shall have the meaning set forth in Section 9(d).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Notice of
Conversion</U>&rdquo; shall have the meaning set forth in Section 4(a).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Optional Redemption</U>&rdquo;
shall have the meaning set forth in Section 6(b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Optional Redemption
Amount</U>&rdquo; means the sum of (a) 105% of the then outstanding principal amount of the Debenture subject to the Optional Redemption,
(b) accrued but unpaid interest and (c) all liquidated damages and other amounts due in respect of the Debenture.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Optional Redemption
Date</U>&rdquo; shall have the meaning set forth in Section 6(b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Optional Redemption
Notice</U>&rdquo; shall have the meaning set forth in Section 6(b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Optional Redemption
Notice Date</U>&rdquo; shall have the meaning set forth in Section 6(b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Optional Redemption
Period</U>&rdquo; shall have the meaning set forth in Section 6(b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Original Issue
Date</U>&rdquo; means the date of the first issuance of the Debentures, regardless of any transfers of any Debenture and regardless of
the number of instruments which may be issued to evidence such Debentures.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Permitted
Indebtedness</U>&rdquo; means (a) the indebtedness evidenced by the Debentures, (b) the Indebtedness existing on the Original Issue Date
and set forth on <U>Schedule 3.1(bb)</U> attached to the Purchase Agreement, (c) lease obligations and purchase money indebtedness of
up to $500,000, in the aggregate, incurred in connection with the acquisition of capital assets and lease obligations with respect to
newly acquired or leased assets), (d) any factoring or revolving line of credit secured by accounts receivables of up to $500,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Permitted
Lien</U>&rdquo; means the individual and collective reference to the following: (a) Liens for taxes, assessments and other governmental
charges or levies not yet due or Liens for taxes, assessments and other governmental charges or levies being contested in good faith and
by appropriate proceedings for which adequate reserves (in the good faith judgment of the management of the Company) have been established
in accordance with GAAP, (b) Liens imposed by law which were incurred in the ordinary course of the Company&rsquo;s business, such as
carriers&rsquo;, warehousemen&rsquo;s and mechanics&rsquo; Liens, statutory landlords&rsquo; Liens, and other similar Liens arising in
the ordinary course of the Company&rsquo;s business, and which (x) do not individually or in the aggregate materially detract from the
value of such property or assets or materially impair the use thereof in the operation of the business of the Company and its consolidated
Subsidiaries or (y) are being contested in good faith by appropriate proceedings, which proceedings have the effect of preventing for
the foreseeable future the forfeiture or sale of the property or asset subject to such Lien, (c) Liens incurred in connection with Permitted
Indebtedness under clauses (a), (b) and (d), and (d) Liens incurred in connection with Permitted Indebtedness under clause (c) thereunder,
provided that such Liens are not secured by assets of the Company or its Subsidiaries other than the assets so acquired or leased.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Purchase Agreement</U>&rdquo;
means the Securities Purchase Agreement, dated as of December21, 2022 among the Company and the Holder, as amended, modified or supplemented
from time to time in accordance with its terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Registration
Rights Agreement</U>&rdquo; means the Registration Rights Agreement, dated as of the date of the Purchase Agreement, among the Company
and the Holder, in the form of <U>Exhibit B</U> attached to the Purchase Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Registration
Statement</U>&rdquo; means a registration statement meeting the requirements set forth in the Registration Rights Agreement and covering
the resale of the Underlying Shares by each Holder as provided for in the Registration Rights Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Securities
Act</U>&rdquo; means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Share Delivery
Date</U>&rdquo; shall have the meaning set forth in Section 4(c)(ii).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Successor
Entity</U>&rdquo; shall have the meaning set forth in Section 5(e).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Trading Day</U>&rdquo;
means a day on which the principal Trading Market is open for trading.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Trading Market</U>&rdquo;
means any of the following markets or exchanges on which the Common Stock is listed or quoted for trading on the date in question: the
NYSE American, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market, the New York Stock Exchange, OTCQB
or OTCQX (or any successors to any of the foregoing).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>VWAP</U>&rdquo;
means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed or
quoted on a Trading Market, the daily volume weighted average price of the Common Stock for such date (or the nearest preceding date)
on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based on a Trading Day from 9:30
a.m. (New York City time) to 4:02 p.m. (New York City time)), (b) if OTCQB or OTCQX is not a Trading Market, the volume weighted average
price of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Stock is not
then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported on The Pink Open Market (or a
similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of the Common Stock
so reported, or (d) in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser selected
in good faith by the Purchasers of a majority in interest of the Securities then outstanding and reasonably acceptable to the Company,
the reasonable, actual and documented fees and expenses which shall be paid by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><U>Section 2</U>. <U>Interest</U>.</P>

<P STYLE="font: 10pt Courier New, Courier, Monospace; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">a) <U>Payment of Interest
in Cash or Kind</U>. No interest shall accrue or be payable until December 1, 2023. Thereafter, the Company shall pay interest to the
Holder on the aggregate unconverted and then outstanding principal amount of this Debenture at the rate of 8% per annum, payable quarterly
on January 1, April 1, July 1 and October 1, beginning on the first such date after December 1, 2023, on each Monthly Redemption Date
(as to that principal amount then being redeemed), on each Optional Redemption Date (as to that principal amount then being redeemed),
on each Conversion Date (as to that principal amount then being converted), and on the Maturity Date (each such date, an &ldquo;<U>Interest
Payment Date</U>&rdquo;) (if any Interest Payment Date is not a Business Day, then the applicable payment shall be due on the next succeeding
Business Day), in cash or, at the Company&rsquo;s option, in duly authorized, validly issued, fully paid and non-assessable shares of
Common Stock at the Interest Conversion Rate (the dollar amount to be paid in shares, the &ldquo;<U>Interest Share Amount</U>&rdquo;)
or a combination thereof; <U>provided</U>, <U>however</U>, that payment in shares of Common Stock may only occur if (i) all of the Equity
Conditions have been met (unless waived by the Holder in writing) during the 5 Trading Days immediately prior to the applicable Interest
Payment Date (the &ldquo;<U>Interest Notice Period</U>&rdquo;) and through and including the date such shares of Common Stock are actually
issued to the Holder, and (ii) the Company shall have given the Holder notice in accordance with the notice requirements set forth below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">b) <U>Company&rsquo;s
Election to Pay Interest in Cash or Kind</U>. Subject to the terms and conditions herein, the decision whether to pay interest hereunder
in cash, shares of Common Stock or a combination thereof shall be at the sole discretion of the Company. Prior to the commencement of
any Interest Notice Period, the Company shall deliver to the Holder a written notice of its election to pay interest hereunder on the
applicable Interest Payment Date either in cash, shares of Common Stock or a combination thereof and the Interest Share Amount as to the
applicable Interest Payment Date, provided that the Company may indicate in such notice that the election contained in such notice shall
apply to future Interest Payment Dates until revised by a subsequent notice. During any Interest Notice Period, the Company&rsquo;s election
(whether specific to an Interest Payment Date or continuous) shall be irrevocable as to such Interest Payment Date. Subject to the aforementioned
conditions, failure to timely deliver such written notice to the Holder shall be deemed an election by the Company to pay the interest
on such Interest Payment Date in cash. At any time the Company delivers a notice to the Holder of its election to pay the interest in
shares of Common Stock, the Company shall timely file a prospectus supplement pursuant to Rule 424 disclosing such election.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">c) <U>Interest
Calculations</U>. Interest shall be calculated on the basis of a 360-day year, consisting of twelve 30 calendar day periods, and shall
accrue daily commencing on the Original Issue Date until payment in full of the outstanding principal, together with all accrued and unpaid
interest, liquidated damages and other amounts which may become due hereunder, has been made. Payment of interest in shares of Common
Stock shall otherwise occur pursuant to Section 4(c)(ii) herein and, solely for purposes of the payment of interest in shares, the Interest
Payment Date shall be deemed the Conversion Date. Interest shall cease to accrue with respect to any principal amount converted, provided
that, the Company actually delivers the Conversion Shares within the time period required by Section 4(c)(ii) herein. Interest hereunder
will be paid to the Person in whose name this Debenture is registered on the records of the Company regarding registration and transfers
of this Debenture (the &ldquo;<U>Debenture Register</U>&rdquo;). Except as otherwise provided herein, if at any time the Company pays
interest partially in cash and partially in shares of Common Stock to the holders of the Debentures, then such payment of cash shall be
distributed ratably among the holders of the then-outstanding Debentures based on their (or their predecessor&rsquo;s) initial purchases
of Debentures pursuant to the Purchase Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">d) <U>Late
Fee</U>. All overdue accrued and unpaid interest to be paid hereunder shall entail a late fee at an interest rate equal to the lesser
of 15% per annum or the maximum rate permitted by applicable law (the &ldquo;<U>Late Fees</U>&rdquo;) which shall accrue daily from the
date such interest is due hereunder through and including the date of actual payment in full.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">e) <U>Prepayment</U>.
Except as otherwise set forth in this Debenture, the Company may not prepay any portion of the principal amount of this Debenture without
the prior written consent of the Holder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><U>Section 3.</U>&nbsp;<U>Registration
of Transfers and Exchanges</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">a) <U>Different
Denominations</U>. This Debenture is exchangeable for an equal aggregate principal amount of Debentures of different authorized denominations,
as requested by the Holder surrendering the same. No service charge will be payable for such registration of transfer or exchange.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">b) <U>Investment
Representations</U>. This Debenture has been issued subject to certain investment representations of the original Holder set forth in
the Purchase Agreement and may be transferred or exchanged only in compliance with the Purchase Agreement and applicable federal and state
securities laws and regulations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">c) <U>Reliance
on Debenture Register</U>. Prior to due presentment for transfer to the Company of this Debenture, the Company and any agent of the Company
may treat the Person in whose name this Debenture is duly registered on the Debenture Register as the owner hereof for the purpose of
receiving payment as herein provided and for all other purposes, whether or not this Debenture is overdue, and neither the Company nor
any such agent shall be affected by notice to the contrary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><U>Section 4.</U>&nbsp;<U>Conversion</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">a) <U>Voluntary
Conversion</U>. At any time after the Original Issue Date until this Debenture is no longer outstanding, this Debenture shall be convertible,
in whole or in part, into shares of Common Stock at the option of the Holder, at any time and from time to time (subject to the conversion
limitations set forth in Section 4(d) and Section 4(e) hereof). The Holder shall effect conversions by delivering to the Company a Notice
of Conversion, the form of which is attached hereto as <U>Annex A</U> (each, a &ldquo;<U>Notice of Conversion</U>&rdquo;), specifying
therein the principal amount of this Debenture to be converted and the date on which such conversion shall be effected (such date, the
&ldquo;<U>Conversion Date</U>&rdquo;). If no Conversion Date is specified in a Notice of Conversion, the Conversion Date shall be the
first (1st) Business Day immediately following the date that such Notice of Conversion is deemed delivered hereunder. No ink-original
Notice of Conversion shall be required, nor shall any medallion guarantee (or other type of guarantee or notarization) of any Notice of
Conversion form be required. To effect conversions hereunder, the Holder shall not be required to physically surrender this Debenture
to the Company unless the entire principal amount of this Debenture, plus all accrued and unpaid interest thereon, has been so converted
in which case the Holder shall surrender this Debenture as promptly as is reasonably practicable after such conversion without delaying
the Company&rsquo;s obligation to deliver the shares on the Share Delivery Date. Conversions hereunder shall have the effect of lowering
the outstanding principal amount of this Debenture in an amount equal to the applicable conversion. The Holder and the Company shall maintain
records showing the principal amount(s) converted and the date of such conversion(s). The Company may deliver an objection to any Notice
of Conversion within one (1) Business Day of delivery of such Notice of Conversion. In the event of any dispute or discrepancy, the records
of the Holder shall be controlling and determinative in the absence of manifest error. <B>The Holder, and any assignee by acceptance of
this Debenture, acknowledge and agree that, by reason of the provisions of this paragraph, following conversion of a portion of this Debenture,
the unpaid and unconverted principal amount of this Debenture may be less than the amount stated on the face hereof.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">b) <U>Conversion
Price</U>. The conversion price in effect on any Conversion Date shall be equal to $1.32<B>,</B> subject to adjustment herein (the &ldquo;<U>Conversion
Price</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"> c) <U>Mechanics of Conversion</U>.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in">i. <U>Conversion
Shares Issuable Upon Conversion of Principal Amount</U>. The number of Conversion Shares issuable upon a conversion hereunder shall be
determined by the quotient obtained by dividing (x) the outstanding principal amount of this Debenture to be converted by (y) the Conversion
Price.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in">ii. <U>Delivery
of Conversion Shares Upon Conversion</U>. Not later than the earlier of (i) 2 Trading Days and (ii) the number of Trading Days comprising
the Standard Settlement Period (as defined below) after each Conversion Date (the &ldquo;<U>Share Delivery Date</U>&rdquo;), the Company
shall deliver, or cause to be delivered, to the Holder (A) the Conversion Shares which, on or after the Effective Date, shall be free
of restrictive legends and trading restrictions (other than those which may then be required by the Purchase Agreement) representing the
number of Conversion Shares being acquired upon the conversion of this Debenture (including, if the Company has given continuous notice
pursuant to Section 2(b) for payment of interest in shares of Common Stock at least 20 Trading Days prior to the date on which the Notice
of Conversion is delivered to the Company, shares of Common Stock representing the payment of accrued interest otherwise determined pursuant
to Section 2(a) but assuming that the Interest Notice Period is the 20 Trading Days period immediately prior to the date on which the
Notice of Conversion is delivered to the Company) and (B) a bank check in the amount of accrued and unpaid interest (if the Company has
elected or is required to pay accrued interest in cash). On or after the Effective Date, the Company shall use its best efforts to deliver
any Conversion Shares required to be delivered by the Company under this Section 4(c)(ii) electronically through the Depository Trust
Company or another established clearing corporation performing similar functions. As used herein, &ldquo;<U>Standard Settlement Period</U>&rdquo;
means the standard settlement period, expressed in a number of Trading Days, on the Company&rsquo;s primary Trading Market with respect
to the Common Stock as in effect on the date of delivery of the Notice of Conversion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in">iii. <U>Failure
to Deliver Conversion Shares</U>. If, in the case of any Notice of Conversion, such Conversion Shares are not delivered to or as directed
by the Holder by the Share Delivery Date, the Holder shall be entitled to elect by written notice to the Company at any time on or before
its receipt of such Conversion Shares, to rescind such conversion, in which event the Company shall promptly return to the Holder any
original Debenture delivered to the Company and the Holder shall promptly return to the Company the Conversion Shares issued to such Holder
pursuant to the rescinded Conversion Notice.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in">iv. <U>Obligation
Absolute; Partial Liquidated Damages</U>. The Company&rsquo;s obligations to issue and deliver the Conversion Shares upon conversion of
this Debenture in accordance with the terms hereof are absolute and unconditional, irrespective of any action or inaction by the Holder
to enforce the same, any waiver or consent with respect to any provision hereof, the recovery of any judgment against any Person or any
action to enforce the same, or any setoff, counterclaim, recoupment, limitation or termination, or any breach or alleged breach by the
Holder or any other Person of any obligation to the Company or any violation or alleged violation of law by the Holder or any other Person,
and irrespective of any other circumstance which might otherwise limit such obligation of the Company to the Holder in connection with
the issuance of such Conversion Shares; <U>provided</U>, <U>however</U>, that such delivery shall not operate as a waiver by the Company
of any such action the Company may have against the Holder. In the event the Holder of this Debenture shall elect to convert any or all
of the outstanding principal amount hereof, the Company may not refuse conversion based on any claim that the Holder or anyone associated
or affiliated with the Holder has been engaged in any violation of law, agreement or for any other reason, unless an injunction from a
court, on notice to Holder, restraining and or enjoining conversion of all or part of this Debenture shall have been sought and obtained.
In the absence of such injunction, the Company shall issue Conversion Shares or, if applicable, cash, upon a properly noticed conversion.
If the Company fails for any reason to deliver to the Holder such Conversion Shares pursuant to Section 4(c)(ii) by the Share Delivery
Date, the Company shall pay to the Holder, in cash, as liquidated damages and not as a penalty, for each $1,000 of principal amount being
converted, $10 per Trading Day for each Trading Day after such Share Delivery Date until such Conversion Shares are delivered or Holder
rescinds such conversion. Nothing herein shall limit a Holder&rsquo;s right to pursue actual damages or declare an Event of Default pursuant
to Section 8 hereof for the Company&rsquo;s failure to deliver Conversion Shares within the period specified herein and the Holder shall
have the right to pursue all remedies available to it hereunder, at law or in equity including, without limitation, a decree of specific
performance and/or injunctive relief. The exercise of any such rights shall not prohibit the Holder from seeking to enforce damages pursuant
to any other Section hereof or under applicable law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in">v. <U>Compensation
for Buy-In on Failure to Timely Deliver Conversion Shares Upon Conversion</U>. In addition to any other rights available to the Holder,
if the Company fails for any reason to deliver to the Holder such Conversion Shares by the Share Delivery Date pursuant to Section 4(c)(ii),
and if after such Share Delivery Date the Holder is required by its brokerage firm to purchase (in an open market transaction or otherwise),
or the Holder&rsquo;s brokerage firm otherwise purchases, shares of Common Stock to deliver in satisfaction of a sale by the Holder of
the Conversion Shares which the Holder was entitled to receive upon the conversion relating to such Share Delivery Date (a &ldquo;<U>Buy-In</U>&rdquo;),
then the Company shall (A) pay in cash to the Holder (in addition to any other remedies available to or elected by the Holder) the amount,
if any, by which (x) the Holder&rsquo;s total purchase price (including any brokerage commissions) for the Common Stock so purchased exceeds
(y) the product of (1) the aggregate number of shares of Common Stock that the Holder was entitled to receive from the conversion at issue
multiplied by (2) the actual sale price at which the sell order giving rise to such purchase obligation was executed (including any brokerage
commissions) and (B) at the option of the Holder, either reissue (if surrendered) this Debenture in a principal amount equal to the principal
amount of the attempted conversion (in which case such conversion shall be deemed rescinded) or deliver to the Holder the number of shares
of Common Stock that would have been issued if the Company had timely complied with its delivery requirements under Section 4(c)(ii).
For example, if the Holder purchases Common Stock having a total purchase price of $11,000 to cover a Buy-In with respect to an attempted
conversion of this Debenture with respect to which the actual sale price of the Conversion Shares (including any brokerage commissions)
giving rise to such purchase obligation was a total of $10,000 under clause (A) of the immediately preceding sentence, the Company shall
be required to pay the Holder $1,000. The Holder shall provide the Company written notice indicating the amounts payable to the Holder
in respect of the Buy-In and, upon request of the Company, evidence of the amount of such loss. Nothing herein shall limit a Holder&rsquo;s
right to pursue any other remedies available to it hereunder, at law or in equity including, without limitation, a decree of specific
performance and/or injunctive relief with respect to the Company&rsquo;s failure to timely deliver Conversion Shares upon conversion of
this Debenture as required pursuant to the terms hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in">vi. <U>Reservation
of Shares Issuable Upon Conversion</U>. The Company covenants that it will at all times reserve and keep available out of its authorized
and unissued shares of Common Stock for the sole purpose of issuance upon conversion of this Debenture and payment of interest on this
Debenture, each as herein provided, free from preemptive rights or any other actual contingent purchase rights of Persons other than the
Holder (and the other holders of the Debentures), not less than such aggregate number of shares of the Common Stock as shall (subject
to the terms and conditions set forth in the Purchase Agreement) be issuable (taking into account the adjustments and restrictions of
Section 5) upon the conversion of the then outstanding principal amount of this Debenture and payment of interest hereunder. The Company
covenants that all shares of Common Stock that shall be so issuable shall, upon issue, be duly authorized, validly issued, fully paid
and nonassessable and, if the Registration Statement is then effective under the Securities Act, shall be registered for public resale
in accordance with such Registration Statement (subject to such Holder&rsquo;s compliance with its obligations under the Registration
Rights Agreement).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in">vii. <U>Fractional
Shares</U>. No fractional shares or scrip representing fractional shares shall be issued upon the conversion of this Debenture. As to
any fraction of a share which the Holder would otherwise be entitled to purchase upon such conversion, the Company shall at its election,
either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied by the Conversion Price
or round up to the next whole share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in">viii. <U>Transfer
Taxes and Expenses</U>. The issuance of Conversion Shares on conversion of this Debenture shall be made without charge to the Holder hereof
for any documentary stamp or similar taxes that may be payable in respect of the issue or delivery of such Conversion Shares, provided
that the Company shall not be required to pay any tax that may be payable in respect of any transfer involved in the issuance and delivery
of any such Conversion Shares upon conversion in a name other than that of the Holder of this Debenture so converted and the Company shall
not be required to issue or deliver such Conversion Shares unless or until the Person or Persons requesting the issuance thereof shall
have paid to the Company the amount of such tax or shall have established to the satisfaction of the Company that such tax has been paid.
The Company shall pay all Transfer Agent fees required for same-day processing of any Notice of Conversion and all fees to the Depository
Trust Company (or another established clearing corporation performing similar functions) required for same-day electronic delivery of
the Conversion Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">d) <U>Holder&rsquo;s
Conversion Limitations</U>. The Company shall not effect any conversion of this Debenture, and a Holder shall not have the right to convert
any portion of this Debenture, to the extent that after giving effect to the conversion set forth on the applicable Notice of Conversion,
the Holder (together with the Holder&rsquo;s Affiliates, and any other Persons acting as a group together with the Holder or any of the
Holder&rsquo;s Affiliates (such Persons, &ldquo;<U>Attribution Parties</U>&rdquo;)) would beneficially own in excess of the Beneficial
Ownership Limitation (as defined below). For purposes of the foregoing sentence, the number of shares of Common Stock beneficially owned
by the Holder and its Attribution Parties shall include the number of shares of Common Stock issuable upon conversion of this Debenture
with respect to which such determination is being made, but shall exclude the number of shares of Common Stock which would be issuable
upon (i) conversion of the remaining, unconverted principal amount of this Debenture beneficially owned by the Holder or any of its Attribution
Parties and (ii) exercise or conversion of the unexercised or unconverted portion of any other securities of the Company subject to a
limitation on conversion or exercise analogous to the limitation contained herein (including, without limitation, any other Debentures
or the Warrants) beneficially owned by the Holder or any of its Attribution Parties. Except as set forth in the preceding sentence, for
purposes of this Section 4(d), beneficial ownership shall be calculated in accordance with Section 13(d) of the Exchange Act and the rules
and regulations promulgated thereunder. To the extent that the limitation contained in this Section 4(d) applies, the determination of
whether this Debenture is convertible (in relation to other securities owned by the Holder together with any Attribution Parties) and
of which principal amount of this Debenture is convertible shall be in the sole discretion of the Holder, and the submission of a Notice
of Conversion shall be deemed to be the Holder&rsquo;s determination of whether this Debenture may be converted (in relation to other
securities owned by the Holder together with any Attribution Parties) and which principal amount of this Debenture is convertible, in
each case subject to the Beneficial Ownership Limitation, and the Company shall have no obligation to verify or confirm the accuracy of
such determination. In addition, a determination as to any group status as contemplated above shall be determined in accordance with Section
13(d) of the Exchange Act and the rules and regulations promulgated thereunder. For purposes of this Section 4(d), in determining the
number of outstanding shares of Common Stock, the Holder may rely on the number of outstanding shares of Common Stock as reflected in
(A) the Company&rsquo;s most recent periodic or annual report filed with the Commission, as the case may be, (B) a more recent public
announcement by the Company, or (C) a more recent written notice by the Company or the Company&rsquo;s transfer agent setting forth the
number of shares of Common Stock outstanding. Upon the written or oral request of a Holder, the Company shall within one Trading Day confirm
orally and in writing to the Holder the number of shares of Common Stock then outstanding. In any case, the number of outstanding shares
of Common Stock shall be determined after giving effect to the conversion or exercise of securities of the Company, including this Debenture,
by the Holder or its Affiliates since the date as of which such number of outstanding shares of Common Stock was reported. The &ldquo;<U>Beneficial
Ownership Limitation</U>&rdquo; shall be 9.99% of the number of shares of the Common Stock outstanding immediately after giving effect
to the issuance of shares of Common Stock issuable upon conversion of this Debenture. The Holder, upon not less than 61 days&rsquo; prior
notice to the Company, may increase or decrease the Beneficial Ownership Limitation provisions of this Section 4(d), provided that the
Beneficial Ownership Limitation in no event exceeds 9.99% of the number of shares of the Common Stock outstanding immediately after giving
effect to the issuance of shares of Common Stock upon conversion of this Debenture held by the Holder and the Beneficial Ownership Limitation
provisions of this Section 4(d) shall continue to apply. Any increase in the Beneficial Ownership Limitation will not be effective until
the 61<SUP>st</SUP> day after such notice is delivered to the Company. The Beneficial Ownership Limitation provisions of this paragraph
shall be construed and implemented in a manner otherwise than in strict conformity with the terms of this Section 4(d) to correct this
paragraph (or any portion hereof) which may be defective or inconsistent with the intended Beneficial Ownership Limitation contained herein
or to make changes or supplements necessary or desirable to properly give effect to such limitation. The limitations contained in this
paragraph shall apply to a successor holder of this Debenture.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">e) <U>Issuance
Limitations</U>. Notwithstanding anything herein to the contrary, if the Company has not obtained Shareholder Approval, then the Company
may not issue, upon conversion of this Debenture, a number of shares of Common Stock which, when aggregated with any shares of Common
Stock issued on or after the Original Issue Date and prior to such Conversion Date (i) in connection with the conversion of any Debentures
issued pursuant to the Purchase Agreement, (ii) in connection with the exercise of any Warrants issued pursuant to the Purchase Agreement
and (iii) in connection with any Warrants issued to any registered broker-dealer as a fee in connection with the issuance of the Securities
pursuant to the Purchase Agreement, would exceed 841,726 shares of Common Stock (subject to adjustment for forward and reverse stock splits,
recapitalizations and the like) (such number of shares, the &ldquo;<U>Issuable Maximum</U>&rdquo;). Each Holder shall be entitled to a
portion of the Issuable Maximum equal to the quotient obtained by dividing (x) the original principal amount of the Holder&rsquo;s Debenture
by (y) the aggregate original principal amount of all Debentures issued on the Original Issue Date to all Holders. In addition, each Holder
may allocate its pro-rata portion of the Issuable Maximum among Debentures and Warrants held by it in its sole discretion. Such portion
shall be adjusted upward ratably in the event a Holder no longer holds any Debentures or Warrants and the amount of shares issued to the
Holder pursuant to the Holder&rsquo;s Debentures and Warrants was less than the Holder&rsquo;s pro-rata share of the Issuable Maximum.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><U>Section 5</U>.&nbsp;<U>Certain Adjustments</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">a) <U>Stock
Dividends and Stock Splits</U>. If the Company, at any time while this Debenture is outstanding: (i) makes a Distribution or Distributions
payable in shares of Common Stock on shares of Common Stock or any Common Stock Equivalents (which, for avoidance of doubt, shall not
include any shares of Common Stock issued by the Company upon conversion of, or payment of interest on, this Debenture), (ii) subdivides
outstanding shares of Common Stock into a larger number of shares, (iii) combines (including by way of a reverse stock split) outstanding
shares of Common Stock into a smaller number of shares or (iv) issues, in the event of a reclassification of shares of the Common Stock,
any shares of capital stock of the Company, then the Conversion Price shall be multiplied by a fraction of which the numerator shall be
the number of shares of Common Stock (excluding any treasury shares of the Company) outstanding immediately before such event, and of
which the denominator shall be the number of shares of Common Stock outstanding immediately after such event. Any adjustment made pursuant
to this Section 5 shall become effective immediately after the record date for the determination of stockholders entitled to receive such
Distribution and shall become effective immediately after the effective date in the case of a subdivision, combination or re-classification.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">b) <U>Subsequent
Equity Sales</U>. Following receipt of Shareholder Approval, if, at any time while this Debenture is outstanding, the Company or any Subsidiary,
as applicable, sells or grants any option to purchase or sells or grants any right to reprice, or otherwise disposes of or issues (or
announces any sale, grant or any option to purchase or other disposition), any Common Stock or Common Stock Equivalents entitling any
Person to acquire shares of Common Stock at an effective price per share that is lower than the then Conversion Price (such lower price,
the &ldquo;<U>Base Conversion Price</U>&rdquo; and such issuances, collectively, a &ldquo;<U>Dilutive Issuance</U>&rdquo;) (if the holder
of the Common Stock or Common Stock Equivalents so issued shall at any time, whether by operation of purchase price adjustments, reset
provisions, floating conversion, exercise or exchange prices or otherwise, or due to warrants, options or rights per share which are issued
in connection with such issuance, be entitled to receive shares of Common Stock at an effective price per share that is lower than the
Conversion Price, such issuance shall be deemed to have occurred for less than the Conversion Price on such date of the Dilutive Issuance),
then simultaneously with the consummation (or, if earlier, the announcement) of each Dilutive Issuance the Conversion Price shall be reduced
to equal the Base Conversion Price, provided that the Base Conversion Price shall not be less than $0.260 (subject to adjustment for reverse
and forward stock splits, recapitalizations and similar transactions following the date of the Purchase Agreement). Notwithstanding the
foregoing, no adjustment will be made under this Section 5(b) in respect of an Exempt Issuance. If the Company enters into a Variable
Rate Transaction, despite the prohibition set forth in the Purchase Agreement, the Company shall be deemed to have issued Common Stock
or Common Stock Equivalents at the lowest possible conversion price at which such securities may be converted or exercised. The Company
shall notify the Holder in writing, no later than the Trading Day following the issuance of any Common Stock or Common Stock Equivalents
subject to this Section 5(b), indicating therein the applicable issuance price, or applicable reset price, exchange price, conversion
price and other pricing terms (such notice, the &ldquo;<U>Dilutive Issuance Notice</U>&rdquo;). For purposes of clarification, whether
or not the Company provides a Dilutive Issuance Notice pursuant to this Section 5(b), upon the occurrence of any Dilutive Issuance, the
Holder is entitled to receive a number of Conversion Shares based upon the Base Conversion Price on or after the date of such Dilutive
Issuance, regardless of whether the Holder accurately refers to the Base Conversion Price in the Notice of Conversion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">c) <U>Subsequent
Rights Offerings</U>. In addition to any adjustments pursuant to Section 5(a) above, if at any time the Company grants, issues or sells
any Common Stock Equivalents or rights to purchase stock, warrants, securities or other property pro rata to the record holders of any
class of shares of Common Stock (the &ldquo;<U>Purchase Rights</U>&rdquo;), then the Holder will be entitled to acquire, upon the terms
applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired if the Holder had held the number
of shares of Common Stock acquirable upon complete conversion of this Debenture (without regard to any limitations on exercise hereof,
including without limitation, the Beneficial Ownership Limitation) immediately before the date on which a record is taken for the grant,
issuance or sale of such Purchase Rights, or, if no such record is taken, the date as of which the record holders of shares of Common
Stock are to be determined for the grant, issue or sale of such Purchase Rights (<U>provided</U>, <U>however</U>, that, to the extent
that the Holder&rsquo;s right to participate in any such Purchase Right would result in the Holder exceeding the Beneficial Ownership
Limitation, then the Holder shall not be entitled to participate in such Purchase Right to such extent (or beneficial ownership of such
shares of Common Stock as a result of such Purchase Right to such extent) and such Purchase Right to such extent shall be held in abeyance
for the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">d) <U>Pro
Rata Distributions</U>. During such time as this Debenture is outstanding, if the Company shall declare or make any dividend or other
distribution of its assets (or rights to acquire its assets) to holders of shares of Common Stock, by way of return of capital or otherwise
(including, without limitation, any distribution of cash, stock or other securities, property or options by way of a dividend, spin off,
reclassification, corporate rearrangement, scheme of arrangement or other similar transaction) (a &ldquo;<U>Distribution</U>&rdquo;),
at any time after the issuance of this Debenture, then, in each such case, the Holder shall be entitled to participate in such Distribution
to the same extent that the Holder would have participated therein if the Holder had held the number of shares of Common Stock acquirable
upon complete conversion of this Debenture (without regard to any limitations on conversion hereof, including without limitation, the
Beneficial Ownership Limitation) immediately before the date of which a record is taken for such Distribution, or, if no such record is
taken, the date as of which the record holders of shares of Common Stock are to be determined for the participation in such Distribution
(<U>provided</U>, <U>however</U>, that, to the extent that the Holder&rsquo;s right to participate in any such Distribution would result
in the Holder exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such Distribution
to such extent (or in the beneficial ownership of any shares of Common Stock as a result of such Distribution to such extent) and the
portion of such Distribution shall be held in abeyance for the benefit of the Holder until such time, if ever, as its right thereto would
not result in the Holder exceeding the Beneficial Ownership Limitation).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">e) <U>Fundamental
Transaction</U>. If, at any time while this Debenture is outstanding, (i) the Company, directly or indirectly, in one or more related
transactions effects any merger or consolidation of the Company with or into another Person, (ii) the Company (and all of its Subsidiaries,
taken as a whole), directly or indirectly, effects any sale, lease, license, assignment, transfer, conveyance or other disposition of
all or substantially all of its assets in one or a series of related transactions, (iii) any, direct or indirect, purchase offer, tender
offer or exchange offer (whether by the Company or another Person) is completed pursuant to which holders of Common Stock are permitted
to sell, tender or exchange their shares for other securities, cash or property and has been accepted by the holders of 50% or more of
the outstanding Common Stock, (iv) the Company, directly or indirectly, in one or more related transactions effects any reclassification,
reorganization or recapitalization of the Common Stock or any compulsory share exchange pursuant to which the Common Stock is effectively
converted into or exchanged for other securities, cash or property, or (v) the Company, directly or indirectly, in one or more related
transactions consummates a stock or share purchase agreement or other business combination (including, without limitation, a reorganization,
recapitalization, spin-off, merger or scheme of arrangement) with another Person or group of Persons whereby such other Person or group
acquires more than 50% of the outstanding shares of Common Stock (not including any shares of Common Stock held by the other Person or
other Persons making or party to, or associated or affiliated with the other Persons making or party to, such stock or share purchase
agreement or other business combination) (each a &ldquo;<U>Fundamental Transaction</U>&rdquo;), then, upon any subsequent conversion of
this Debenture, the Holder shall have the right to receive, for each Conversion Share that would have been issuable upon such conversion
immediately prior to the occurrence of such Fundamental Transaction (without regard to any limitation in Section 4(d) and Section 4(e)
on the conversion of this Debenture), the number of shares of Common Stock of the successor or acquiring corporation or of the Company,
if it is the surviving corporation, and any additional consideration (the &ldquo;<U>Alternate Consideration</U>&rdquo;) receivable as
a result of such Fundamental Transaction by a holder of the number of shares of Common Stock for which this Debenture is convertible immediately
prior to such Fundamental Transaction (without regard to any limitation in Section 4(d) and Section 4(e) on the conversion of this Debenture).
For purposes of any such conversion, the determination of the Conversion Price shall be appropriately adjusted to apply to such Alternate
Consideration based on the amount of Alternate Consideration issuable in respect of one (1) share of Common Stock in such Fundamental
Transaction, and the Company shall apportion the Conversion Price among the Alternate Consideration in a reasonable manner reflecting
the relative value of any different components of the Alternate Consideration. If holders of Common Stock are given any choice as to the
securities, cash or property to be received in a Fundamental Transaction, then the Holder shall be given the same choice as to the Alternate
Consideration it receives upon any conversion of this Debenture following such Fundamental Transaction. The Company shall cause any successor
entity in a Fundamental Transaction in which the Company is not the survivor (the &ldquo;<U>Successor Entity</U>&rdquo;) to assume in
writing all of the obligations of the Company under this Debenture and the other Transaction Documents (as defined in the Purchase Agreement)
in accordance with the provisions of this Section 5(e) pursuant to written agreements in form and substance reasonably satisfactory to
the Holder and approved by the Holder (without unreasonable delay) prior to such Fundamental Transaction and shall, at the option of the
Holder of this Debenture, deliver to the Holder in exchange for this Debenture a security of the Successor Entity evidenced by a written
instrument substantially similar in form and substance to this Debenture which is convertible for a corresponding number of shares of
capital stock of such Successor Entity (or its parent entity) equivalent to the shares of Common Stock acquirable and receivable upon
conversion of this Debenture (without regard to any limitations on the conversion of this Debenture) prior to such Fundamental Transaction,
and with a conversion price which applies the Conversion Price hereunder to such shares of capital stock (but taking into account the
relative value of the shares of Common Stock pursuant to such Fundamental Transaction and the value of such shares of capital stock, such
number of shares of capital stock and such conversion price being for the purpose of protecting the economic value of this Debenture immediately
prior to the consummation of such Fundamental Transaction), and which is reasonably satisfactory in form and substance to the Holder.
Upon the occurrence of any such Fundamental Transaction, the Successor Entity shall succeed to, and be substituted for (so that from and
after the date of such Fundamental Transaction, the provisions of this Debenture and the other Transaction Documents referring to the
&ldquo;Company&rdquo; shall refer instead to the Successor Entity), and may exercise every right and power of the Company and shall assume
all of the obligations of the Company under this Debenture and the other Transaction Documents with the same effect as if such Successor
Entity had been named as the Company herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">f) <U>Calculations</U>.
All calculations under this Section 5 shall be made to the nearest cent or the nearest 1/100th of a share, as the case may be. For purposes
of this Section 5, the number of shares of Common Stock deemed to be issued and outstanding as of a given date shall be the sum of the
number of shares of Common Stock (excluding any treasury shares of the Company) issued and outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">g) <U>Notice
to the Holder</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in">i. <U>Adjustment
to Conversion Price</U>. Whenever the Conversion Price is adjusted pursuant to any provision of this Section 5, the Company shall promptly
deliver to each Holder a notice setting forth the Conversion Price after such adjustment and setting forth a brief statement of the facts
requiring such adjustment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in">ii. <U>Notice
to Allow Conversion by Holder</U>. If (A) the Company shall declare a dividend (or any other Distribution in whatever form) on the Common
Stock, (B) the Company shall declare a special nonrecurring cash dividend on or a redemption of the Common Stock, (C) the Company shall
authorize the granting to all holders of the Common Stock of rights or warrants to subscribe for or purchase any shares of capital stock
of any class or of any rights, (D) the approval of any stockholders of the Company shall be required in connection with any reclassification
of the Common Stock, any consolidation or merger to which the Company(and all of its Subsidiaries, taken as a whole) is a party, any sale
or transfer of all or substantially all of the assets of the Company, or any compulsory share exchange whereby the Common Stock is converted
into other securities, cash or property or (E) the Company shall authorize the voluntary or involuntary dissolution, liquidation or winding
up of the affairs of the Company, then, in each case, the Company shall cause to be filed at each office or agency maintained for the
purpose of conversion of this Debenture, and shall cause to be delivered to the Holder at its last address as it shall appear upon the
Debenture Register, at least twenty (20) calendar days prior to the applicable record or effective date hereinafter specified, a notice
stating (x) the date on which a record is to be taken for the purpose of such dividend, Distribution, redemption, rights or warrants,
or if a record is not to be taken, the date as of which the holders of the Common Stock of record to be entitled to such dividend, Distributions,
redemption, rights or warrants are to be determined or (y) the date on which such reclassification, consolidation, merger, sale, transfer
or share exchange is expected to become effective or close, and the date as of which it is expected that holders of the Common Stock of
record shall be entitled to exchange their shares of the Common Stock for securities, cash or other property deliverable upon such reclassification,
consolidation, merger, sale, transfer or share exchange, provided that the failure to deliver such notice or any defect therein or in
the delivery thereof shall not affect the validity of the corporate action required to be specified in such notice. To the extent that
any notice provided hereunder constitutes, or contains, material, non-public information regarding the Company or any of the Subsidiaries,
the Company shall simultaneously file such notice with the Commission pursuant to a Current Report on Form 8-K. The Holder shall remain
entitled to convert this Debenture during the 20-day period commencing on the date of such notice through the effective date of the event
triggering such notice except as may otherwise be expressly set forth herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><U>Section 6</U>.<U>&nbsp;Redemption</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">a) <U>Monthly
Redemption</U>. On each Monthly Redemption Date, the Company shall redeem the Monthly Redemption Amount (the &ldquo;<U>Monthly Redemption</U>&rdquo;).
The Monthly Redemption Amount payable on each Monthly Redemption Date shall be paid in cash; <U>provided</U>, <U>however</U>, as to any
Monthly Redemption after the first two Monthly Redemptions (which must be paid in cash) and upon 30 Trading Days&rsquo; prior written
irrevocable notice (the &ldquo;<U>Monthly Redemption Notice</U>&rdquo;), in lieu of a cash redemption payment the Company may elect to
pay all or part of a Monthly Redemption Amount in Conversion Shares based on a conversion price equal to the lesser of (i) the then Conversion
Price and (ii) 85% of the average of the VWAPs for the 5 consecutive Trading Days ending on the Trading Day that is immediately prior
to the applicable Monthly Redemption Date (subject to adjustment for any stock dividend, stock split, stock combination or other similar
event affecting the Common Stock during such 5 Trading Day period) (the price calculated during the 20 Trading Day period immediately
prior to the Monthly Redemption Date, the &ldquo;<U>Monthly Conversion Price</U>&rdquo; and such 5 Trading Day period, the &ldquo;<U>Monthly
Conversion Period</U>&rdquo;); <U>provided</U>, <U>further</U>, that the Company may not pay the Monthly Redemption Amount in Conversion
Shares unless (x) from the date the Holder receives the duly delivered Monthly Redemption Notice through and until the date such Monthly
Redemption is paid in full, the Equity Conditions have been satisfied, unless waived in writing by the Holder, and (y) as to such Monthly
Redemption, prior to such Monthly Conversion Period (but not more than 5 Trading Days prior to the commencement of the Monthly Conversion
Period), the Company shall have delivered to the Holder&rsquo;s account with The Depository Trust Company a number of shares of Common
Stock to be applied against such Monthly Redemption Amount equal to the quotient of (x) the applicable Monthly Redemption Amount divided
by (y) the lesser of (A) the Conversion Price and (B) 85% of the average of the 5 VWAPs during the period ending on the 3<SUP>rd</SUP>
Trading Day immediately prior to the date of the Monthly Redemption Notice (the &ldquo;<U>Pre-Redemption Conversion Shares</U>&rdquo;).
The Holder may convert, pursuant to Section 4(a), any principal amount of this Debenture subject to a Monthly Redemption at any time prior
to the date that the Monthly Redemption Amount, plus accrued but unpaid interest, liquidated damages and any other amounts then owing
to the Holder are due and paid in full. Unless otherwise indicated by the Holder in the applicable Notice of Conversion, any principal
amount of this Debenture converted during the applicable Monthly Conversion Period until the date the Monthly Redemption Amount is paid
in full shall be first applied to the principal amount subject to the Monthly Redemption Amount payable in cash and then to the Monthly
Redemption Amount payable in Conversion Shares. Any principal amount of this Debenture converted during the applicable Monthly Conversion
Period in excess of the Monthly Redemption Amount shall be applied against the last principal amount of this Debenture scheduled to be
redeemed hereunder, in reverse time order from the Maturity Date; <U>provided</U>, <U>however</U>, if any such conversion is applied against
such Monthly Redemption Amount, the Pre-Redemption Conversion Shares, if any were issued in connection with such Monthly Redemption or
were not already applied to such conversions, shall be first applied against such conversion. The Company covenants and agrees that it
will honor all Notices of Conversion tendered up until such amounts are paid in full. The Company&rsquo;s determination to pay a Monthly
Redemption in cash, shares of Common Stock or a combination thereof shall be applied ratably to all of the holders of the then outstanding
Debentures based on their (or their predecessor&rsquo;s) initial purchases of Debentures pursuant to the Purchase Agreement. At any time
the Company delivers a notice to the Holder of its election to pay the Monthly Redemption Amount in shares of Common Stock, the Company
shall file a prospectus supplement pursuant to Rule 424 disclosing such election.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 17; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">b) <U>Optional
Redemption at Election of Company</U>. Subject to the provisions of this Section 6(b), at any time after the Original Issue Date,
the Company may deliver a notice to the Holder (an &ldquo;<U>Optional Redemption Notice</U>&rdquo; and the date such notice is
deemed delivered hereunder, the &ldquo;<U>Optional Redemption Notice Date</U>&rdquo;) of its irrevocable election to redeem some or
all of the then outstanding principal amount of this Debenture for cash in an amount equal to the Optional Redemption Amount on the
20th Trading Day following the Optional Redemption Notice Date (such date, the &ldquo;<U>Optional Redemption Date</U>&rdquo;, such
20 Trading Day period, the &ldquo;<U>Optional Redemption Period</U>&rdquo; and such redemption, the &ldquo;<U>Optional
Redemption</U>&rdquo;). The Optional Redemption Amount shall be payable in full on the Optional Redemption Date. The Company may
only effect an Optional Redemption if each of the Equity Conditions shall have been met (unless waived in writing by the Holder) on
each Trading Day during the period commencing on the Optional Redemption Notice Date through the Optional Redemption Date and
through and including the date payment of the Optional Redemption Amount is actually made in full. If any of the Equity Conditions
shall cease to be satisfied at any time during the Optional Redemption Period, then the Holder may elect to nullify the Optional
Redemption Notice by notice to the Company within 3 Trading Days after the first day on which any such Equity Condition has not been
met (provided that if, by a provision of the Transaction Documents, the Company is obligated to notify the Holder of the
nonexistence of an Equity Condition, such notice period shall be extended to the third Trading Day after proper notice from the
Company) in which case the Optional Redemption Notice shall be null and void, ab <I>initio</I>.&#9; The Company covenants and agrees
that it will honor all Notices of Conversion tendered from the time of delivery of the Optional Redemption Notice through the date
all amounts owing thereon are due and paid in full. The Company&rsquo;s determination to pay an Optional Redemption in cash shall be
applied ratably to all of the holders of the then outstanding Debentures based on their (or their predecessor&rsquo;s) initial
purchases of Debentures pursuant to the Purchase Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">c) <U>Redemption
Procedure</U>. The payment of cash or issuance of Common Stock, as applicable, pursuant to a Monthly Redemption or Optional Redemption
shall be payable on the Monthly Redemption Date and Optional Redemption Date, as applicable. If any portion of the payment pursuant to
a Monthly Redemption or Optional Redemption shall not be paid by the Company by the applicable due date, interest shall accrue thereon
at an interest rate equal to the lesser of 15% per annum or the maximum rate permitted by applicable law until such amount is paid in
full. Notwithstanding anything herein contained to the contrary, if any portion of the Monthly Redemption Amount or Optional Redemption
Amount remains unpaid after such date, the Holder may elect, by written notice to the Company given at any time thereafter, to invalidate
such Monthly Redemption or Optional Redemption, <U>ab initio</U>, and, with respect to the Company&rsquo;s failure to honor the Optional
Redemption, the Company shall have no further right to exercise such Optional Redemption. Notwithstanding anything to the contrary in
this Section 6, the Company&rsquo;s determination to redeem in cash or its elections under Section 6(b) shall be applied ratably among
the Holders of Debentures. The Holder may elect to convert the outstanding principal amount of the Debenture pursuant to Section 4(a)
prior to actual payment in cash for any redemption under this Section 6 by the delivery of a Notice of Conversion to the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<!-- Field: Page; Sequence: 18; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><U>Section 7</U>.&nbsp;<U>Negative
Covenants</U>. As long as any portion of this Debenture remains outstanding, unless the holders of at least 50% in principal amount of
the then outstanding Debentures shall have otherwise given prior written consent, the Company shall not, and shall not permit any of the
Subsidiaries to, directly or indirectly:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">a) other
than Permitted Indebtedness, enter into, create, incur, assume, guarantee or suffer to exist any indebtedness for borrowed money of any
kind, including, but not limited to, a guarantee, on or with respect to any of its property or assets now owned or hereafter acquired
or any interest therein or any income or profits therefrom;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">b) other
than Permitted Liens, enter into, create, incur, assume or suffer to exist any Liens of any kind, on or with respect to any of its property
or assets now owned or hereafter acquired or any interest therein or any income or profits therefrom;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">c) amend
its charter documents, including, without limitation, its certificate of incorporation and bylaws, in any manner that materially and adversely
affects any rights of the Holder (provided, however, that nothing herein shall prevent the Company from amending its charter documents
to effectuate a forward or reverse stock split);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">d) repay,
repurchase or offer to repay, repurchase or otherwise acquire more than a <U>de minimis</U> number of shares of its Common Stock or Common
Stock Equivalents other than as to (i) the Conversion Shares or Warrant Shares as permitted or required under the Transaction Documents
and (ii) repurchases of Common Stock or Common Stock Equivalents of departing employees, officers and directors of the Company, provided
that such repurchases shall not exceed an aggregate of $200,000 for all employees, officers and directors during the term of this Debenture;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">e) repay,
repurchase or offer to repay, repurchase or otherwise acquire any Indebtedness, other than (i) this Debenture and (ii) regularly scheduled
principal and interest payments under the terms of any Permitted Indebtedness, provided that such payments shall not be permitted if,
at such time, or after giving effect to such payment, any Event of Default exist or occur;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">f) pay
cash dividends or Distributions on any equity securities of the Company, except that any Subsidiary may, directly or indirectly, pay any
dividend or Distribution to the Company;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">g) enter
into any transaction with any Affiliate of the Company which would be required to be disclosed in any public filing with the Commission,
unless such transaction is made on an arm&rsquo;s-length basis and expressly approved by a majority of the disinterested directors of
the Company (even if less than a quorum otherwise required for board approval); or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 19; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">h) enter
into any agreement with respect to any of the foregoing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in; text-align: justify"><U>Section 8</U>.<U>&nbsp;Events of Default</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">a) &ldquo;<U>Event
of Default</U>&rdquo; means, wherever used herein, any of the following events (whatever the reason for such event and whether such event
shall be voluntary or involuntary or effected by operation of law or pursuant to any judgment, decree or order of any court, or any order,
rule or regulation of any administrative or governmental body):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in">i. any
default in the payment of (A) the principal amount of any Debenture or (B) interest, liquidated damages and other amounts owing to a Holder
on any Debenture, as and when the same shall become due and payable (whether on a Conversion Date or the Maturity Date or by acceleration
or otherwise) which default is not cured within 3 Trading Days;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in">ii. the
Company shall fail to materially observe or perform any other covenant or agreement contained in the Debentures (other than a breach by
the Company of its obligations to deliver shares of Common Stock to the Holder upon conversion, which breach is addressed in clause (xi)
below), which failure is not cured, if possible to cure, within the earlier to occur of (A) 15 Trading Days after notice of such failure
sent by the Holder or by any other Holder to the Company and (B) 15 Trading Days after the Company has become or should have become aware
of such failure;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in">iii. a
default or event of default (subject to any grace or cure period provided in the applicable agreement, document or instrument) shall occur
under (A) any of the Transaction Documents, which failure is not cured, if possible to cure, within 15 Trading Days following notice of
failure sent by the Holder to the Company;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in">iv. any
representation or warranty made in this Debenture, any other Transaction Documents, any written statement pursuant hereto or thereto or
any other report, financial statement or certificate made or delivered to the Holder or any other Holder pursuant to the Transaction Documents
shall be untrue or incorrect in any material respect as of the date when made or deemed made, which default is not cured within 5 Trading
Days;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in">v. the
Company or any Significant Subsidiary (as such term is defined in Rule 1-02(w) of Regulation S-X) shall be subject to a Bankruptcy Event;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 20; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in">vi. the
Company or any Subsidiary shall default on any of its obligations under any mortgage, credit agreement or other facility, indenture agreement,
factoring agreement or other instrument under which there may be issued, or by which there may be secured or evidenced, any indebtedness
for borrowed money or money due under any long term leasing or factoring arrangement that (a) involves an obligation greater than $500,000,
whether such indebtedness now exists or shall hereafter be created, and (b) results in such indebtedness becoming or being declared due
and payable prior to the date on which it would otherwise become due and payable;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in">vii. the
Common Stock shall not be eligible for listing or quotation for trading on a Trading Market and shall not be eligible to resume listing
or quotation for trading thereon within 10 Trading Days;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in">viii. the
Company (and all of its Subsidiaries, taken as a whole) shall be a party to any Change of Control Transaction or Fundamental Transaction
or shall agree to sell or dispose of all or in excess of 50% of its assets in one transaction or a series of related transactions (whether
or not such sale would constitute a Change of Control Transaction);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in">ix. the
Initial Registration Statement (as defined in the Registration Rights Agreement) shall not have been declared effective by the Commission
on or prior to the 210<SUP>th</SUP> calendar day after the Closing Date or the Company does not meet the current public information requirements
under Rule 144 in respect of the Registrable Securities (as defined in the Registration Rights Agreement);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in">x. if,
during the Effectiveness Period (as defined in the Registration Rights Agreement), either (a) the effectiveness of the Registration Statement
lapses for any reason or (b) the Holder shall not be permitted to resell Registrable Securities (as defined in the Registration Rights
Agreement) under the Registration Statement for a period of more than 30 consecutive Trading Days or 45 non-consecutive Trading Days during
any 12 month period; <U>provided</U>, <U>however</U>, that if the Company is negotiating a merger, consolidation, acquisition or sale
of all or substantially all of its assets or a similar transaction and, in the written opinion of counsel to the Company, the Registration
Statement would be required to be amended to include information concerning such pending transaction(s) or the parties thereto which information
is not available or may not be publicly disclosed at the time, the Company shall be permitted an additional 10 consecutive Trading Days
during any 12 month period pursuant to this Section 8(a)(x);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 21; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in">xi. the
Company shall fail for any reason to deliver Conversion Shares to a Holder prior to the 7th Trading Day after a Conversion Date pursuant
to Section 4(c) or the Company shall provide at any time notice to the Holder, including by way of public announcement, of the Company&rsquo;s
intention to not honor requests for conversions of any Debentures in accordance with the terms hereof;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in">xii. the
electronic transfer by the Company of shares of Common Stock through the Depository Trust Company or another established clearing corporation
is no longer available or is subject to a &ldquo;chill&rdquo; that lasts for more than 3 Trading Days;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in">xiii. any
monetary judgment, writ or similar final process not covered by any insurance shall be entered or filed against the Company, any Subsidiary
or any of their respective property or other assets for more than $1,000,000, and such judgment, writ or similar final process shall remain
unvacated, unbonded or unstayed for a period of 60 calendar days; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in">xiv. a
false or inaccurate certification (including a false or inaccurate deemed certification) by the Company that the Equity Conditions are
satisfied or that there has been no Equity Conditions Failure or as to whether any Event of Default has occurred.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">b) <U>Remedies
Upon Event of Default</U>. If any Event of Default occurs, the outstanding principal amount of this Debenture, plus accrued but unpaid
interest, liquidated damages and other amounts owing in respect thereof through the date of acceleration, shall become, at the Holder&rsquo;s
election, immediately due and payable in cash at the Mandatory Default Amount. Commencing 5 days after the occurrence of any Event of
Default that results in the eventual acceleration of this Debenture, the interest rate on this Debenture shall accrue at an interest rate
equal to the lesser of 18% per annum or the maximum rate permitted under applicable law. Upon the payment in full of the Mandatory Default
Amount, the Holder shall promptly surrender this Debenture to or as directed by the Company. In connection with such acceleration described
herein, the Holder need not provide, and the Company hereby waives, any presentment, demand, protest or other notice of any kind, and
the Holder may immediately and without expiration of any grace period enforce any and all of its rights and remedies hereunder and all
other remedies available to it under applicable law. Such acceleration may be rescinded and annulled by Holder at any time prior to payment
hereunder and the Holder shall have all rights as a holder of the Debenture until such time, if any, as the Holder receives full payment
pursuant to this Section 8(b). No such rescission or annulment shall affect any subsequent Event of Default or impair any right consequent
thereon.<BR STYLE="clear: both">
&nbsp;</P>

<!-- Field: Page; Sequence: 22; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"></P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><U>Section 9</U>.<U>&nbsp;Miscellaneous</U>.<BR STYLE="clear: both">
&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">a) <U>Notices</U>.
Any and all notices or other communications or deliveries to be provided by the Holder hereunder, including, without limitation, any Notice
of Conversion, shall be in writing and delivered personally, by email attachment, or sent by a nationally recognized overnight courier
service, addressed to the Company, at the address set forth above, or such other email address, or address as the Company may specify
for such purposes by notice to the Holder delivered in accordance with this Section 9(a). Any and all notices or other communications
or deliveries to be provided by the Company hereunder shall be in writing and delivered personally, by email attachment, or sent by a
nationally recognized overnight courier service addressed to each Holder at the email address or address of the Holder appearing on the
books of the Company, or if no such email attachment or address appears on the books of the Company, at the principal place of business
of such Holder, as set forth in the Purchase Agreement. Any notice or other communication or deliveries hereunder shall be deemed given
and effective on the earliest of (i) the date of transmission, if such notice or communication is delivered via email attachment to the
email address set forth on the signature pages attached hereto prior to 5:30 p.m. (New York City time) on any date, (ii) the next Trading
Day after the date of transmission, if such notice or communication is delivered via email attachment to the email address set forth on
the signature pages attached hereto on a day that is not a Trading Day or later than 5:30 p.m. (New York City time) on any Trading Day,
(iii) the second Trading Day following the date of mailing, if sent by U.S. nationally recognized overnight courier service or (iv) upon
actual receipt by the party to whom such notice is required to be given.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">b)&#9;<U>Absolute Obligation</U>.
Except as expressly provided herein, no provision of this Debenture shall alter or impair the obligation of the Company, which is absolute
and unconditional, to pay the principal of, liquidated damages and accrued interest, as applicable, on this Debenture at the time, place,
and rate, and in the coin or currency, herein prescribed. This Debenture is a direct debt obligation of the Company. This Debenture ranks
<U>pari passu</U> with all other Debentures now or hereafter issued under the terms set forth herein.&#9;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">c) <U>Lost
or Mutilated Debenture</U>. If this Debenture shall be mutilated, lost, stolen or destroyed, the Company shall execute and deliver, in
exchange and substitution for and upon cancellation of a mutilated Debenture, or in lieu of or in substitution for a lost, stolen or destroyed
Debenture, a new Debenture for the principal amount of this Debenture so mutilated, lost, stolen or destroyed, but only upon receipt of
evidence of such loss, theft or destruction of such Debenture, and of the ownership hereof, reasonably satisfactory to the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 23; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">d) <U>Governing
Law</U>. All questions concerning the construction, validity, enforcement and interpretation of this Debenture shall be governed by and
construed and enforced in accordance with the internal laws of the State of New York, without regard to the principles of conflict of
laws thereof. Each party agrees that all legal proceedings concerning the interpretation, enforcement and defense of the transactions
contemplated by any of the Transaction Documents (whether brought against a party hereto or its respective Affiliates, directors, officers,
shareholders, employees or agents) shall be commenced in the state and federal courts sitting in the City of New York, Borough of Manhattan
(the &ldquo;<U>New York Courts</U>&rdquo;). Each party hereto hereby irrevocably submits to the exclusive jurisdiction of the New York
Courts for the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated hereby or discussed
herein (including with respect to the enforcement of any of the Transaction Documents), and hereby irrevocably waives, and agrees not
to assert in any suit, action or proceeding, any claim that it is not personally subject to the jurisdiction of such New York Courts,
or such New York Courts are improper or inconvenient venue for such proceeding. Each party hereby irrevocably waives personal service
of process and consents to process being served in any such suit, action or proceeding by mailing a copy thereof via registered or certified
mail or overnight delivery (with evidence of delivery) to such party at the address in effect for notices to it under this Debenture and
agrees that such service shall constitute good and sufficient service of process and notice thereof. Nothing contained herein shall be
deemed to limit in any way any right to serve process in any other manner permitted by applicable law. Each party hereto hereby irrevocably
waives, to the fullest extent permitted by applicable law, any and all right to trial by jury in any legal proceeding arising out of or
relating to this Debenture or the transactions contemplated hereby. If any party shall commence an action or proceeding to enforce any
provisions of this Debenture, then the prevailing party in such action or proceeding shall be reimbursed by the other party for its attorneys
fees and other costs and expenses incurred in the investigation, preparation and prosecution of such action or proceeding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">e) <U>Waiver</U>.
Any waiver by the Company or the Holder of a breach of any provision of this Debenture shall not operate as or be construed to be a waiver
of any other breach of such provision or of any breach of any other provision of this Debenture. The failure of the Company or the Holder
to insist upon strict adherence to any term of this Debenture on one or more occasions shall not be considered a waiver or deprive that
party of the right thereafter to insist upon strict adherence to that term or any other term of this Debenture on any other occasion.
Any waiver or amendment by the Company or the Holder must be in writing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">f) <U>Severability</U>.
If any provision of this Debenture is invalid, illegal or unenforceable, the balance of this Debenture shall remain in effect, and if
any provision is inapplicable to any Person or circumstance, it shall nevertheless remain applicable to all other Persons and circumstances.
If it shall be found that any interest or other amount deemed interest due hereunder violates the applicable law governing usury, the
applicable rate of interest due hereunder shall automatically be lowered to equal the maximum rate of interest permitted under applicable
law. The Company covenants (to the extent that it may lawfully do so) that it shall not at any time insist upon, plead, or in any manner
whatsoever claim or take the benefit or advantage of, any stay, extension or usury law or other law which would prohibit or forgive the
Company from paying all or any portion of the principal of or interest on this Debenture as contemplated herein, wherever enacted, now
or at any time hereafter in force, or which may affect the covenants or the performance of this Debenture, and the Company (to the extent
it may lawfully do so) hereby expressly waives all benefits or advantage of any such law, and covenants that it will not, by resort to
any such law, hinder, delay or impede the execution of any power herein granted to the Holder, but will suffer and permit the execution
of every such as though no such law has been enacted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 24; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">g) <U>Remedies,
Characterizations, Other Obligations, Breaches and Injunctive Relief. </U>The remedies provided in this Debenture shall be cumulative
and in addition to all other remedies available under this Debenture and any of the other Transaction Documents at law or in equity (including
a decree of specific performance and/or other injunctive relief), and nothing herein shall limit the Holder&rsquo;s right to pursue actual
and consequential damages for any failure by the Company to comply with the terms of this Debenture. The Company covenants to the Holder
that there shall be no characterization concerning this instrument other than as expressly provided herein. Amounts set forth or provided
for herein with respect to payments, conversion and the like (and the computation thereof) shall be the amounts to be received by the
Holder and shall not, except as expressly provided herein, be subject to any other obligation of the Company (or the performance thereof).
The Company acknowledges that a breach by it of its obligations hereunder will cause irreparable harm to the Holder and that the remedy
at law for any such breach may be inadequate. The Company therefore agrees that, in the event of any such breach or threatened breach,
the Holder shall be entitled, in addition to all other available remedies, to an injunction restraining any such breach or any such threatened
breach, without the necessity of showing economic loss and without any bond or other security being required. The Company shall provide
all information and documentation to the Holder that is reasonably requested by the Holder to enable the Holder to confirm the Company&rsquo;s
compliance with the terms and conditions of this Debenture.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">h) <U>Next
Business Day</U>. Whenever any payment or other obligation hereunder shall be due on a day other than a Business Day, such payment shall
be made on the next succeeding Business Day.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">i) <U>Headings</U>.
The headings contained herein are for convenience only, do not constitute a part of this Debenture and shall not be deemed to limit or
affect any of the provisions hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">Section 10. <U>Disclosure</U>. Upon receipt
or delivery by the Company of any notice in accordance with the terms of this Debenture, unless the Company has in good faith determined
that the matters relating to such notice do not constitute material, nonpublic information relating to the Company or its Subsidiaries,
the Company shall within two (2) Business Days after such receipt or delivery publicly disclose such material, nonpublic information on
a Current Report on Form 8-K or otherwise. In the event that the Company believes that a notice contains material, non-public information
relating to the Company or its Subsidiaries, the Company so shall indicate to the Holder contemporaneously with delivery of such notice,
and in the absence of any such indication, the Holder shall be allowed to presume that all matters relating to such notice do not constitute
material, nonpublic information relating to the Company or its Subsidiaries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">*********************</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"><I>(Signature Page Follows)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"><I>&nbsp;</I></P>


<!-- Field: Page; Sequence: 25; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">IN WITNESS WHEREOF, the Company
has caused this Debenture to be duly executed by a duly authorized officer as of the date first above indicated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>qualigen
  therapeutics, inc.</B></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
  <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
  Michael S. Poirier</I></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Michael
  S. Poirier&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
  Executive Officer</FONT></TD></TR>
</TABLE>


<P STYLE="margin-top: 0pt; margin-bottom: 0pt"> </P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>


<!-- Field: Page; Sequence: 26; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Courier New, Courier, Monospace; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Courier New, Courier, Monospace; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>ANNEX
A</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>NOTICE OF CONVERSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The undersigned hereby elects
to convert principal under the 8% Senior Convertible Debenture due December 22, 2025 of Qualigen Therapeutics, Inc., a Delaware corporation
(the &ldquo;<U>Company</U>&rdquo;), into shares of common stock (the &ldquo;<U>Common Stock</U>&rdquo;), of the Company according to the
conditions hereof, as of the date written below. If shares of Common Stock are to be issued in the name of a person other than the undersigned,
the undersigned will pay all transfer taxes payable with respect thereto and is delivering herewith such certificates and opinions as
reasonably requested by the Company in accordance therewith. No fee will be charged to the holder for any conversion, except for such
transfer taxes, if any.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">By the delivery of this Notice
of Conversion the undersigned represents and warrants to the Company that its ownership of the Common Stock does not exceed the amounts
specified under Section 4 of this Debenture, as determined in accordance with Section 13(d) of the Exchange Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The undersigned agrees to comply
with the prospectus delivery requirements under the applicable securities laws in connection with any transfer of the aforesaid shares
of Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Conversion calculations:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
  <TD COLSPAN="2" STYLE="text-align: justify">Date to Effect Conversion:</TD></TR>

<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
  <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
  <TD COLSPAN="2" STYLE="text-align: justify">Principal Amount of Debenture to be Converted:</TD></TR>

<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
  <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
  <TD COLSPAN="2" STYLE="text-align: justify">Payment of Interest in Common Stock __ yes __ no</TD></TR>

<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
  <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
  <TD STYLE="text-align: justify; width: 5%"></TD>
  <TD STYLE="text-align: justify; width: 45%">If yes, $_____ of Interest Accrued on Account of Conversion at Issue.</TD></TR>

<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
  <TD STYLE="text-align: justify">&nbsp;</TD>
  <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
  <TD COLSPAN="2" STYLE="text-align: justify">Number of shares of Common Stock to be issued:</TD></TR>

<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
  <TD STYLE="text-align: justify">&nbsp;</TD>
  <TD STYLE="text-align: justify">&nbsp;</TD></TR>

<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
  <TD COLSPAN="2" STYLE="text-align: justify">Signature:</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
  <TD STYLE="text-align: justify">&nbsp;</TD>
  <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
  <TD COLSPAN="2" STYLE="text-align: justify">Name:</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
  <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
  <TD COLSPAN="2" STYLE="text-align: justify">Address for Delivery of Common
Stock Certificates:</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
  <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
  <TD COLSPAN="2" STYLE="text-align: justify"><U>Or</U></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
  <TD COLSPAN="2" STYLE="text-align: justify">DWAC Instructions:</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
  <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
  <TD STYLE="text-align: justify; width: 11%">Broker No:</TD>
  <TD STYLE="text-align: justify; width: 39%"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
  <TD STYLE="text-align: justify">&nbsp;</TD>
  <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
  <TD STYLE="text-align: justify">Account No:</TD>
  <TD STYLE="text-align: justify"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 27; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><U><BR STYLE="clear: both">
</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Schedule 1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CONVERSION SCHEDULE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The 8% Senior Convertible Debentures due onDecember
22, 2025 in the aggregate principal amount of $3,300,000 are issued by Qualigen Therapeutics, Inc., a Delaware corporation. This Conversion
Schedule reflects conversions made under Section 4 of the above referenced Debenture.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Dated:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding: 0.02in; width: 23%; border: Black 1pt solid">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Date of Conversion</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(or for first entry,</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Original Issue Date)</P></TD>
    <TD STYLE="padding: 0.02in; width: 23%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Amount of</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Conversion</P></TD>
    <TD STYLE="padding: 0.02in; width: 31%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Aggregate Principal Amount Remaining Subsequent to Conversion (or original Principal Amount)</FONT></TD>
    <TD STYLE="padding: 0.02in; width: 23%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Company Attest</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.02in; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="padding: 0.02in; border-bottom: Black 1pt solid; border-right: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="padding: 0.02in; border-bottom: Black 1pt solid; border-right: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="padding: 0.02in; border-bottom: Black 1pt solid; border-right: Black 1pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.02in; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="padding: 0.02in; border-bottom: Black 1pt solid; border-right: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="padding: 0.02in; border-bottom: Black 1pt solid; border-right: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="padding: 0.02in; border-bottom: Black 1pt solid; border-right: Black 1pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.02in; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="padding: 0.02in; border-bottom: Black 1pt solid; border-right: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="padding: 0.02in; border-bottom: Black 1pt solid; border-right: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="padding: 0.02in; border-bottom: Black 1pt solid; border-right: Black 1pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.02in; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="padding: 0.02in; border-bottom: Black 1pt solid; border-right: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="padding: 0.02in; border-bottom: Black 1pt solid; border-right: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="padding: 0.02in; border-bottom: Black 1pt solid; border-right: Black 1pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.02in; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="padding: 0.02in; border-bottom: Black 1pt solid; border-right: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="padding: 0.02in; border-bottom: Black 1pt solid; border-right: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="padding: 0.02in; border-bottom: Black 1pt solid; border-right: Black 1pt solid">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 28; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.3
<SEQUENCE>5
<FILENAME>ex10-3.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibit
10.3</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">REGISTRATION
RIGHTS AGREEMENT</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Registration Rights Agreement (this &ldquo;<U>Agreement</U>&rdquo;) is made and entered into as of December 22, 2022, between Qualigen
Therapeutics, Inc., a Delaware corporation (the &ldquo;<U>Company</U>&rdquo;), and the purchaser signatory hereto (the &ldquo;<U>Purchaser</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Agreement is made pursuant to the Securities Purchase Agreement, dated as of the date hereof, between the Company and the Purchaser (the
&ldquo;<U>Purchase Agreement</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company and the Purchaser hereby agrees as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.
<U>Definitions</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Capitalized
terms used and not otherwise defined herein that are defined in the Purchase Agreement shall have the meanings given such terms in the
Purchase Agreement.</B> As used in this Agreement, the following terms shall have the following meanings:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Advice</U>&rdquo;
shall have the meaning set forth in Section 6(c).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Effectiveness
Date</U>&rdquo; means, with respect to the Initial Registration Statement required to be filed hereunder, the 90<SUP>th</SUP> calendar
day following the date hereof (or, in the event of a &ldquo;full review&rdquo; by the Commission, the 120<SUP>th</SUP> calendar day following
the date hereof) and with respect to any additional Registration Statements which may be required pursuant to Section 2(c) or Section
3(c), the 90<SUP>th</SUP> calendar day following the date on which an additional Registration Statement is required to be filed hereunder
(or, in the event of a &ldquo;full review&rdquo; by the Commission, the 120<SUP>th</SUP> calendar day following the date such additional
Registration Statement is required to be filed hereunder); <U>provided</U>, <U>however</U>, that in the event the Company is notified
by the Commission that one or more of the above Registration Statements will not be reviewed or is no longer subject to further review
and comments, the Effectiveness Date as to such Registration Statement shall be the fifth Trading Day following the date on which the
Company is so notified if such date precedes the dates otherwise required above, provided, further, if such Effectiveness Date falls
on a day that is not a Trading Day, then the Effectiveness Date shall be the next succeeding Trading Day.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Effectiveness
Period</U>&rdquo; shall have the meaning set forth in Section 2(a).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Event</U>&rdquo;
shall have the meaning set forth in Section 2(d).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Event
Date</U>&rdquo; shall have the meaning set forth in Section 2(d).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Filing
Date</U>&rdquo; means, with respect to the Initial Registration Statement required hereunder, the 60<SUP>th</SUP> calendar day following
the date hereof and, with respect to any additional Registration Statements which may be required pursuant to Section 2(c) or Section
3(c), the earliest practical date on which the Company is permitted by SEC Guidance to file such additional Registration Statement related
to the Registrable Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Holder</U>&rdquo;
or &ldquo;<U>Holders</U>&rdquo; means the holder or holders, as the case may be, from time to time of Registrable Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Indemnified
Party</U>&rdquo; shall have the meaning set forth in Section 5(c).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Indemnifying
Party</U>&rdquo; shall have the meaning set forth in Section 5(c).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Initial
Registration Statement</U>&rdquo; means the initial Registration Statement filed pursuant to this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Losses</U>&rdquo;
shall have the meaning set forth in Section 5(a).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Plan
of Distribution</U>&rdquo; shall have the meaning set forth in Section 2(a).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Prospectus</U>&rdquo;
means the prospectus included in a Registration Statement (including, without limitation, a prospectus that includes any information
previously omitted from a prospectus filed as part of an effective registration statement in reliance upon Rule 430A promulgated by the
Commission pursuant to the Securities Act), as amended or supplemented by any prospectus supplement, with respect to the terms of the
offering of any portion of the Registrable Securities covered by a Registration Statement, and all other amendments and supplements to
the Prospectus, including post-effective amendments, and all material incorporated by reference or deemed to be incorporated by reference
in such Prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Registrable
Securities</U>&rdquo; means, as of any date of determination, (a) all shares of Common Stock then issued and issuable upon conversion
in full of the Debentures (assuming on such date the Debentures are converted in full without regard to any conversion limitations therein),
(b) all shares of Common Stock issued and issuable as interest or principal on the Debentures (assuming all permissible interest and
principal payments are made in shares of Common Stock and the Debentures are held until maturity), (c) all Warrant Shares then issued
and issuable upon exercise of the Warrants (assuming on such date the Warrants are exercised in full without regard to any exercise limitations
therein), (d) any additional shares of Common Stock issued and issuable in connection with any anti-dilution provisions in the Debentures
or the Warrants (in each case, without giving effect to any limitations on conversion set forth in the Debentures or limitations on exercise
set forth in the Warrants) and (e) any securities issued or then issuable upon any stock split, dividend or other distribution, recapitalization
or similar event with respect to the foregoing; <U>provided, however</U>, that any such Registrable Securities shall cease to be Registrable
Securities (and the Company shall not be required to maintain the effectiveness of any, or file another, Registration Statement hereunder
with respect thereto) once (a) a Registration Statement with respect to the sale of such Registrable Securities is declared effective
by the Commission under the Securities Act and such Registrable Securities have been disposed of by the Holder in accordance with such
effective Registration Statement, (b) such Registrable Securities have been previously sold or otherwise transferred in accordance with
Rule 144, or (c) such Registrable Securities become eligible for resale without volume or manner-of-sale restrictions and without current
public information pursuant to Rule 144 as set forth in a written opinion letter to such effect, addressed, delivered and acceptable
to the Transfer Agent , as reasonably determined by the Company, upon the advice of counsel to the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Registration
Statement</U>&rdquo; means any registration statement required to be filed hereunder pursuant to Section 2(a) and any additional registration
statements contemplated by Section 2(c) or Section 3(c), including (in each case) the Prospectus, amendments and supplements to any such
registration statement or Prospectus, including pre- and post-effective amendments, all exhibits thereto, and all material incorporated
by reference or deemed to be incorporated by reference in any such registration statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Rule
415</U>&rdquo; means Rule 415 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended or interpreted
from time to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same purpose and effect
as such Rule.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Rule
424</U>&rdquo; means Rule 424 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended or interpreted
from time to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same purpose and effect
as such Rule.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>SEC
Guidance</U>&rdquo; means (i) any publicly-available written or oral guidance of the Commission staff, or any comments, requirements
or requests of the Commission staff and (ii) the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Selling
Stockholder Questionnaire</U>&rdquo; shall have the meaning set forth in Section 3(a).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.
<U>Shelf Registration</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
On or prior to each Filing Date, the Company shall prepare and file with the Commission a Registration Statement covering the resale
of all of the Registrable Securities that are not then registered on an effective Registration Statement for an offering to be made on
a continuous basis pursuant to Rule 415. Each Registration Statement filed hereunder shall be on Form S-3 (except if the Company is not
then eligible to register for resale the Registrable Securities on Form S-3, in which case such registration shall be on another appropriate
form in accordance herewith, subject to the provisions of Section 2(e)) and shall contain (unless otherwise directed by at least 50%
in interest of the Holders) substantially the &ldquo;<U>Plan of Distribution</U>&rdquo; attached hereto as <U>Annex A</U> (as may be
modified to respond to comments, if any, provided by the Commission, or otherwise reasonably modified by the Company, with the prior
written consent of at least 50% in interest of the Holders, not to be unreasonably withheld); <U>provided</U>, <U>however</U>, that no
Holder shall be required to be named as an &ldquo;underwriter&rdquo; without such Holder&rsquo;s express prior written consent. Subject
to the terms of this Agreement, the Company shall use its commercially reasonable efforts to cause a Registration Statement filed under
this Agreement (including, without limitation, under Section 3(c)) to be declared effective under the Securities Act as promptly as practicable
after the filing thereof, but in any event no later than the applicable Effectiveness Date, and shall use its commercially reasonable
efforts to keep such Registration Statement continuously effective under the Securities Act until the earliest date that all Registrable
Securities covered by such Registration Statement (i) have been sold, thereunder or pursuant to Rule 144, or (ii) may be sold without
volume or manner-of-sale restrictions pursuant to Rule 144 and without the requirement for the Company to be in compliance with the current
public information requirement under Rule 144, as determined by the counsel to the Company pursuant to a written opinion letter to such
effect, addressed and acceptable to the Transfer Agent (the &ldquo;<U>Effectiveness Period</U>&rdquo;). The Company shall telephonically
request effectiveness of a Registration Statement as of 4:00 p.m. (New York City time) on a Trading Day. The Company shall immediately
notify the Holders via e-mail of the effectiveness of a Registration Statement on the same Trading Day that the Company telephonically
confirms effectiveness with the Commission,. The Company shall, by 5:30 p.m. (New York City time) on the Trading Day after the effective
date of such Registration Statement, file a final Prospectus with the Commission as required by Rule 424.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
Notwithstanding the registration obligations set forth in Section 2(a), if the Commission informs the Company that all of the Registrable
Securities cannot, as a result of the application of Rule 415, be registered for resale as a secondary offering on a single registration
statement, the Company agrees to promptly inform each of the Holders thereof and use its commercially reasonable efforts to file amendments
to the Initial Registration Statement as required by the Commission, covering the maximum number of Registrable Securities permitted
to be registered by the Commission, on Form S-3 or such other form available to register for resale the Registrable Securities as a secondary
offering, subject to the provisions of Section 2(e) with respect to filing on Form S-3 or other appropriate form, and subject to the
provisions of Section 2(d) with respect to the payment of liquidated damages; <U>provided</U>, <U>however</U>, that prior to filing such
amendment, the Company shall be obligated to use commercially reasonable efforts to advocate with the Commission for the registration
of all of the Registrable Securities in accordance with the SEC Guidance, including without limitation, Compliance and Disclosure Interpretation
612.09.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
Notwithstanding any other provision of this Agreement and subject to the payment of liquidated damages pursuant to Section 2(d), if the
Commission or any SEC Guidance sets forth a limitation on the number of Registrable Securities permitted to be registered on a particular
Registration Statement as a secondary offering (and notwithstanding that the Company used commercially reasonable efforts to advocate
with the Commission for the registration of all or a greater portion of Registrable Securities), unless otherwise directed in writing
by a Holder as to its Registrable Securities, the number of Registrable Securities to be registered on such Registration Statement will
be reduced as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">First,
                                            the Company shall reduce or eliminate any securities to be included other than Registrable
                                            Securities;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Second,
                                            the Company shall reduce Registrable Securities represented by Warrant Shares (applied, in
                                            the case that some Warrant Shares may be registered, to the Holders on a pro rata basis based
                                            on the total number of unregistered Warrant Shares held by such Holders); and</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Third,
                                            the Company shall reduce Registrable Securities represented by Conversion Shares (applied,
                                            in the case that some Conversion Shares may be registered, to the Holders on a pro rata basis
                                            based on the total number of unregistered Conversion Shares held by such Holders).</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the event of a cutback hereunder, the Company shall give the Holder at least three (3) Trading Days prior written notice along with the
calculations as to such Holder&rsquo;s allotment. In the event the Company amends the Initial Registration Statement in accordance with
the foregoing, the Company will use its commercially reasonable efforts to file with the Commission, as promptly as allowed by Commission
or SEC Guidance provided to the Company or to registrants of securities in general, one or more registration statements on Form S-3 or
such other form available to register for resale those Registrable Securities that were not registered for resale on the Initial Registration
Statement, as amended.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
If: (i) the Initial Registration Statement is not filed on or prior to its Filing Date, the Company files the Initial Registration Statement
without affording the Holders the opportunity to review and comment on the same as required by Section 3(a) herein, or the Company subsequent
withdraws the filing of the Registration Statement, the Company shall be deemed to have not satisfied this clause as of the Filing Date),
or (ii) the Company fails to file with the Commission a request for acceleration of a Registration Statement in accordance with Rule
461 promulgated by the Commission pursuant to the Securities Act, within five (5) Trading Days of the date that the Company is notified
(orally or in writing, whichever is earlier) by the Commission that such Registration Statement will not be &ldquo;reviewed&rdquo; or
will not be subject to further review, or (iii) a Registration Statement registering for resale all of the Registrable Securities is
not declared effective by the Commission by the Effectiveness Date or (iv) after the effective date of a Registration Statement, such
Registration Statement ceases for any reason to remain continuously effective as to all Registrable Securities included in such Registration
Statement, or the Holders are otherwise not permitted to utilize the Prospectus therein to resell such Registrable Securities, for more
than fifteen (15) consecutive calendar days or more than an aggregate of forty-five (45) calendar days (which need not be consecutive
calendar days) during any 12-month period (any such failure or breach being referred to as an &ldquo;<U>Event</U>&rdquo;, and for purposes
of clauses (i) and (iii), the date on which such Event occurs, and for purpose of clause (ii) the date on which such five (5) Trading
Day period is exceeded and for purpose of clause (iv) the date on which such fifteen (15) or forty-five (45) calendar day period, as
applicable, is exceeded being referred to as &ldquo;<U>Event Date</U>&rdquo;), then, in addition to any other rights the Holders may
have hereunder or under applicable law, on each such Event Date and on each monthly anniversary of each such Event Date (if the applicable
Event shall not have been cured by such date) until the applicable Event is cured, the Company shall pay to each Holder an amount in
cash, as partial liquidated damages and not as a penalty, equal to the product of 1.0% multiplied by the aggregate Subscription Amount
paid by such Holder pursuant to the Purchase Agreement. The parties agree that the maximum aggregate liquidated damages payable to a
Holder under this Agreement shall be 6% of the aggregate Subscription Amount paid by such Holder pursuant to the Purchase Agreement.
The partial liquidated damages pursuant to the terms hereof shall apply on a daily pro rata basis for any portion of a month prior to
the cure of an Event. Notwithstanding anything to the contrary herein or in the Purchase Agreement, The parties agree that no liquidated
damages shall accrue during any time in which the Registrable Securities may be sold without volume or manner-of-sale restrictions pursuant
to Rule 144 and without the requirement for the Company to be in compliance with the current public information requirement under Rule
144, as determined by the counsel to the Company pursuant to a written opinion letter to such effect, addressed and acceptable to the
Transfer Agent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)
If Form S-3 is not available for the registration of the resale of Registrable Securities hereunder, the Company shall (i) register the
resale of the Registrable Securities on another appropriate form and (ii) undertake to register the Registrable Securities on Form S-3
as soon as reasonably practicable after such form is available, provided that the Company shall maintain the effectiveness of the Registration
Statement then in effect until such time as a Registration Statement on Form S-3 covering the Registrable Securities has been declared
effective by the Commission.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.
<U>Registration Procedures</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.35in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the Company&rsquo;s registration obligations hereunder, the Company shall:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
Not less than three (3) Trading Days prior to the filing of each Registration Statement and not less than one (1) Trading Day prior to
the filing of any related Prospectus or any amendment or supplement thereto (including any document that would be incorporated or deemed
to be incorporated therein by reference), the Company shall (i) furnish to each Holder copies of all such documents proposed to be filed,
which documents (other than those incorporated or deemed to be incorporated by reference) will be subject to the review of such Holders,
and (ii) cause its officers and directors, counsel and independent registered public accountants to respond to such inquiries as shall
be necessary, in the reasonable opinion of respective counsel to each Holder, to conduct a reasonable investigation within the meaning
of the Securities Act. The Company shall not file a Registration Statement or any such Prospectus or any amendments or supplements thereto
to which the Holders of a majority of the Registrable Securities shall reasonably object in good faith, provided that, the Company is
notified of such objection in writing no later than three (3) Trading Days after the Holders have been so furnished copies of a Registration
Statement or one (1) Trading Day after the Holders have been so furnished copies of any related Prospectus or amendments or supplements
thereto. Each Holder agrees to furnish to the Company a completed questionnaire in the form attached to this Agreement as <U>Annex B
</U>(a &ldquo;<U>Selling Stockholder Questionnaire</U>&rdquo;) on a date that is not less than the earlier of (A) two (2) Trading Days
prior to the Filing Date and (B) the fourth (4<SUP>th</SUP>) Trading Day following the date on which such Holder receives draft materials
in accordance with this Section.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
(i) Prepare and file with the Commission such amendments, including post-effective amendments, to a Registration Statement and the Prospectus
used in connection therewith as may be necessary to keep a Registration Statement continuously effective as to the applicable Registrable
Securities for the Effectiveness Period and prepare and file with the Commission such additional Registration Statements in order to
register for resale under the Securities Act all of the Registrable Securities, (ii) cause the related Prospectus to be amended or supplemented
by any required Prospectus supplement (subject to the terms of this Agreement), and, as so supplemented or amended, to be filed pursuant
to Rule 424, (iii) respond as promptly as reasonably practicable to any comments received from the Commission with respect to a Registration
Statement or any amendment thereto and provide as promptly as reasonably practicable to the Holders true and complete copies of all correspondence
from and to the Commission relating to a Registration Statement (provided that, the Company shall excise any information contained therein
which would constitute material non-public information regarding the Company or any of its Subsidiaries), and (iv) comply in all material
respects with the applicable provisions of the Securities Act and the Exchange Act with respect to the disposition of all Registrable
Securities covered by a Registration Statement during the applicable period in accordance (subject to the terms of this Agreement) with
the intended methods of disposition by the Holders thereof set forth in such Registration Statement as so amended or in such Prospectus
as so supplemented.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
If during the Effectiveness Period, the number of Registrable Securities at any time exceeds 100% of the number of shares of Common Stock
then registered in all Registration Statements filed pursuant hereto, then the Company shall file as soon as reasonably practicable,
but in any case prior to the applicable Filing Date, an additional Registration Statement covering the resale by the Holders of not less
than the number of such Registrable Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
Notify the Holders of Registrable Securities to be sold (which notice shall, pursuant to clauses (iii) through (vi) hereof, be accompanied
by an instruction to suspend the use of the Prospectus until the requisite changes have been made) as promptly as reasonably practicable
(and, in the case of (i)(A) below, not less than one (1) Trading Day prior to such filing) and (if requested by any such Person) confirm
such notice in writing no later than one (1) Trading Day following the day (i)(A) when a Prospectus or any Prospectus supplement or post-effective
amendment to a Registration Statement is proposed to be filed, (B) when the Commission notifies the Company whether there will be a &ldquo;review&rdquo;
of such Registration Statement and whenever the Commission comments in writing on such Registration Statement, and (C) with respect to
a Registration Statement or any post-effective amendment, when the same has become effective, (ii) of any request by the Commission or
any other federal or state governmental authority for amendments or supplements to a Registration Statement or Prospectus or for additional
information, (iii) of the issuance by the Commission or any other federal or state governmental authority of any stop order suspending
the effectiveness of a Registration Statement covering any or all of the Registrable Securities or the initiation of any Proceedings
for that purpose, (iv) of the receipt by the Company of any notification with respect to the suspension of the qualification or exemption
from qualification of any of the Registrable Securities for sale in any jurisdiction, or the initiation or threatening of any Proceeding
for such purpose, (v) of the occurrence of any event or passage of time that makes the financial statements included in a Registration
Statement ineligible for inclusion therein or any statement made in a Registration Statement or Prospectus or any document incorporated
or deemed to be incorporated therein by reference untrue in any material respect or that requires any revisions to a Registration Statement,
Prospectus or other documents so that, in the case of a Registration Statement or the Prospectus, as the case may be, it will not contain
any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary to make the statements
therein, in light of the circumstances under which they were made, not misleading, and (vi) of the occurrence or existence of any pending
corporate development with respect to the Company that the Company believes may be material and that, in the determination of the Company,
makes it not in the best interest of the Company to allow continued availability of a Registration Statement or Prospectus; <U>provided</U>,
<U>however</U>, that in no event shall any such notice contain any information which would constitute material, non-public information
regarding the Company or any of its Subsidiaries.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)
Use its commercially reasonable efforts to avoid the issuance of, or, if issued, obtain the withdrawal of (i) any order stopping or suspending
the effectiveness of a Registration Statement, or (ii) any suspension of the qualification (or exemption from qualification) of any of
the Registrable Securities for sale in any jurisdiction, at the earliest practicable moment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)
If requested by a Holder, furnish to each Holder, without charge, at least one conformed copy of each such Registration Statement and
each amendment thereto, including financial statements and schedules, all documents incorporated or deemed to be incorporated therein
by reference to the extent requested by such Person, and all exhibits to the extent requested by such Person (including those previously
furnished or incorporated by reference) promptly after the filing of such documents with the Commission, provided that any such item
which is available on the EDGAR system (or successor thereto) need not be furnished.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)
Subject to the terms of this Agreement, the Company hereby consents to the use of such Prospectus and each amendment or supplement thereto
by each of the selling Holders in connection with the offering and sale of the Registrable Securities covered by such Prospectus and
any amendment or supplement thereto, except after the giving of any notice pursuant to Section 3(d).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)
Prior to any resale of Registrable Securities by a Holder, use its commercially reasonable efforts to register or qualify or cooperate
with the selling Holders in connection with the registration or qualification (or exemption from the registration or qualification) of
such Registrable Securities for the resale by the Holder under the securities or Blue Sky laws of such jurisdictions within the United
States as any Holder reasonably requests in writing, to keep each registration or qualification (or exemption therefrom) effective during
the Effectiveness Period and to do any and all other acts or things reasonably necessary to enable the disposition in such jurisdictions
of the Registrable Securities covered by each Registration Statement, provided that the Company shall not be required to qualify generally
to do business in any jurisdiction where it is not then so qualified, subject the Company to any material tax in any such jurisdiction
where it is not then so subject or file a general consent to service of process in any such jurisdiction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
If requested by a Holder, cooperate with such Holder to facilitate the timely preparation and delivery of certificates representing Registrable
Securities to be delivered to a transferee pursuant to a Registration Statement, which certificates shall be free, to the extent permitted
by the Purchase Agreement, of all restrictive legends, and to enable such Registrable Securities to be in such denominations and registered
in such names as any such Holder may reasonably request.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(j)
Upon the occurrence of any event contemplated by Section 3(d), as promptly as reasonably practicable under the circumstances taking into
account the Company&rsquo;s good faith assessment of any adverse consequences to the Company and its stockholders of the premature disclosure
of such event, prepare a supplement or amendment, including a post-effective amendment, to a Registration Statement or a supplement to
the related Prospectus or any document incorporated or deemed to be incorporated therein by reference, and file any other required document
so that, as thereafter delivered, neither a Registration Statement nor such Prospectus will contain an untrue statement of a material
fact or omit to state a material fact required to be stated therein or necessary to make the statements therein, in light of the circumstances
under which they were made, not misleading. If the Company notifies the Holders in accordance with clauses (iii) through (vi) of Section
3(d) above to suspend the use of any Prospectus until the requisite changes to such Prospectus have been made, then the Holders shall
suspend use of such Prospectus. The Company will use its commercially reasonable efforts to ensure that the use of the Prospectus may
be resumed as promptly as is practicable. The Company shall be entitled to exercise its right under this Section 3(j) to suspend the
availability of a Registration Statement and Prospectus, subject to the payment of partial liquidated damages otherwise required pursuant
to Section 2(d), for a period not to exceed 60 calendar days (which need not be consecutive days) in any 12-month period.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(k)
Otherwise use commercially reasonable efforts to comply with all applicable rules and regulations of the Commission under the Securities
Act and the Exchange Act, including, without limitation, Rule 172 under the Securities Act, file any final Prospectus, including any
supplement or amendment thereof, with the Commission pursuant to Rule 424 under the Securities Act, promptly inform the Holders in writing
if, at any time during the Effectiveness Period, the Company does not satisfy the conditions specified in Rule 172 and, as a result thereof,
the Holders are required to deliver a Prospectus in connection with any disposition of Registrable Securities and take such other actions
as may be reasonably necessary to facilitate the registration of the Registrable Securities hereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(l)
The Company shall use its commercially reasonable efforts to maintain eligibility for use of Form S-3 (or any successor form thereto)
for the registration of the resale of Registrable Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(m)
The Company may require each selling Holder to furnish to the Company a certified statement as to the number of shares of Common Stock
beneficially owned by such Holder and, if required by the Commission, the natural persons thereof that have voting and dispositive control
over the shares. The Company shall be entitled to rely on such certified statement of each Holder. During any periods that the Company
is unable to meet its obligations hereunder with respect to the registration of the Registrable Securities solely because any Holder
fails to furnish such information within three (3) Trading Days of the Company&rsquo;s request, any liquidated damages that are accruing
at such time as to such Holder only shall be tolled and any Event that may otherwise occur solely because of such delay shall be suspended
as to such Holder only, until the period that is three (3) Trading Days after such information is delivered to the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(n)
Each Holder agrees, by acquisition of the Registrable Securities, that no Holder shall be entitled to sell any of such Registrable Securities
pursuant to a Registration Statement or to receive a Prospectus relating thereto, unless such Holder has furnished the Company with all
material information required to be set forth in the Selling Stockholder Questionnaire. Any sale of any Registrable Securities by any
Holder shall constitute a representation and warranty by such Holder that the information regarding such Holder is as set forth in the
Prospectus delivered by such Holder in connection with such disposition, and that such Prospectus does not as of the date of such Prospectus
contain any untrue statement of a material fact regarding such Holder or omit to state any material fact regarding such Holder necessary
to make the statements in such Prospectus, in the light of the circumstances under which they were made, not misleading, solely to the
extent such facts are based upon information regarding such Holder furnished in writing to the Company by such Holder for use in such
Prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.
<U>Registration Expenses</U>. All fees and expenses incident to the performance of or compliance with, this Agreement by the Company
shall be borne by the Company whether or not any Registrable Securities are sold pursuant to a Registration Statement. The fees and expenses
referred to in the foregoing sentence shall include, without limitation, (i) all registration and filing fees (including, without limitation,
fees and expenses of the Company&rsquo;s counsel and independent registered public accountants) (A) with respect to filings made with
the Commission, (B) with respect to filings required to be made with any Trading Market on which the Common Stock is then listed for
trading, and (C) in compliance with applicable state securities or Blue Sky laws reasonably agreed to by the Company in writing (including,
without limitation, fees and disbursements of counsel for the Company in connection with Blue Sky qualifications or exemptions of the
Registrable Securities), (ii) printing expenses (including, without limitation, expenses of printing certificates for Registrable Securities),
(iii) messenger, telephone and delivery expenses, (iv) fees and disbursements of counsel for the Company, (v) Securities Act liability
insurance, if the Company so desires such insurance, and (vi) fees and expenses of all other Persons retained by the Company in connection
with the consummation of the transactions contemplated by this Agreement. In addition, the Company shall be responsible for all of its
internal expenses incurred in connection with the consummation of the transactions contemplated by this Agreement (including, without
limitation, all salaries and expenses of its officers and employees performing legal or accounting duties), the expense of any annual
audit and the fees and expenses incurred in connection with the listing of the Registrable Securities on any securities exchange as required
hereunder. In no event shall the Company be responsible for any broker or similar commissions of any Holder or, except to the extent
provided for in the Transaction Documents, any legal fees or other costs of the Holders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.
<U>Indemnification</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
<U>Indemnification by the Company</U>. The Company shall, notwithstanding any termination of this Agreement, indemnify and hold harmless
each Holder, the officers, directors, agents, employees (and any other Persons with a functionally equivalent role of a Person holding
such titles, notwithstanding a lack of such title or any other title) of each of them, each Person who controls any such Holder (within
the meaning of Section 15 of the Securities Act or Section 20 of the Exchange Act) and the officers, directors, agents and employees
(and any other Persons with a functionally equivalent role of a Person holding such titles, notwithstanding a lack of such title or any
other title) of each such controlling Person, to the fullest extent permitted by applicable law, from and against any and all losses,
claims, damages, liabilities, costs (including, without limitation, reasonable attorneys&rsquo; fees) and expenses (collectively, &ldquo;<U>Losses</U>&rdquo;),
as incurred, arising out of or relating to (1) any untrue or alleged untrue statement of a material fact contained in any Registration
Statement, any Prospectus or any form of prospectus or in any amendment or supplement thereto or in any preliminary prospectus, or arising
out of or relating to any omission or alleged omission of a material fact required to be stated therein or necessary to make the statements
therein (in the case of any Prospectus or supplement thereto, in light of the circumstances under which they were made) not misleading
or (2) any violation or alleged violation by the Company of the Securities Act, the Exchange Act or any state securities law, or any
rule or regulation thereunder, in connection with the performance of its obligations under this Agreement, provided, however, that <FONT STYLE="background-color: white">the
Company will not be liable in any such case to the extent</FONT> that (i) such untrue statements, alleged untrue statements, omissions
or alleged omissions are based solely upon information regarding such Holder furnished in writing to the Company by such Holder expressly
for use therein, (ii) such information relates to such Holder&rsquo;s information provided by the Selling Stockholder in the Selling
Stockholder Questionnaire or the proposed method of distribution of Registrable Securities and was reviewed and expressly approved in
writing by such Holder expressly for use in a Registration Statement, such Prospectus or in any amendment or supplement thereto (it being
understood that the Holder has approved Annex A hereto for this purpose) or (iii) in the case of an occurrence of an event of the type
specified in Section 3(d)(iii)-(vi), the use by such Holder of an outdated, defective or otherwise unavailable Prospectus after the Company
has notified such Holder in writing that the Prospectus is outdated, defective or otherwise unavailable for use by such Holder and prior
to the receipt by such Holder of the Advice contemplated in Section 6(c). The Company shall notify the Holders promptly of the institution,
threat or assertion of any Proceeding arising from or in connection with the transactions contemplated by this Agreement of which the
Company is aware. Such indemnity shall remain in full force and effect regardless of any investigation made by or on behalf of such indemnified
person and shall survive the transfer of any Registrable Securities by any of the Holders in accordance with Section 6(f).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
<U>Indemnification by Holders</U>. Each Holder shall, severally and not jointly, indemnify and hold harmless the Company, its directors,
officers, agents and employees (and any other Persons with a functionally equivalent role of a Person holding such titles, notwithstanding
a lack of such title or any other title), each Person who controls the Company (within the meaning of Section 15 of the Securities Act
and Section 20 of the Exchange Act), and the directors, officers, agents or employees (and any other Persons with a functionally equivalent
role of a Person holding such titles, notwithstanding a lack of such title or any other title) of such controlling Persons, to the fullest
extent permitted by applicable law, from and against all Losses, as incurred, to the extent arising out of or relating to any untrue
or alleged untrue statement of a material fact contained in any Registration Statement, any Prospectus, or any form of prospectus or
in any amendment or supplement thereto or in any preliminary prospectus, or arising out of or relating to any omission or alleged omission
of a material fact required to be stated therein or necessary to make the statements therein (in the case of any Prospectus or supplement
thereto, in light of the circumstances under which they were made) not misleading, in each case to the extent, but only to the extent,
that (i) such untrue statement, alleged untrue statements, omissions or alleged omissions or omission is contained in any information
so furnished in writing by such Holder to the Company expressly for inclusion in such Registration Statement or such Prospectus or (ii)
such information relates to such Holder&rsquo;s information provided in the Selling Stockholder Questionnaire or the proposed method
of distribution of Registrable Securities and was reviewed and expressly approved in writing by such Holder expressly for use in a Registration
Statement, such Prospectus or in any amendment or supplement thereto (it being understood that the Holder has approved Annex A hereto
for this purpose), or (iii) in the case of an occurrence of an event of the type specified in Section 3(d)(iii)-(vi), the use by such
Holder of an outdated, defective or otherwise unavailable Prospectus after the Company has notified such Holder in writing that the Prospectus
is outdated, defective or otherwise unavailable for use by such Holder and prior to the receipt by such Holder of the Advice contemplated
in Section 6(c). In no event shall the liability of a selling Holder be greater in amount than the dollar amount of the proceeds (net
of all expenses paid by such Holder in connection with any claim relating to this Section 5 and the amount of any damages such Holder
has otherwise been required to pay by reason of such untrue statement or omission) received by such Holder upon the sale of the Registrable
Securities included in the Registration Statement giving rise to such indemnification obligation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
<U>Conduct of Indemnification Proceedings</U>. If any Proceeding shall be brought or asserted against any Person entitled to indemnity
hereunder (an &ldquo;<U>Indemnified Party</U>&rdquo;), such Indemnified Party shall promptly notify the Person from whom indemnity is
sought (the &ldquo;<U>Indemnifying Party</U>&rdquo;) in writing, and the Indemnifying Party shall have the right to assume the defense
thereof, including the employment of counsel reasonably satisfactory to the Indemnified Party and the payment of all fees and expenses
incurred in connection with defense thereof, provided that the failure of any Indemnified Party to give such notice shall not relieve
the Indemnifying Party of its obligations or liabilities pursuant to this Agreement, except (and only) to the extent that it shall be
finally determined by a court of competent jurisdiction (which determination is not subject to appeal or further review) that such failure
shall have materially and adversely prejudiced the Indemnifying Party.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
Indemnified Party shall have the right to employ separate counsel in any such Proceeding and to participate in the defense thereof, but
the fees and expenses of such counsel shall be at the expense of such Indemnified Party or Parties unless: (1) the Indemnifying Party
has agreed in writing to pay such fees and expenses, (2) the Indemnifying Party shall have failed promptly to assume the defense of such
Proceeding and to employ counsel reasonably satisfactory to such Indemnified Party in any such Proceeding, or (3) the named parties to
any such Proceeding (including any impleaded parties) include both such Indemnified Party and the Indemnifying Party, and counsel to
the Indemnified Party shall reasonably determine in writing that a material conflict of interest is likely to exist if the same counsel
were to represent such Indemnified Party and the Indemnifying Party (in which case, if such Indemnified Party notifies the Indemnifying
Party in writing that it elects to employ separate counsel at the expense of the Indemnifying Party, the Indemnifying Party shall not
have the right to assume the defense thereof and the reasonable fees and expenses of no more than one separate counsel shall be at the
expense of the Indemnifying Party). The Indemnifying Party shall not be liable for any settlement of any such Proceeding effected without
its written consent, which consent shall not be unreasonably withheld or delayed. No Indemnifying Party shall, without the prior written
consent of the Indemnified Party, effect any settlement of any pending Proceeding in respect of which any Indemnified Party is a party,
unless such settlement includes an unconditional release of such Indemnified Party from all liability on claims that are the subject
matter of such Proceeding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
to the terms of this Agreement, all reasonable fees and expenses of the Indemnified Party (including reasonable fees and expenses to
the extent incurred in connection with investigating or preparing to defend such Proceeding in a manner not inconsistent with this Section)
shall be paid to the Indemnified Party, as incurred, within ten Trading Days of written notice thereof to the Indemnifying Party, provided
that the Indemnified Party shall promptly reimburse the Indemnifying Party for that portion of such fees and expenses applicable to such
actions for which such Indemnified Party is finally determined by a court of competent jurisdiction (which determination is not subject
to appeal or further review) not to be entitled to indemnification hereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
<U>Contribution</U>. If the indemnification under Section 5(a) or 5(b) is unavailable to an Indemnified Party or insufficient to hold
an Indemnified Party harmless for any Losses, then each Indemnifying Party shall contribute to the amount paid or payable by such Indemnified
Party, in such proportion as is appropriate to reflect the relative fault of the Indemnifying Party and Indemnified Party in connection
with the actions, statements or omissions that resulted in such Losses as well as any other relevant equitable considerations. The relative
fault of such Indemnifying Party and Indemnified Party shall be determined by reference to, among other things, whether any action in
question, including any untrue or alleged untrue statement of a material fact or omission or alleged omission of a material fact, has
been taken or made by, or relates to information supplied by, such Indemnifying Party or Indemnified Party, and the parties&rsquo; relative
intent, knowledge, access to information and opportunity to correct or prevent such action, statement or omission. The amount paid or
payable by a party as a result of any Losses shall be deemed to include, subject to the limitations set forth in this Agreement, any
reasonable attorneys&rsquo; or other reasonable fees or expenses incurred by such party in connection with any Proceeding to the extent
such party would have been indemnified for such fees or expenses if the indemnification provided for in this Section was available to
such party in accordance with its terms.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
parties hereto agree that it would not be just and equitable if contribution pursuant to this Section 5(d) were determined by pro rata
allocation or by any other method of allocation that does not take into account the equitable considerations referred to in the immediately
preceding paragraph. In no event shall the contribution obligation of a Holder of Registrable Securities be greater in amount than the
dollar amount of the proceeds (net of all expenses paid by such Holder in connection with any claim relating to this Section 5 and the
amount of any damages such Holder has otherwise been required to pay by reason of such untrue or alleged untrue statement or omission
or alleged omission) received by it upon the sale of the Registrable Securities giving rise to such contribution obligation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
indemnity and contribution agreements contained in this Section are in addition to any liability that the Indemnifying Parties may have
to the Indemnified Parties.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.
<U>Miscellaneous</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
<U>Remedies</U>. In the event of a breach by the Company or by a Holder of any of their respective obligations under this Agreement,
each Holder or the Company, as the case may be, in addition to being entitled to exercise all rights granted by law and under this Agreement,
including recovery of damages, shall be entitled to specific performance of its rights under this Agreement. Each of the Company and
each Holder agrees that monetary damages would not provide adequate compensation for any losses incurred by reason of a breach by it
of any of the provisions of this Agreement and hereby further agrees that, in the event of any action for specific performance in respect
of such breach, it shall not assert or shall waive the defense that a remedy at law would be adequate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
<U>Compliance</U>. Each Holder covenants and agrees that it will comply with the prospectus delivery requirements of the Securities Act
as applicable to it in connection with sales of Registrable Securities pursuant to the Registration Statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
<U>Discontinued Disposition</U>. By its acquisition of Registrable Securities, each Holder agrees that, upon receipt of a notice from
the Company of the occurrence of any event of the kind described in Section 3(d)(iii) through (vi), such Holder will forthwith discontinue
disposition of such Registrable Securities under a Registration Statement until it is advised in writing (the &ldquo;<U>Advice</U>&rdquo;)
by the Company that the use of the applicable Prospectus (as it may have been supplemented or amended) may be resumed. The Company will
use its commercially reasonable efforts to ensure that the use of the Prospectus may be resumed as promptly as is practicable. The Company
agrees and acknowledges that any periods during which the Holder is required to discontinue the disposition of the Registrable Securities
hereunder shall be subject to the provisions of Section 2(d).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
<U>Amendments and Waivers</U>. The provisions of this Agreement, including the provisions of this sentence, may not be amended, modified
or supplemented, and waivers or consents to departures from the provisions hereof may not be given, unless the same shall be in writing
and signed by the Company and the Holders of a majority or more of the then outstanding Registrable Securities (for purposes of clarification,
this includes any Registrable Securities issuable upon exercise or conversion of any Security), provided that, if any amendment, modification
or waiver disproportionately and adversely impacts a Holder (or group of Holders), the consent of such disproportionately impacted Holder
(or group of Holders) shall be required. If a Registration Statement does not register all of the Registrable Securities pursuant to
a waiver or amendment done in compliance with the previous sentence, then the number of Registrable Securities to be registered for each
Holder shall be reduced pro rata among all Holders and each Holder shall have the right to designate which of its Registrable Securities
shall be omitted from such Registration Statement. Notwithstanding the foregoing, a waiver or consent to depart from the provisions hereof
with respect to a matter that relates exclusively to the rights of a Holder or some Holders and that does not directly or indirectly
affect the rights of other Holders may be given only by such Holder or Holders of all of the Registrable Securities to which such waiver
or consent relates; <U>provided</U>, <U>however</U>, that the provisions of this sentence may not be amended, modified, or supplemented
except in accordance with the provisions of the first sentence of this Section 6(d). No consideration shall be offered or paid to any
Person to amend or consent to a waiver or modification of any provision of this Agreement unless the same consideration also is offered
to all of the parties to this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)
<U>Notices</U>. Any and all notices or other communications or deliveries required or permitted to be provided hereunder shall be delivered
as set forth in the Purchase Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)
<U>Successors and Assigns</U>. This Agreement shall inure to the benefit of and be binding upon the successors and permitted assigns
of each of the parties and shall inure to the benefit of each Holder. The Company may not assign (except by merger) its rights or obligations
hereunder without the prior written consent of all of the Holders of the then outstanding Registrable Securities. Each Holder may assign
their respective rights hereunder in the manner and to the Persons as permitted under Section 5.7 of the Purchase Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)
<U>No Inconsistent Agreements</U>. Neither the Company nor any of its Subsidiaries has entered, as of the date hereof, nor shall the
Company or any of its Subsidiaries, on or after the date of this Agreement, enter into any agreement with respect to its securities,
that would have the effect of impairing the rights granted to the Holders in this Agreement or otherwise conflicts with the provisions
hereof. Except as set forth on <U>Schedule 6(i)</U>, neither the Company nor any of its Subsidiaries has previously entered into any
agreement granting any registration rights with respect to any of its securities to any Person that have not been satisfied in full.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)
<U>Execution and Counterparts</U>. This Agreement may be executed in two or more counterparts, all of which when taken together shall
be considered one and the same agreement and shall become effective when counterparts have been signed by each party and delivered to
the other party, it being understood that both parties need not sign the same counterpart. In the event that any signature is delivered
by e-mail delivery of a &ldquo;.pdf&rdquo; format data file or any electronic signature complying with the U.S. federal ESIGN Act of
2000 (e.g., www.docusign.com), such signature shall create a valid and binding obligation of the party executing (or on whose behalf
such signature is executed) with the same force and effect as if such &ldquo;.pdf&rdquo; signature page were an original thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
<U>Governing Law</U>. All questions concerning the construction, validity, enforcement and interpretation of this Agreement shall be
determined in accordance with the provisions of the Purchase Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(j)
<U>Cumulative Remedies</U>. The remedies provided herein are cumulative and not exclusive of any other remedies provided by law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(k)
<U>Severability</U>. If any term, provision, covenant or restriction of this Agreement is held by a court of competent jurisdiction to
be invalid, illegal, void or unenforceable, the remainder of the terms, provisions, covenants and restrictions set forth herein shall
remain in full force and effect and shall in no way be affected, impaired or invalidated, and the parties hereto shall use their commercially
reasonable efforts to find and employ an alternative means to achieve the same or substantially the same result as that contemplated
by such term, provision, covenant or restriction. It is hereby stipulated and declared to be the intention of the parties that they would
have executed the remaining terms, provisions, covenants and restrictions without including any of such that may be hereafter declared
invalid, illegal, void or unenforceable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(l)
<U>Headings</U>. The headings in this Agreement are for convenience only, do not constitute a part of the Agreement and shall not be
deemed to limit or affect any of the provisions hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(m)
<U>Independent Nature of Holders&rsquo; Obligations and Rights</U>. The obligations of each Holder hereunder are several and not joint
with the obligations of any other Holder hereunder, and no Holder shall be responsible in any way for the performance of the obligations
of any other Holder hereunder. Nothing contained herein or in any other agreement or document delivered at any closing, and no action
taken by any Holder pursuant hereto or thereto, shall be deemed to constitute the Holders as a partnership, an association, a joint venture
or any other kind of group or entity, or create a presumption that the Holders are in any way acting in concert or as a group or entity
with respect to such obligations or the transactions contemplated by this Agreement or any other matters, and the Company acknowledges
that the Holders are not acting in concert or as a group, and the Company shall not assert any such claim, with respect to such obligations
or transactions. Each Holder shall be entitled to protect and enforce its rights, including without limitation the rights arising out
of this Agreement, and it shall not be necessary for any other Holder to be joined as an additional party in any proceeding for such
purpose. The use of a single agreement with respect to the obligations of the Company contained was solely in the control of the Company,
not the action or decision of any Holder, and was done solely for the convenience of the Company and not because it was required or requested
to do so by any Holder. It is expressly understood and agreed that each provision contained in this Agreement is between the Company
and a Holder, solely, and not between the Company and the Holders collectively and not between and among Holders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">********************</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal"><I>(Signature
Pages Follow)</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: normal; font-weight: normal"><I>&nbsp;</I></FONT></P>


<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IN
WITNESS WHEREOF, the parties have executed this Registration Rights Agreement as of the date first written above.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>qualigen
  therapeutics, inc.</B> &nbsp;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
  Michael S. Poirier</I></FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Michael
  S. Poirier</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
  Executive Officer &nbsp;</FONT></TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 2in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[SIGNATURE
PAGE OF HOLDERS FOLLOWS]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 17 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">[SIGNATURE
PAGE OF HOLDERS TO QLGN RRA]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
of Holder: __<U>Alpha Capital Anstalt</U>________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Signature
of Authorized Signatory of Holder</I>: __<I><U>/s/ Nicola Feuerstein</U></I>_________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
of Authorized Signatory: __<U>Nicola Feuerstein</U>_______________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title
of Authorized Signatory: __<U>Chief Executive Officer</U>___________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 18; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>qlgn-20221221.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.17a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: 96Mps7xRiXgen8uDanwsWa2PSbP9z5Z8WekhvWB4bZnqLyMuMJDtcCoHZKmmkQgI -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:us-gaap="http://fasb.org/srt-sup/2022q3" xmlns:srt="http://fasb.org/srt/2022" xmlns:srt-types="http://fasb.org/srt-types/2022" xmlns:QLGN="http://qualigeninc.com/20221221" elementFormDefault="qualified" targetNamespace="http://qualigeninc.com/20221221">
    <annotation>
      <appinfo>
	<link:roleType roleURI="http://qualigeninc.com/role/Cover" id="Cover">
	  <link:definition>00000001 - Document - Cover</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:linkbaseRef xlink:type="simple" xlink:href="qlgn-20221221_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="qlgn-20221221_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd" />
    <import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd" />
    <import namespace="http://fasb.org/us-gaap-sup/2022q3" schemaLocation="https://xbrl.fasb.org/us-gaap/2022q3/us-gaap-sup-2022q3.xsd" />
    <import namespace="http://fasb.org/srt-sup/2022q3" schemaLocation="https://xbrl.fasb.org/srt/2022q3/srt-sup-2022q3.xsd" />
    <import namespace="http://fasb.org/us-types/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2022" schemaLocation="https://xbrl.sec.gov/country/2022/country-2022.xsd" />
    <import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd" />
    <import namespace="http://fasb.org/srt-types/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>7
<FILENAME>qlgn-20221221_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.17a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>8
<FILENAME>qlgn-20221221_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.17a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://qualigeninc.com/role/Cover" xlink:href="qlgn-20221221.xsd#Cover" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139821331463760">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Dec. 21, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 21,  2022<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-37428<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Qualigen
Therapeutics, Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001460702<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">26-3474527<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">2042
Corte Del Nogal<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Carlsbad<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">92011<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(760)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">918-9165<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common
    Stock, par value $.001 per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">QLGN<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>form8-k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="qlgn-20221221.xsd" xlink:type="simple"/>
    <context id="From2022-12-21to2022-12-21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
        </entity>
        <period>
            <startDate>2022-12-21</startDate>
            <endDate>2022-12-21</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:EntityCentralIndexKey contextRef="From2022-12-21to2022-12-21">0001460702</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="From2022-12-21to2022-12-21">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="From2022-12-21to2022-12-21">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="From2022-12-21to2022-12-21">2022-12-21</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="From2022-12-21to2022-12-21">Qualigen Therapeutics, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2022-12-21to2022-12-21">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="From2022-12-21to2022-12-21">001-37428</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="From2022-12-21to2022-12-21">26-3474527</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2022-12-21to2022-12-21">2042 Corte Del Nogal</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="From2022-12-21to2022-12-21">Carlsbad</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2022-12-21to2022-12-21">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2022-12-21to2022-12-21">92011</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2022-12-21to2022-12-21">(760)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2022-12-21to2022-12-21">918-9165</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="From2022-12-21to2022-12-21">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="From2022-12-21to2022-12-21">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="From2022-12-21to2022-12-21">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="From2022-12-21to2022-12-21">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="From2022-12-21to2022-12-21">Common     Stock, par value $.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2022-12-21to2022-12-21">QLGN</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2022-12-21to2022-12-21">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="From2022-12-21to2022-12-21">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>11
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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MIR1-\SR. !9GD*88 J<11S &P %#TG1X#SY['R73>RHY_U=3_ 102P,$%
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M)508H'Q3F:B\]E-L.>F.7F=Z_S!YU!Y:YU;*O8=7LN48<?R>Y0]02P,$%
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MO-9.&G_FB^$_7G\!4$L! A0#%     @ [8&650=!36*!    L0   !
M         ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4    " #M@995
M)HT]C^T    K @  $0              @ &O    9&]C4')O<',O8V]R92YX
M;6Q02P$"% ,4    " #M@995F5R<(Q &  "<)P  $P              @ '+
M 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( .V!EE5ZI<\;4P0
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M2P$"% ,4    " #M@995)!Z;HJT   #X 0  &@              @ &Z$0
M>&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4    " #M@99599!Y
MDAD!  #/ P  $P              @ &?$@  6T-O;G1E;G1?5'EP97-=+GAM
7;%!+!08     "0 ) #X"  #I$P     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="form8-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://qualigeninc.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="form8-k.htm">form8-k.htm</File>
    <File>ex10-1.htm</File>
    <File>ex10-2.htm</File>
    <File>ex10-3.htm</File>
    <File>ex4-1.htm</File>
    <File>qlgn-20221221.xsd</File>
    <File>qlgn-20221221_lab.xml</File>
    <File>qlgn-20221221_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>16
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "form8-k.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2022": 22
   },
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "form8-k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "qlgn-20221221_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "qlgn-20221221_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "qlgn-20221221.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/srt/2022q3/srt-sup-2022q3.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022q3/us-gaap-sup-2022q3.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 59,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2022": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 22,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "QLGN",
   "nsuri": "http://qualigeninc.com/20221221",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "form8-k.htm",
      "contextRef": "From2022-12-21to2022-12-21",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00000001 - Document - Cover",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://qualigeninc.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "form8-k.htm",
      "contextRef": "From2022-12-21to2022-12-21",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of changes contained within amended document.",
        "label": "Amendment Description"
       }
      }
     },
     "localname": "AmendmentDescription",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://qualigeninc.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://qualigeninc.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AnnualInformationForm": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.",
        "label": "Annual Information Form"
       }
      }
     },
     "localname": "AnnualInformationForm",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://qualigeninc.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditedAnnualFinancialStatements": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.",
        "label": "Audited Annual Financial Statements"
       }
      }
     },
     "localname": "AuditedAnnualFinancialStatements",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://qualigeninc.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://qualigeninc.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CountryRegion": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Region code of country",
        "label": "Country Region"
       }
      }
     },
     "localname": "CountryRegion",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://qualigeninc.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://qualigeninc.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAccountingStandard": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.",
        "label": "Document Accounting Standard"
       }
      }
     },
     "localname": "DocumentAccountingStandard",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://qualigeninc.com/role/Cover"
     ],
     "xbrltype": "accountingStandardItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r11",
      "r13",
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://qualigeninc.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://qualigeninc.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://qualigeninc.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://qualigeninc.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentPeriodStartDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.",
        "label": "Document Period Start Date"
       }
      }
     },
     "localname": "DocumentPeriodStartDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://qualigeninc.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://qualigeninc.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentRegistrationStatement": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a registration statement.",
        "label": "Document Registration Statement"
       }
      }
     },
     "localname": "DocumentRegistrationStatement",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://qualigeninc.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentShellCompanyEventDate": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date of event requiring a shell company report.",
        "label": "Document Shell Company Event Date"
       }
      }
     },
     "localname": "DocumentShellCompanyEventDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://qualigeninc.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentShellCompanyReport": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.",
        "label": "Document Shell Company Report"
       }
      }
     },
     "localname": "DocumentShellCompanyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://qualigeninc.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://qualigeninc.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://qualigeninc.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://qualigeninc.com/role/Cover"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://qualigeninc.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://qualigeninc.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine3": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 3 such as an Office Park",
        "label": "Entity Address, Address Line Three"
       }
      }
     },
     "localname": "EntityAddressAddressLine3",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://qualigeninc.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://qualigeninc.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://qualigeninc.com/role/Cover"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://qualigeninc.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://qualigeninc.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not.  Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.",
        "label": "Entity Bankruptcy Proceedings, Reporting Current"
       }
      }
     },
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://qualigeninc.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://qualigeninc.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://qualigeninc.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://qualigeninc.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://qualigeninc.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Elected Not To Use the Extended Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://qualigeninc.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://qualigeninc.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://qualigeninc.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://qualigeninc.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://qualigeninc.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPrimarySicNumber": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.",
        "label": "Entity Primary SIC Number"
       }
      }
     },
     "localname": "EntityPrimarySicNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://qualigeninc.com/role/Cover"
     ],
     "xbrltype": "sicNumberItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://qualigeninc.com/role/Cover"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://qualigeninc.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://qualigeninc.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://qualigeninc.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://qualigeninc.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://qualigeninc.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://qualigeninc.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_Extension": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Extension number for local phone number.",
        "label": "Extension"
       }
      }
     },
     "localname": "Extension",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://qualigeninc.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://qualigeninc.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_NoTradingSymbolFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a security having no trading symbol.",
        "label": "No Trading Symbol Flag"
       }
      }
     },
     "localname": "NoTradingSymbolFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://qualigeninc.com/role/Cover"
     ],
     "xbrltype": "trueItemType"
    },
    "dei_OtherReportingStandardItemNumber": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.",
        "label": "Other Reporting Standard Item Number"
       }
      }
     },
     "localname": "OtherReportingStandardItemNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://qualigeninc.com/role/Cover"
     ],
     "xbrltype": "otherReportingStandardItemNumberItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://qualigeninc.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://qualigeninc.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://qualigeninc.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_Security12gTitle": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(g) registered security.",
        "label": "Title of 12(g) Security"
       }
      }
     },
     "localname": "Security12gTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://qualigeninc.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://qualigeninc.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SecurityReportingObligation": {
     "auth_ref": [
      "r9"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.",
        "label": "Security Reporting Obligation"
       }
      }
     },
     "localname": "SecurityReportingObligation",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://qualigeninc.com/role/Cover"
     ],
     "xbrltype": "securityReportingObligationItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://qualigeninc.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://qualigeninc.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://qualigeninc.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 3
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r10": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r11": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r12": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r13": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r14": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r15": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r16": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r17": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r18": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r19": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "g",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r6": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12, 13, 15d",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r7": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r8": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r9": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "15",
   "Subsection": "d",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>17
<FILENAME>0001493152-22-036302-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001493152-22-036302-xbrl.zip
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M. +#X9 $UX=L*MH:#D*38*V0*+UWM,S 4)BM\ 2;P4>&241(B\%/EP6")Y$
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M6(F@%'^6BKC^56*\\=Y1:[[E=R7GD3.:K&G7N7W1C4<G"EVIPII(H.56BX4
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MQ'J]<VQ3,B;6SKI<;>/B !1 X=(Z2_GM0AEVL3=%;WFYV8+9G.C!&(V+XW)
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M;ERL!C#PS7#=ZDJBX7"O>4:%)D3ATQFJ]U7:),DHH@RN'YQ^(WEQ\ BR'D#
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MAJLU%+(46\PUB7O' HR8Z&9/J%E* [:V"8;%I26V%,3K?F:-1DQQ!''5,/>
MJTP28C4.KK5;@*[W8B<C#)8M?LNV8\')&E1OJ*E@V<F.:]UZ5BA-K!:')Q'&
MEMC;\L ?/;ORKDYJ]/Z]):D4RM_H9Y(<9F!K>^*67DXZ0(5L?$@FGIN-] 8Q
M%T\BF]3&PX,]PC8)H-1X<C+%P3UK+C/'ZIE_VW0(3#U=KC+?AW'G:UB$VJK_
MGX-7G*$Z,E(>23 C<DVE,JT3]B2V#>*BP'9(B?LYMDXB-T9A%"8!!Q:(HN#Q
MS5TA++6%E)]4PHF[=FW<O(=Q62@94^F,?6,T';762] 0BNVZY9%*7(<_5J_6
M4594'K2K;TWX1\J^'/;9E_O-OASVV9<^^[)[NN+^S($L$Y#DB[%%0VBT$MP.
M8DCWF,SQ+ @J$=0VWS_'.EF)J+PH5Y?1> 9VMB-"&+D*67F6-GUCGX;/WI=<
M84&WBOD^>,/CHEH81/8QF[#7P53CH'X'@]JU/@B>>AP^5LD789U6R&V#X(@8
MH1G3]R"V<.\LF9B,HC.FHE9GEH"2V@C2P2_!&';I.R,F'@%'4'DRHC4FRUP6
M.G8^,_:_ !=GD4S-BG;Q</"6+_*G$(NK'EP9R84X-?83@@E&'S._YO1:1?U=
M?6HW]Z<5[Q7?!+TX+9=%ILQX0SL*0IV2@QCRZ%-#<81S"Z@$)KY"],L2GL7Q
M%:+!Q7'!3,$2I$:4W/C:8TQ5*HTXND3I=4M%EIDBA>5;6#"$C"(7L/MJ.*#O
MIAE(.T%.W8]T PF7<4S,R&@4T\K3)QX6/I9VE=%[8Y9:A(]Q#8X_E<K]+!%/
MBI,J-4)&5?T*<PO>B99=:51F0ZV4%K(0+7.T-.*\TYT,$X+8#N3-8)5U![#@
M"D[#VN2TE<2F;]"XXML&IQCF7DY2?9O<2_V26[TFGNK0.C"2"%YY(I#@T5&]
MDHP26:*Y':$O%WN(OFXCM39O3-8I?K3W#IOYBN",#6IPE+R;I*2R EC#&I6<
M Y$5B\4J5S&T9!B@&^USVO5:AIJ[QQ*K0]>*4C,85Y#*\:VRW]@_A<<D0\3I
M<(N5^B'X1T"XJQ^&6X2<'%0H+*5\"8[(_UO\J%B(A:SX<]4&-HHN/+*<#?I,
M_"W4,;,2J76)\<(?/ZH:NQ;P-D 3H8:LT U2&:M,^F^*0?-H[-WXS:#5Q3_7
M+^C6_BZ-++V1'7?B"LX"?17?-AM$RRZ84B*Q"D3BZ^K%J5H)A/KNQTPL\=3\
MUP+V@&HDTGR,!!?OM^D8LW1LO"?=LA:"0@3KT23"C&5"@23,[,S,%'Q5ZAAC
M8"URYCW_=94W$KJMZ8".;ST;'>%K6#F+>,03QS!,8!W"XE7;Z-GB%(EF&>ZX
MB%S92;L.]*\P/=Y:Q,JJ]PYJ5^&.-#]+BTTUF_!QHMR5S18*V@N6 HCMJ""%
ML[UB2 V.5EW<#XU3>\N);&,"H*HZ(T4\*&:0=!81*C8;UL0_B(5'(]M>7H04
M.^XP55UT & D2%:8:W*' RG*E?>L9ZT(HZVN--<F@U6<Z6G,U6R;[#6_Y0,.
M4F#G1J,XL%YE+CA5UCT4CL9T@Y+NS^WM]<#3H6D(6D;D;9W6:!OCZN,N.S"I
MT6)A"\X6T?FCQ]$)=9H@]=K9@<MVHK"VK20!7.@Q3'Q$DO>8N_"D"(H'L<F1
ML&@!^P-&@&?4*KM,7.JHD:WIJQEW8U*C/)?B!4J4OEG2&?<V2[2[PPEYD_1E
MP5]>(KE16\5M;GH0_!KL:3B90=/I;:BVQS\XO&8M3+:\(97=OJVM[1$&8^U!
MH#%[."6P9J#&[)E#9!$#G-BW?F)P. ARR()O(DHQ9EWTGW^CQ%)HFZ0SJBW0
M&?+*( L2'ZG!<4C=9SO7URXH#>26J7N8K.E[XJSJ/D/1I8(-#Z:%/,:&.JR/
MAG_;V\'?UG+#\L?IFH\7]D5Q"1MWC(/!5<*)*:V7G&WE?C4MF,&J9J>3;D(=
M>(+;X!N->3' $N;"#UOV*I5@>5Z Z6>9MCR."4=CW<W"C&96T_4JE*S4[Q^/
MR2(FRP8-R%9/K^:^;.[BJ,]=W&_NXJC/7?2YB]W3%?=G$A6%-(I?3]"CY@0_
M6T-@K"#3)H<T_4/2X@ 4U^+%X]!83AG?3?:U"SQ[ (#F$=\F$'7]C?RV#&9Z
ME1=9<;D6I-YBN4)KOUJ#T;] 0FY3WQ3E^PHY'LH9UOMC"'Y>\[_ 4DC\.*I8
M.(E&*_P6!%-8_F)!-)N6, 'C8&C.T*?73'5I(?OU55K.&.''-Z6&>PD1.W6T
M3TAKI-#\;94N%;;K36ZDA)@(>HR' X\7%=XZ3Y9S1/"@(!U#1N%ZKX4J)X<E
MC+52$_M:WVG->%/M6,P65,#1P0@3\*USX>Q4MF./F.P.3&-QB"39(D$"DPFG
M/!S@G)^QY7OK+)/2>(C*V_,LW&VLI*IWZO6A7&2_KABL3:$SC&_"6]G8^9NC
M'*N2UDGC\UQK$@2BPY"\):R*&>B&$5$R0K65%\.WIS5:\UX=,-F(=I,)9N<:
M&?(I.^1!=CJ$1_%(_#/M=6=[0G;]@J+LJUR&BRRHF#+"/ 4RJ<;888*".C *
MARPJ9K;'I\V]@(A]/)W=QAC@,XX%A^&]S:*?8D8&WX.0(GN[%9,*Z$G12*Q$
M8P!^;I#MEDG.] ?T:UDZDE?'5$9=75!O-^UR'193ZM,K9R+@%0)%;;@R)KAD
MCGYB^V6B5':\GF<._AL$HN^V$NA/K99TBQF\QDI:E:/0KGT%17X??)L+9RV\
M/-"7< T!5FF)>%DDB]>[#3LPJ=%RR:; &^+$(U(;X04:,T'!,:/!/X;R"3^Z
M2\H3?S63]IF856-:OIB+U]P9S(4%TH'C5JJGL&6MA\# RPAM426Y@, U76H<
ME\IP<-M*!,B-"]05*WCJ"X-F )WK'G3BS<OQL7]6]WMB!R8U^NTWWA/TAL\,
MYQZ95>.G(B,S\MCU(NT,4*.596TJ@X44G'!BJ2D-MR#A>U[)/?W^ILROQP>;
M1["GK6N^^?9K%<-3M1O.T$Q;X2AF)+V'WW[S53?D1\?)Q2%5(4U;U\R7TBI(
M0V.#\L.]].[ I$9ER=+[/,G?>_+*KWS,.*CMFKP+IP%?N2Y('G6NJOFNIPT'
M8VYF</CMTT 4HQ'^Q*G)YS\U$&9BH3H;6V/QMNWRCV14%X[$50%P0H8@1A(]
MR7>F&I<%ROEW+DIQDU=>_=3FSD_#P1S1.;#[IW1>//VO/5MH)+,)^GAPZDJ=
MC"SAW@7716V[?*3*U5??P!W7CX+[-VY=%P2(H?(:2DDG8 +"RY-Y,E+&8OR:
MK_DG0:!UOIW&XG[T@E(^V%M1S6Y4#(G 5<VX!':><<R.:M0$7 -F@_K5UH?Z
MQ.E)9^[;YO? 5,<?21_>)3#^N ^,WV]@_'$?&.\#X[NG*^[/=JHJMIU^)G*_
M5PEEJ&U/2K3Q UQ9)Y%'*QC)?H!BSAS*#'&$V&> !MF.4PX'7I#23]$BC."1
M#W5F@#/W!O8PXSH^<H8EFJ0N[85?PWYF?V_MM:\/ M<A& LS'V9V<1J14P_!
MWADL]8L,@IAW%!J%S7< _[RI A _1[CR@I@R..CXUF*<)0 OW 1!>#;LY'")
MBQ/[O0.PJ=C,AA:\8&Z:7Q?9=2.W;@&?7@RBBR>H<SYH@PADW,>)?PQ/M@..
M]_;(#DQJ5->V#<&+M$*<C@V31R>8:1%<TB\=,N3ASQCWJ*3_%"E&]+/;7-1/
M3O0)W%JX^;_R43?-#JH=V/W8M]67\"AJ8UV451SP1R!H%IE/RD94#TWXZ8J+
M$32\QTD?^;.%SB4*CFFZY.R&MH#33K5>;TN\> )BSS3GZ'W1W:*C@_]JNCRM
MU*/G78D;I?Z03Q<"YL)TQ=Q-@HWB!B#.^5H6-S@4=6D8V(Z*+5$N!L/\T3,8
M9L[(8GH13PZ>;H05[E$6(><T6@OB+50;EIDML>TG:;H$;:0**5PAO[LBO1ZX
M#=/"<KVSWV81U@/USR71ZL:M7R)&R_]IH(H;KI27]97;/$]F.+6BU*?-&J*/
M2U1-RW3B+1)(ZVBV-SK<HU+X M'KE.W9M'"P[-ZPNS=76 7F<2 E&W:C)=*%
M\\0?U=$>*7[\Y^.]-A1-7=>9GTV:HCE C$5"IF%9C/%GG6^HN;*M40X'-,SV
M"-B<$(ZDFN@V*'GC#NA8$CG8?)0I^ZG PZ,;YI6VTS9[+E,\7Y5Y6ET9324.
M!WY3$7CZTG;A<3>7KD0SY9*C^_?'U@Y,:K1:2:*(Y+5#%W3'P&^2TC)!2 <'
MO_GJ1KF7*E.+0*&2(^H^C(6FZ0PV7F=P;0_VVV*5BY'NTS?8XI:ED],-_(@^
M?85'5OC 7NG#E-/K:S6O:DGC;;6R?)DE 2-83*,T@ 3EIDRYQ$8!OWPL>\SW
MD;2\QWMM4-,M<%2WTK<X;P>_<8B;V GJ,JFJ1+P$6!>D8N.^>1LF'>)&-CZ_
ME_0O&]A\T@<V[S>P^:0/;/:!S2^I*[[(5![O'PECF:,6UO:AOR2EMG!O4;-Z
M=5$>3^:<:TA,-F=^A:(D#C.RY;S+A.78XW"F?-H-/Z^*$OM *C1BWD6.'':V
MDVG@B/"J.>R2XJ:*1JL\HWI?R?,IU2G?N68BW)C.;BK[GR85,Y4I]&&"_&M@
MWE%/VLHB(/'G>]\]"!'X(YU\]V?C)>**E)=)+EQVSZ*Q!G!9?,];7*R2B^;N
M/H([Y8"J9H5G*^;(U0YW5&G,U=@Q5LZE,_C>LE:27(-P$8N)C2>YX 0#B^>=
MU#\I%9/[B!]YDH/_4/<\[GP4NZ9[,07(P+^IKM)ES'R@6-.=I0G7RY+?+Z%B
MI8FA,!7O,1OE;E .<$H?,9ZKQ4)+U39SF4M"O)/.DL/RKA*." E+I-I?,5K6
MCS"X>*6MTN.@ %GF$CT4BUA(2[>3:3((U92TF%1L.6D1\RH2XI.FY^5R2%X\
M4#2R+Z,+03%2S .XUX9>:_N]15M?6Z)]BZL@:".Q2+R?55EV;J*WNT9.%-1^
M]VLA)W9.-LV'UYQG$]Z;@S\W5W@EOXJNJ[I($ERIJ_#L8@DLK)1'F(J7T!:C
MAQ"C#584I)(;L2+3GC)VXH2W/3448U/.FK3N&@B*'PU$8W_# 7ELE7TC,!]M
MMTLQ8;HIN'SY-%UF[1P78DNP.>J4(/Q@:%]S.@EFZ6FG&,/1F$)*5XO(M117
M#2$/M%DVEGB"N%-LFJ>G99_<E;=P5+FD(RJ]2Z;M0\-)T;.:50/)=0*2-K$\
M)GJ"@K2Z'11;RA'J-<%=#;5VPZT1IAUG6K<@'"VP(',4Y(JZ)BQRYX[:X@9E
MR;&--9EA&8YFJ]MP6X4EQ0_L0'N8I_1$3NF;/)*VFYTGL\_YO8D66Z+Z2 1=
MII07<7D:+W_1J'!RO32WY PTR^L$C-I?^K@Z;!)+V7UL+(,)=LT ^Z.L5$F
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MQ(!/0\73\$ ["C80L%-E7[5I2L,Z#'-*=-"&ZZ3='@$<6\%273A?>EI;-X
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M28>KB[&'(NS!Z'K4"*XC3J>BZQ=VDCVC&LWQ-/<L<I$4%MF#L':R#IQQTUP
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M+V,PT%E&)Q"VM4749C2FZ-L2/;/+,3%6;%$ASZRQLK$:F=P&EUXR))R3LOK
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M\)G?RO)QN9D*Z:G,25U9:;I&=X)+)B^B*56 090O3T2'V%^R/@Z%5C]<5Q<
M]:6R7T+'B<H:<AE5 U81H))#ZYKZVH:R*A&72GR*HX#R62#%S(_X4'O]7,)
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M QB$K[8D8.@&075?=]SOJ0K=722X5R"EN$;.I,(T;4*EDAT,$DNV$C<2%H3
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M=5>25EL#<[[?$ZPAK8<68W!*KGR# 75?#=B%N041:]<..WS#TS:EUP-=$J2
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M[!X C#08@\4"L6CFX <M>12FT)I+XQ&H=V.*?U5A\(+MIA339VB.LJ2N4<D
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M,?C'Y@(5M2 RX\"^#68=W2G8@6Y)PWC2A3+&+4,\N=QJDJA ^[AMPA9(=?D
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M")"(;1@CQ^ TV#"I3:D:X#+1]53RIRU$RU5N'$?=)=YN"\1QQ"3XB<7U84=
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M\G-]]=-C^&_T)BN*<NVZ]C5C?IM5M?Q5_5K),2NL2E_=T2"=D)@M*N]60%N
M%AI\?^4),9O)6]CLT>.BWWM(1W/'&5=?;0ZV[W="U'7^LM\[!P[4&.'JJH[7
MKA=KNL//YA?5J$QG1)ZVAW1A+Z._/AON[.S _Z]=ATX<]:SJS;,U[<V:KBJ6
MC>SWSI [Z&7T=+B[F8$EFKU,%LCS?T3O<+^:<3T"BK=-*L@*4D&>?VDJR+<E
M??CZ2_OQJW>O?\>L_U_/WQ[]_/\!4$L#!!0    ( .V!EE6[.Y(1U7,  -R1
M @ *    97@Q,"TR+FAT;>V]:W/;2)(V^IT1_ \X?7HFQ!.T6I+MGFZWMR-D
M6Y[6KF]KV=T[GS9 $I30)@$. $KF_OJ3MZK**A0HRI8MJ<U]XYVV2! H5&5E
MY>7))Q__]N[EBU_[O<>_'1T^@_\F^'^/WQV_>W'TZ^,?^+_P[0_R]>,GKY_]
M*SEY]Z\71__QW;0LFD?)_MZB2=[E\ZQ.7F47R=MRGA9#_F"8G&15/OT.?@@_
M?6-^-T^KT[QXE.Q]]^O?BU&]^.7Q#V^"2YKL8W,OG>6G<%F5GYXUOR3J5^WK
M-QV*NLTO2>0A]%%>3#*\W5Y>P+.>_'KT\2P?Y0W<?O?@\0]/OO;CS1Q]D0?_
MN:R;?+J*/?K5T?&[WX[>)N]^.SY)3HZ>OG][_.Y?R:O7^,F1^>#XZ*3?.W[U
M[G7RQV_'3W\++H9_/WW]ZO>CM^^.G[PX2GX[_/TH>7)T]"IY>_3/XY-W1V^/
MGB5_P%.".R:'KYXE1__S]+?#5_\\@CN\?'E\<G+\^E72>K;ZLM][_1Q^B-)Y
M^.XH.<:'O#@^?/7T*'G_!GY[^ IN>?3RS3N\T?.WKU_*(-X>TB?O7ST[:MW]
M\.F[!.ZZ__/]^\/D$/Y^>027/4MV\+J_SR;_7I:_/'[_J_^+QS^\__7O%7TW
M&/9[\"[PVZ=/7[]]=OSJGR_^-4Q>'N(TOH.9@)L_ITF %SMY_8)>^NC-N^3-
M^[<G[P]?O4M@7G'<<-73=\<P>=Z0Z45A1._6#/ZMO5>_QS<[_/WP^,4A+H<_
M'4.\&&;M,('[OSJ!7^,W.,Z3]T_^$YX/@QG2,[Q!O#WZ[_?';VD8)SA7D4'@
M:N*-:0YP0?H]6O3#-V]>'#^EH?":J=^]./SC9#>0)KQ/<'M8^O=T UIBEC66
ME.?!CW'28<+?O#AZ]L\C&@]<_>J(WM*,)WGR^M5A\OSXV1%<_O:?,N;WKV@>
M7]-F>/$:II!N"C=Y L+V'H3>#6CW2^F&;E5Y72K@NU]?PY/R(ITEQW6]S))G
M:9,]2IYEXVP^RJKDX&"8'.P=''R5$3PMB_.LJO.R2-Y4^3A+=NKEZ,]LW"1-
MF:03_,$<-%5REE597@P>X<GTZ_>H(_=W[W^)(<HB?']_>']O;[BWMW<'%WH,
M,Y95<*8\?PTBK4_:IDJ+>EI6\T?)<K'(JG%:9W3V_/0W$.Y7QZ_?]GM:D3\[
M>@+['?8 GTIXOR]Q.'W"@)^]Q]$]/7KYY C&+#+[\,L.TXKOE]ZBX2F]^Q#/
M:=)S=J&2Z#KU>WF=E$66E-,D36IX&(P"_CU9SE9)NFS.RBK_OVR2I,4D.8>'
M3N#C'+7 A.Z<%7E9R:9L\M$,E$,V@C$L*[[-?R]QH%F1O(,-F2ZR99./X:6.
MB_'N$)[W+)NE%VF5)>.R6I15VL"^[O=VFK-,':)/R_DB+5;>Z9F<I>=Y<9KD
M39TLJKP8YPM0#HM9.J8W&2WKO,CJ.DD;6.8'!S#"JLF229:\*D_3V3!YFE:S
M>I1.X%^'R<\'>_O[0_BVACD%W09O6^.=^[U+7A%F*6OIP8<)C!\F=6*N&N+M
M4M!*DPR>!Q/3X#.&20T".LM06\$3X1$EO'9UD==9,B\G^32'3Z=5.4\:$(1^
M#]0;_F.8^)-CQZ*F!Q=K"%,ZFX%>S,\S6+*+O#FC7])#W-AHD>KE^$R6OO/V
MM9[^+W&8W?!>>0X;Y/?#%^_1B'EZ!!;5,YX*$;Y^;P%+ 6M3XSFS2%?XG\/9
MXBP%45KD#0C?80$+.VMP)5$JJ^PTKT%)D32A8-5)(->_E;-)5OEB#3^NS]+9
M#.4[@^?DDV2QK.IE6M !!S< 2<BJ>4T'W!+>H>)QNDU0+^>XJ.Y @NT=%U(]
MF)<IK'+>K.APUV.B(:& 9+!E<I0=N !>"<:!4N[V0H[O_.]E7K$T@^Z=YPV*
M-HQ[E,%W]#8I[M?R/(>]H%\!U8M,;(ZJ'3:)O&_"TX0O@7^EIZ<PLSB$93'F
M/9E-^CWZ_1GHF7+9P#(4$U0.;D[2>;F$&81I"0==).D8E,\D+4!SV%U"0T0C
M@^>YG(+%V7I;97C@;Z:PW\H+>"Z,9C+)496A2K)W>O2U1?IF-A)Z/:AV8+WV
M48YV$U(CT[R@*2$]LMOO/0<1H9E>@N+';<7S/*05D>DS,\L"/\%[@-1DLSJ[
MP*OQ4G\YA\E..DC&O"'IV.*?%F6CM*O<J-]C&U%O.'S:/$L+6$58WZR!1:U
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M =.E6XS([0^E6KI*(@^1;P>V'%V..9X-S+V=Y^4,4T5<9&$0O'4W0)=6QGT
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MHJ<85$D8Z#!:R391_'[G>>TB0' K,"C@)^GB;*@K@MV\$U3'BX9[SV?Y%37
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M[RYXK>_WV=PF-Y7 H^;\:\=KW"(8&[P#&1#^U$EO6[AM,"'4HQMM_7[O*IO
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M,?K!-=1H^P^I<E= P!^O,#2^O5D[.])^CX:*Y?GMN%25S1D7.[PJ2TQ[YCM
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MIORB\3D]^[TWEK>,:B!^>FCAOBE:&J=65?_^Q^&;VIJY#^G4!(N%5+J>?["
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M2+E*U:"G%%Y]\ W+T@09CL&?HZI3UW0 PS"B%/CK)/C6&@BFV9M#-Z<8'YC
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MVMN&G6@!0Q5ZU18GKBR*&YT8A_LIL_QSJ5!3E7X[6%B8CA:AIHT!5B6B[B2
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M"\KWF,H)"<=-"08*%@=-,P^!-2[KQI)LXQ%><SN=RAUZ.:@6$.13.?H7V"Q
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MVZ@\ U^7/HBH9^>)DK*EQ];DKV<%2-8J9O=ZC7G2LJWS"U6*MTP>B_<,OH[
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MH8![G-0W"#+N#6Z'/OEG9=ZN& $=@ZJI'I3+!_0!5/-5EO IUFAZ_ 8\O2*
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MU>,Z%ZM-86*?YD; S<SQ^[?'@[7TD;W9,!>9>X?,HT1"S16\W?DJ0/1 B W
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M;2RCM7Z!]I_8P$PQ74M HB7RLC256^7_=A9J[>>D,5AOCR&?G:@SF3<\9E\
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M2HM#=[9985M;ZTQ_V-K"E#_I ^Q,[-(E..\1+8$" *M@N FI?S8VIAM3[)S
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MI:O46SX_I\HL8+F@JO2_0$JX#,)_+F=J]</$/B!=Q5Q&75J2RE,]&\44YN$
ME7G]Z #K!93)OU1P#6@U@(H_PA\(X2W_VY@V(QI^5,%'JJ/@L:"&*E8#Z(?0
MBT :LJIN[-OTZRT;"Q@86,CBI:WM:2B72SHO!#-C7#O95E)#C?_$07<$S)4[
M5Q&:"A8]S$ @M7O=^ .+\[HDDE >%^.Z[9[:"KENJ/F>&5%CD<UGN\CF]48V
MG^TBF[O(YBUP;NY-9#-E)^HCA79T>U*G"03'?+PF9*M56[BM$R5XB<K>^.AX
M21ER33;YC)T>\,!-;V.*;O;Z.W]NJ^04$Z_W]A*YVT*T9"$Z:@D=7(IA>5"C
MS6T\<<^TT%U>V\I Z>=ID2XSR<A2+G2>L2EMT5W^"ZR$Q?PJRLTZ/6B,$6+9
MK(=>Z3@1?C!-&X7\"K4G5A^8MJNT.DFKF9M:QU-B809NL&FP!MGU'!WSR3&4
M+^&-^RD)'#H/F\*U/AQ"1FQ'J F&N=!2&!4:0])#>'^[XIVRC?V_F8#A[JS>
MZK-ZHA6^>N_6T9K=DO/Z,<VD;,(>A4+S+K/S?-3.P1W(N,$H0D')!*'0E]]*
M7M.8% 85T;C4]\-/C9343Q@F3MV:OL<>5#":5G!\!@/8:Z6,K[!]632_K@.D
M)V@(.[LX(AAB5FE_OH/@D?/A\-MWJ?Y=?D]-JE&'?$16%>5R']FY4;]XUR"L
M JK7Y#1=8.N8YWO9C-W:X@J[I*,W2,_-&V;630+U3"V)D]15,%ZG;5F%7ES"
MOK/V?'B';HP6FY:9_6S,<,3(S"($KTC0O5,7MTE=G+*Z./P&6VIJ?=XB,#RM
M\'8-7^\2"DKI6P*_/2]-B#EQOA_I6X]#/>>GI@"J*4^X5(MT!M9&F0@$6IC2
M]MI$)V(/ *9-RP3#77R>\=:CQ[NO=W-M)FA.QL#:5)\9Z]10'; IO):"OB'2
M9*+VT29(@8Q)5 >/9H034S%CZ8 >36Z,(Y=HMF2U:RGC0!^LXBRW\ &*]4E^
M<G^]6$I:4G&I%FK/&)O)&P9]8L*I2C#GG;<P3H'2<%I1_;I_M*^6*<9^<G5X
M]/[GC]SM:CF=/'[X\"%81?LG^Y$Z/S_?7Y1)B\_:A\?H%*Y]MM114O4##/4,
MI)D9L;6MYQ=3:!ON0D2)<K#<P^3\M*2: ^QD(M5(WD)IV9O96=""]UJGQ+6A
M%PJLG'TF!@JXF@4I=T )(D>"$C*(G=*Z34HK8Z7U,V)FJ5O&A_A<7%N0/EWJ
M2?4!B7Q"YW":JI4*19+-C"B "A(:HUN($FN-'>K#73\=CD*G\&GK./'.@K[=
MTO6;@,':52M5V3YTG>N;^2=^U"/CPI/$?E/WOS'I&X-@EWK2[F,8-;X3B-LD
M$%\E_$%=C;A^R./G1140V8,>&:P@UW5C&XED0)-DZ*'G6[+OH'5"8 !276"8
M8-E<G(,J*YF>H"U$E6'8@//6W%C,:1I 5;O.:.NH VUT!NSZ*"+?8JMMZE?F
M!F2PP/*<#<98J.(B<;PXDB@3B@VLP@WM2 DK/TR:,F:5AWKRBK<=V-,R*Q9.
MFRB\U^,<YE_PV<162^S )*=(?&MM"$H%SC$6TS"LROQ&:M)C@3;YK1=T.G1;
M>0 !$@F@8@80YG7+7>78*D6DA0FO<DDW"D7'=LHTSJJA]C3HZ0HIH3'/K2#0
M57@I"="!+9\V0<,@N%*$-Q>GP9Z\'CJ6N&PEJSM]=YOT7<[Z[A?N:^3<>J?R
MDT H!.^]I8;R%!EGP OL^+8HZ08DXPO;,Z;"\F"ZF 3\.HX>H'FE21Z(S(%C
M18:OL5\LM#/6;Y\TK6P;0:33Q(W^R!Z7145IHHU/3@T?2L,7"D59 ?2XQ[V@
MOA/H1E&4#H3&_J+^@PXS3N=!UB+K/BV21Z@^>*E>8[3"Z9.,E]Q2=Y3RR_,Z
M[[3U;L&7$MH(^6R<"F?;$$W>5MK*-QV,1-^<T5TFHB$QAB0O:\.87Y12#S>=
M<"1&B!ED& 8]9CO#-;I96H!^Q3G8;K0TUNRG!?SK-%M'=/W6=0EW-CM@,>^*
MPF@(D:Q[;?\(30ZK) "ZBJL@F2O'Q!?6!%9>6^X(;P25MS,X96:;9+=0>B?
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MBQ?7,KA--JX9_M/K'3_8\C_6/^*P_Y$EIW&:JZ-]];G,J@SK$!WS_D^I#_[
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M7#<[7^H*OM1W]B)D:-=X^[TQ\WS3N\-_?//IW;\HTO3+\3\^O/[_4$L#!!0
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M5R!?J5(Z267+ZL[3,"USBODIOX)QHY*[U/:CDIY+4S"84[A'K&XY!C5%68Y
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M/<'],OPL*%9HFY%TM2GP\Z(F)Y,19=66\HWBFBF0K+<,C[**](;$2 07O,(
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M8\39LM^[QWD&06FZ=7"*TWSRER?/[SRGT,7?N^U6-TK9JYQTDA>@4LRFT[A
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M2P[T5]!-$+;#I^%S0\<W+4,XC)8B4LUAK7&4I,QPYVBZ0NI\:K8>X-?61Z$
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M(\]Y^2CWP@&.XV: %,_N!:F[;4\?2FX$^8MF>O[B17!7RG^^@54:U@('"2T
M4F8[8(YHQ_72 V5>D[M^-5L?HQ3.OW3UUE?KZ\?R1 P.;@QCYMD3/<>^1_%(
M6IQGP(GVQ^0/8*N>HS \?92Z+Z;=ZY-N2)+2H'XW/%E/\.2!80H@(+@3Z0S8
MJ6W8!\;*-_YY=6)6*9H3=U]*N<I:M;P^YZ:9Y*9J@INN>+^A-L\TTAZ/L5:]
M][/?UKWV_H_VQ%AK# "9G?)JKE)=JZZ4UY[):/"/\]IV[OE;VE/OBRR1G9 K
MA'#?]L"_9#\A7'9U@_( "3>%\##M2[);$E C;@[C3N+?54C_N!9Z3_Q7L[M=
MPW5GDM/0($I0I;J:,]ETTFFID;_(7^;E$NO=GFD/A#-[[):TD(KQ[/P(UT4F
ML$!!Y<[,QL33#G5B))I*%YJR.)O,M\!7Q,+=S!,!YJZN.\)UU8]CZ%%*=[V^
M'/9*UZM?5R^N?C^L'':]4B8'MZM8+2\NU# %RR!N!#9K<W.,!Y8=R=!6TE97
M@U_/G"O[P1H3L?3WO_BG&]6B49KTVJ*I,SLU[IAND^O/7LQ&VF+(:SISSB$:
M!S=C3!+@Y\G*B?A>;G_5*F^7!$@'$-=M&C"89? Q*Q]9^%[:PL]M@,#\8?3&
MYSZJW_R3@]U:B:_S21,R,7MF9Z-<+)7&Q@7)'S.B49;42FF/I.< [8P>-YGH
M"\WWC'M,BX(!$.XR6P(T,,3#.\E_3CO4OZWK2TJ.4 OM.H*/EYQ/56O]O/=C
ML'XV"148GP\8:VVUN#Q&5D:+' (-?FQ#,'S>L:U'DTWU>^W;X8_22:/R<P)P
M#\\)<EY:SVV45E?>F:A'NSS__<]ZN;2V!5+O"5/T<.W,HL5G,8PU?<S_,P[$
M!'S.)7[:)-XJ\%GEP0/P+X03;+DYY&\(AW%IA8#[6DQ63$!<B(X$,[D;[,[/
MV3 %ZI^^"S':8))@USI"NP75T!&,]\#W [< BR::=I\UA6D_()'P)=*2K>>.
M6,LP45\8+B@/3P"?ZLRS@7Y=W_2X)6S?-0?,!3YV6P/JJ3K835@#L3?NON*+
MV XL\?OB K<&P<N6;<+LV!$=4@-S..[FS&'WW>[&OABJ8KZ\8EB3UZ"CM9-?
M'<,#QL3<GV^I?(:;[EM<\@W;JSJ#BUIU(J4[3=LV!;?HI%7<ZT@%";EC8ZU:
MW7K*\YA<KN\5.%PM30*H)1;(>JKT#Q4$GA9@U?**%'42\5CI'%;,+9766.W@
M@I4KQ3PT7)[BC9=I3)6^M2Y[QU095[=U:9N&!@QKM4_ 1H*A--/5RM>S7F-/
M6%<_]M9?5:V,PO,^=$JT+@EC5ZUN5*&4JAP0%M,IB1K<4*-4BWG9<JY4IHS4
M_UZE4E1*Y=P1Z!?@>6@Z@8$NM7/6:HW+A[AG*_OW#7[?6M5>5;F,A^M]*!E8
M7TZ++?!Y'DRIJN?*2\WEYZD<V7:N=*:,]/]>I5-)5SH-U_6%\Z3J*;FZ?F'=
MM^M??K\:_3=4SPAT_VH%5!&YZI+V/ 6DVHY10*^U@?]F>92I!SN*<!<79+9+
M.$)/$#4\$4=6126_@)#S7-?4Y+I>HRYW_=7K<J_P$B]5>XDGX+0.TTSNNO/"
MZ6>MJ_CZ!'*X'H:XEX-NTS;GM)D2X<&3<4G9$8&1!5W]T#'@2:30I]63?)L]
MS-'",V7V!J5RD[10NC?96.WM__@^*-FWD[C!8'C.S ZZD$$EXZ5G:[=9UN,.
MN^>F+]@?^6*QQ'IX%5CGL6-+$W<DI[K<]JT9)MBR4:I0*L$Q.=7*T6'1JG76
MOTZB\"LQ868';Y"<L\#;L8"\.H$@'),5"\0YB&W&'Y'^<<Q/CCL]+LR)!*54
M"(G*?K0&,@TF-!6NSN_&U3W6>,_PN,E.N',KZ%8(6#J3?:16"EX=']=26&X>
MK;T=V U+Q[@;.+,Y8!K612  MV#N!9U<&JI9,%P&$T/HCC"V6=NQ'[P.QN\]
M+&/@+M-%R[#DB7*Y^UE<"0*\X:U/Q-C:%NU\!HT,B!F!SWIX"!V+9V3T7V[F
MRL$@R;A?#8%A?]3(H(/L-$9^YN@QHVQ45QRQN##$$H\?DPRZ'5*GFNR3KO(J
MZ_M&YU=G_?#L]TLBGY.'>P2P9Z?@9H5J,\ILC19638W30EC@*74:2ZHT8Z0"
MJP,*2YA"\T!A63:EIGQ74"M8@:KSPNOA#4I7R<MED8MH+G- #/]@P-S(ZA8L
M %XYXMYPH2/H06YIN(/+-;K4'$'%R_EU[NBNK/#2QR7&*DM\.57EA1SX'@H%
M)WSQ9R+"3KWZL]J;7_PYY? &='A=J%,X$(F[!6/<^;@Y 5-)2I/#/LIVCUPI
M*^</6ZS2XJ*4<#P%/)PB3LZAV:;)>R[ $OR6R &GX3#*OZ1D59*X,$6+>NBI
MDA:0(7#' U<\N IY!"V.X+>YI@#E"-#T")<*$22A$@LA-6,TRL1(GA@]+GYO
M('FORGBO8 6WFSL-3W07%TKY8BG/ZG@O#98GVXRSH#2*[:,[;M YI]VV(VC/
M+3^+-UG-J*MR9BTNC%Q3EV7!]6-L]/8QMH0V'\^OE(M;RO&DOTI;RXS02M$5
MD3D649W[#G@);HS,&!W1(.&38!CEL^R:O0X/@_5=_'"0&>N%;X,>V827(E/!
MAL<XCDRE\ 9N5^,OU"V+0>+ZGP"?98!'5+,MTD:H ?=%$R#Q'4'K7%Q0LX6/
MPZ5" $GU^6V8HXW.7'1VCW?1G4+WZ(]*ME(L9HO%(GEE',&4:(#6FE!-BK))
MGM(0$0 /AFFRIL#H(0 O"XZE1\Z<!W3%98 ?!P$%_8G+4X\]%J('3QDQNX=N
M6U;217VX ^;6*!L+C(0I#^7-*9(.D=E2GZ)B\A;_$.\2'K4:@=][02C^*.4K
MY2B1FV6NW_P)KB.^XSJR,3$ A>.NYAA-&9![G6'\IP!PCE,%\[]5_#QKNC=Q
MOROB$<2RZX8[V8' 91,4ATC3'BLRC">Y)63D!^Y0K!(GUU?Y+))G&"7LP-5!
M-X0F8D7L_5QV5,,K7LRJ:5 88$%V6R:&2(7($0+>65Q0/4ANZ%P+-7V>0'@=
M8/4N5YT>((8"X80.@C!%[E-<"8U@/>1L# YUIA8A2: 6=DTGS#!L&Y:S2+:P
M>83 $<F,@/%[\%"+WJ> $6'>M%V<%:\YG<O4F*UA- <4;7--U@%16@?B;([Q
M>7.0E"W"*3P'S$<&MBP-;%*W*=SCG;$1O8'7I!F3FCW&A[HPP5T"*TMB)84S
MJ3F1O?!)R&()1<N;]GU2NUY%BPH5*]DBT1>.9L2M56S8Q!!UU7)Q(:&?,1\+
MQF!UA2V%#%PJK_P9R592KX\P*:*/&L:0I( +P* O_9B8M)6HB%3-XH+?P[_+
MV15EA)\GZ8@_%/1FA &BK_(=#-QLMDTZ/0F_][CC$;T"LXPPH[%O@?BS3[X%
M<"C"5VAH&830FX CUN="]XC0]1Q; Z/D*E<'*!7CV-!-TH7,JNF!EHPYI^0$
MB1;@W2/J<_T><U]X9!(>?#[-58IE\&[O!2P ST."@"",^X[?9AK0S-!I"\*S
M'R@WIID&5@,".V,0XQ)5I2EYL)U;'%937BNP8@_4@#NG[YB3KK+6DA*5)!"E
MF*"@?C4LGPZJ6NK8JN-Z8*4&80D(7<J-[R"^)X'#1*8I4Z1TP3B9R25C>40+
MKR04&$2DM(\(X5!,#Q,82P;TIME]X#10O*#SO32+"DH.07)]^ <9!K1".#R"
M:0[81=0[J>_C^@<Y&FL3=; DH#Y+4G?U3-_%5*WCHS;R\7QNCQL4:\'B7=!!
MIG'G$Z?J,'V7MX4;.CHR)'%Q&H";CO!&M:KI/K<">7$A!O,N#9,T$BE+D\U"
MR51@@E"XG:THL4P.E21:1%OOP98TA1$C5+M9>1HZP!!J9TJ,D[KGZ+N:3 98
M(.**-OP1T ":9]F"+,-/IY(5YS%G"G52(N+!+F"#W(C=R/]#;#]MXT(F6X\L
M(X<^F%-2?W[YNGONLJ7D!B8%J.$PRQ1B2DS>4]3H!E?(>+*R @4'U*"EQR0J
M]DH2!,^0@TSJ>.(<4 ?KQ%'E"GFO9X+>0^]R%+52<B1/Q.E$885B9M>6EPX0
MN5H1CFS?HYT'>;1\-(X>PE?,UM)F!_ 5X(,V752?R-LH1CC]C:F: MM)Z'$O
MY 4RN+CP>T)(& 2?:U0*I)VA7WE<$;EX44@\QL;QY&E_:2/I;B':J@'@O &R
MI&[(GJ,L%4$":DFE4NA&$EP)LI7LJL07EJ4$">9MREA(FF#ICBW%;C-QI5+K
M1LD(0EIX#2G&5-E4O00++T KY?(M$U_AAICHHV.0'4G&9%EI([^Q$5)^..(D
MA#SF L:Y1$D*$G7(Q0=9<<$RPGI]"Z6?"!09H& PW,:SFQXG)--TX#[*NQ7P
M=H=[;L[=@T?<OQ@;D.2Y$>< !]*6J?JDR/J?E'3B%M [X%W=A@[(*TT!@,LA
MI.0AF4*G0/D=,C40&:X!*3N4(,Y I>#7!T DP288;AX<1@6&"A;B=@Z9^GG1
M!IDM:-#$3T-*P8)1T7[)Q=EQ9P.OZ*-NPW;4B,-B6V8"( 6(\5M* -CW'A4A
MZ"RI4PR0N,6%2*Y)VT1<S0*FCNF*T0!TSO'I'+\'FE#Z.F/C^8#R,J4<IE/=
M*.X9<CBP?Q"@RT=9L![X=0WT#DRJ2$!B62*(J,"E)HJ"#:,/DUJZU&TNV'_/
MI7RN2QN19&F1FUQN*DOG&.T.15DM6*+5AM8 +XHH9SH6-AA@-\FEDSZ^<% Q
M@F]M@;F$ 2FJBI(L>?8<C"@#!8($+8"1J:S!?K  #1VCQYHFK$7J?S(+@6Z(
MR\H#!UQ$8;Y,GZV6R&=2(>3B N@11&@RP)RS\B23T&'^N668@K86;.)4<+Q<
M'_Q/:7G'A/A![0RQ,=V<2:WA#[PJ:7'A,E=A2Z=VGE4JE5QY=;5:*2X/Y;&@
M/^5?<Y4P" Q3R;']+"E3JO ENM(Z,=AEO1:.X=GAV83%A;'7K<@/E%4H8X?2
M@.H],6*B>3)ZI,2O%<477=XWNGXWYON,I)=1K-!V2*L1P!<X/'%<)%+;#0MP
M[$M=T<COY5=Q<+J+"EOBAWMLJ?,A)G?!5VU2'($"+6.'*.93>>>)2]#T[^R^
M9B7-(T4CY7G1R#LM&IE^EG^#6G%PTW7I<F8?WXQ[; MTJ(@A85.4<\/#$#!6
MJ1!7U!>Q3HL+%[+72*%#-FU[X\E:!C*,>&$HN']=W$E(MWHN61'PZ2 PY<X@
M*[<=%3*H?-3#:(D,%Y86Q$W4^ O!*-P2Z.U%-P9VP8%#Z$?L"\5=T79I=#@O
M;@+C9D9FC^+(8\.X@U' XZ2$0T=%2 'U$#%9H@@XE)6B3'=)8X-A.LR1)7H2
M]$Z"0I&O0"&\*S>CT67F)N5@E"$3X2X"8$OC035NRI@Q]T-F1G2AF1SY"D:0
MGG>P9PA^@MPS6EQ0>T/X=+6X#0[/CM<!.82?,)LIL#:74G7138QA:@*3&W*5
M 64>Q^,2?NRUK+ $H2&EK<=A!3,=47Y))<+O#1#-: V3K\:8ZS29 4&>:-N4
MIJ4H6F7]TG59&"5E$R%2$#(]SA2Z33)+VU9.P+E43"X\5;B N4;,KH9?9H11
M#8>V81T!D6 3Q05B/W0X G5##(.8(BZE_1'UR50WB,5P6!1@';56O=\QFK@U
M5RKF2UG\MYQEU7P)5[&X ']6AB/8 ++H&T P$B92 , X1/-@[8EJS7*^"&JX
M!AHOVD?9!\J"Y!^$)P;.8O?&8KXM_D!J=GS6:N7VN$DQR65'"(_M(BNV54R&
M T<78K]!T>?,TH9T@&')TT%D6@"7:(4Z"ME(.89EMN$!LYKO.(AE]=%E%0#3
M7<%T27!,2,C-H4XT#-+_=25FX@1X%3FHY(OE/+@TL2MB+I77HQ*HD6?T*LP[
M-WZCC(\5 3Q(4[^(Z\E/5R8CL$K#&9-'\HLN);S'"@TRRS]B9N8L,K1#-$0X
MVLE11^>:\0AD?(3SFSDX9! 8WS2(HRA[+ .M8/.6BI<2$4*X@],<A"?KJDM\
M>:D<GJT;@HUV^.,EB+@TP[JWS7O:807'#0RQAMN;,OL^=W>>4/,;=#@E\FPN
MP_!9I7BE(XH*?B[3;P3VDKZ\N!!A?L:@G[DKUYZ^72TE'_Q\$%-SMN$'"-;D
M!PBFGJJ*'2?_#<F)WI!EQW74W[US1C%FR 5$_Z?H69KL]R1>?IG91'E5#CK)
M!>U'"9QIO:%L2B]!^E>"]5[YHIHOS0#VI_>>XFW..@Y>)R/ZU5PIW_&ZP=UZ
MZ@*K\+QM$ EAZ#!R$ 8+;_B]3=4!J<=MLTS6DX\<8=HN\#%W8KTO1IT933&]
MO/KOT6JX6S%GE<FHM5(QT&N/WB(PJJ#"2PR: W7<SGO XM7'[C3 =JGZ;Z[F
MW@M8<S4W2357GK/*Q-1<6:JYI^XCV??%Z!G&N7YZ+V#-]=,D]5-ESBH3TT\5
MJ9\>+1P:&R?.W;"YFINKN5=2<]4YI_RMNR?N\3 .@D>5^'2<D\O*W'T\KG:
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M:TM<L0&9TTR8Y4&P )@R&5 R)'5(";WTO+Y+0'/Y$"/8'%/FE@"[R28%34U
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M,3 M,BYH=&U02P$"% ,4    " #M@995--/HF;U"   VP@$ "@
M    @ $\*P$ 97@Q,"TS+FAT;5!+ 0(4 Q0    ( .V!EE4%4G]7T$D  #3:
M 0 )              "  2%N 0!E>#0M,2YH=&U02P$"% ,4    " #M@995
M)?MS#^(;  "ES   "P              @ $8N $ 9F]R;3@M:RYH=&U02P$"
M% ,4    " #M@995JF(TE% #  #"#   $0              @ $CU $ <6QG
M;BTR,#(R,3(R,2YX<V102P$"% ,4    " #M@995+LQ\.OX*  " A@  %0
M            @ &BUP$ <6QG;BTR,#(R,3(R,5]L86(N>&UL4$L! A0#%
M  @ [8&65>:()&M:!P  VU<  !4              ( !T^(! '%L9VXM,C R
C,C$R,C%?<')E+GAM;%!+!08     "  ( -T!  !@Z@$    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
